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ABSTRACT 
The first discovery of a growth-regulating signaling molecule was more than 65 
years ago, when the work of Rita Levi-Montalcini, Viktor Hamburger, and Stanley Cohen 
led to the identification and purification of nerve growth factor (NGF). As the prototypical 
growth factor, the identification of NGF was a milestone in developmental biology, 
leading to the subsequent discovery of hundreds of additional secreted growth factors. 
Many decades later, NGF is now recognized as one of many neurotrophic factors 
(NTFs) and the founding member of the neurotrophin family, which includes NGF, brain-
derived neurotrophic factor (BDNF), neurotrophin-4 (NT-4), and neurotrophin-3 (NT-3). 
The physiologic functions of these factors are mediated by the tropomyosin-related 
kinase (Trk) receptor family as well as the p75 neurotrophin receptor (p75). A more 
recently identified family of neurotrophic factors is the the glial cell line-derived 
neurotrophic factor (GDNF) family ligands (GFLs), which are potent growth factors that 
promote the survival of numerous populations of neurons in both the peripheral nervous 
system (PNS) and central nervous system (CNS). The GFLs consist of four homologous 
ligands: GDNF, neurturin , artemin (ARTN) and persephin (PSPN), and signal by first 
binding to one of four GDNF family co-receptors (GFRαs) to initiate their signaling. 
GFRαs are glycerophosphtidylinositol (GPI) linked proteins and, after binding to GFLs, 
they bind to and activate the tyrosine kinase Ret and initiate downstream signaling.  
This thesis work collectively sought to understand the functions of Ret signaling 
in peripheral nervous system development. In the first investigation (Chapter 2), we 
explored the function of a newly identified p75-Ret receptor complex in the development 
of nociceptive sensory neurons of the dorsal root ganglion (DRG), known to be 
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dependent on GFL-Ret signaling for their survival and maintenance. In our investigation 
we found that p75 is required for cell surface localization of Ret. In the absence of p75, 
GFL-dependent, but not NGF-dependent, nociceptors are specifically reduced, with 
sensory populations that normally express lower levels of Ret being most greatly 
affected by p75 deletion. Based on these data, we conclude that p75 has a surprising 
role in augmenting GFL signaling, and collectively serves to promote the establishment 
of postnatal sensory neuron diversity.   
In the second study (Chapter 3), we investigated the function of this p75-Ret 
receptor complex in developing sympathetic neurons of the superior cervical ganglion 
(SCG). Interestingly, p75 signaling regulates programmed cell death (PCD) during 
perinatal development. In this investigation, we found that Ret expression is restricted to 
a subpopulation of apoptotic neurons that are rapidly eliminated. Ret and p75 form a 
complex induced by pro-apoptotic stimuli both in vitro and in vivo. Importantly, p75 
deletion specifically within Ret-expressing neurons, and Ret deletion specifically during 
PCD, result in a significant abrogation in apoptosis. These studies collectively revealed 
a surprising non-canonical function of Ret in augmenting apoptotic signaling through 
p75 during PCD in vivo. 
In the last study (Chapter 4), we explored the function of Ret in the development 
of the peripheral taste system, focusing our studies on the geniculate ganglion (GG) 
which afferently innervates taste buds within fungiform papillae on the anterior 2/3 of the 
dorsal tongue.  We identified a novel, biphasic function for GDNF-Ret signaling in the 
peripheral taste system, initially acting to promote the chemosensory phenotype of all 
GG neurons, while acting postnatally to define a unique subpopulation of lingual 
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mechanoreceptors. These findings collectively broaden our understanding of the cues 
responsible for taste neuron development, and bring to light new information regarding 
taste neuron heterogeneity.   
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CHAPTER 1: INTRODUCTION 
 
The Initial Neurotrophic Factor Hypothesis 
Viktor Hamburger’s experimental findings using the chick embryo transplantation 
model were the first to demonstrate that neuronal populations are affected by the 
population size of their target tissue. In these experiments, the addition of ectopic limb 
buds could increase the neuronal population while removal of a limb bud eliminated the 
neurons that normally innervate this target (Hamburger, 1934). These observations 
gave rise to the idea that neurons are initially generated in excess during 
organogenesis, and that these neuronal populations depend on a trophic supply 
produced by the target tissue these neurons innervate. These observations led to the 
pioneering work of Rita Levi-Montalcini and Stanley Cohen in the 1950s who discovered 
that mouse sarcomas secrete a factor that was able to elicit neurite outgrowth from 
peripheral sensory or sympathetic ganglia (Hamburger and Levi-Montalcini, 1949; Levi-
Montalcini and Hamburger, 1951; Levi-Montalcini and Hamburger, 1953). These data 
gave rise to the idea that a soluble, diffusible “neurotrophic factor” is present, exerting 
cellular effects resulting in growth and survival of neurons. These findings formed the 
basis of the collaborative work of Rita Levi-Montalcini and Stanley Cohen, which led to 
the identification and purification of the first growth factor, which they named nerve 
growth factor (NGF) (Cohen and Levi-Montalcini, 1956; Levi-Montalcini and Angeletti, 
1968). Importantly, based on these experimental observations, Levi-Montalcini and 
Hamburger proposed the “Neurotrophic Factor Hypothesis,” which posited that neurons 
are initially born in excess and extend an overabundance of axons towards their target 
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tissues where they compete for a limited supply of neurotrophic factors. Neurons that 
fail to receive sufficient neurotrophic factor support undergo programmed cell death 
(PCD), thereby directly matching the size of neuronal populations with that of their 
target tissues (Levi-Montalcini, 1987).  
 
The Neurotrophins and Trk Receptors 
  During the initial discovery of nerve growth factor, it was observed that although 
NGF could produce robust neurite extension from sensory and autonomic ganglia, it 
was insufficient to support the survival or growth of other cranial ganglia, leading Levi-
Montalcini and colleagues to postulate that additional growth factors may exist (Levi-
Montalcini and Angeletti, 1968). Nearly 30 years after the identification of NGF, brain-
derived neurotrophic factor (BDNF) was isolated from pig brain and shown to share 
sequence homology with NGF (Hohn et al., 1990; Leibrock L. et al., 1989). Today, there 
are four recognized members of the neurotrophin family of neurotrophic factors: NGF, 
BDNF, neurotrophin-3 (NT-3)(Maisonpierre P. C. et al., 1990), and neurotrophin-4 (NT-
4; also known as NT-4/5)(Eide et al., 1993; Klein, 1994; Lo, 1992). Collectively, the 
neurotrophins are synthesized as proneurotrophins, which undergo intracellular 
proteolytic processing to produce dimeric mature proteins capable of initiating signal 
transduction cascades (Kaplan and Stephens, 1994).  
 High affinity neurotrophin signaling is mediated by the tropomyosin-related 
kinase (Trk) family of receptor tyrosine kinases. Each neurotrophin binds with greatest 
affinity to its cognate Trk receptor: NGF binds preferentially to TrkA (Barker and 
Shooter, 1994; Ehlers et al., 1995), BDNF and NT-4 to TrkB (Klein et al., 1990; Klein et 
3 
 
al., 1993a), and NT-3 to TrkC (Klein et al., 1994; Lamballe et al., 1993), although NT-3 
can also bind with reduced affinity and efficacy to TrkA (Wyatt, 1997). In addition, all 
four neurotrophins can bind to the p75 neurotrophin receptor (p75) with reduced affinity 
(Chao, 1994; Lee et al., 1992a), the functions of which are more complex and described 
in detail later in this chapter. The Trk receptors are type-1 transmembrane receptors 
with large, heavily glycosylated extracellular domains (ECDs), a single pass 
transmembrane domain, and an intracellular tyrosine kinase domain with enzymatic 
activity (Greene, 1995). Neurotrophin binding and subsequent activation occur as a 
result of engagement of a dimeric neurotrophin complex with the immunoglobulin C2 
domain, resulting in homodimerization (Chao, 2003). Upon ligand-mediated activation, 
Trk receptors undergo internalization followed by subsequent recycling or degradation, 
or the formation of signaling endosomes that are retrogradely transported from axons to 
cell bodies (Ehlers et al., 1995; Grimes et al., 1996; Riccio et al., 1997; Tsui-Pierchala 
and Ginty, 1999).  
Neurotrophin binding initiates dimerization and subsequent autophosphorylation 
of the Trk receptors, leading to the activation of three predominant downstream 
signaling pathways: (1) Ras activation controls the activation of the MAP kinase (MAPK) 
signaling cascade, controlling neurite outgrowth and differentiation (Nakamura et al., 
1996); (2) activation of phosphoinositide 3-kinase (PI3K) via Ras or Gab1 promotes 
neuronal survival and growth (Crowder and Freeman, 1998); and (3) activation of PLC-γ 
results in activation of Ca2+ and protein kinase C (PKC)-dependent pathways, 
controlling synaptic plasticity and differentiation (Obermeier et al., 1994; Stephens et al., 
4 
 
1994). All three pathways can lead to changes in gene transcription resulting in short 
and long-term phenotypic changes.  
 For peripheral neurons, PI3K-dependent pathways are the key regulators of 
target-derived neurotrophic factor-mediated survival, through several distinct effectors. 
First, activation of PI3K leads to activation of the serine/threonine protein kinase AKT, 
which in turn regulates phosphorylation of substrates that govern regulation of the 
caspase death cascade such as Bcl-2 associated death promoter (BAD)(Datta et al., 
1997; Kennedy et al., 1997). Phosphorylation of BAD (which promotes apoptosis by 
binding to Bcl-xl thus preventing it from inhibiting the apoptotic activity of Bax) leads to 
inhibition through cytoplasmic sequestration by phospho-protein interacting 14-3-3 
proteins (Ito et al., 1997; Putcha et al., 1999). In addition, PI3K pathways inhibit the 
activity of several transcription factors whose gene products promote apoptosis (Franke 
et al., 1997).  
 
Functions of the Neurotrophins in the Peripheral Nervous System 
 Neurotrophins have wide-ranging roles in peripheral and central nervous system 
development, regulating neuron survival, differentiation, axon outgrowth, synaptic 
plasticity, and many other cellular functions (Chao, 2003; Snider, 1994). Beyond the 
nervous system, the neurotrophins have key developmental roles on several non-
neuronal tissues, including muscle, cochlea, and pancreas. The specificity in 
neurotrophin function is achieved primarily by tissue-specific regulation of neurotrophin 
and Trk receptor expression. With a small number of examples to the contrary (Gatto et 
al.), the Trk receptors are expressed in a mutually exclusive pattern. While TrkA and 
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TrkC are found primarily in distinct subsets of peripheral neurons (Eide et al., 1993; 
Kaplan and Stephens, 1994; Lamballe et al., 1993; Tessarollo et al., 1993), TrkB is 
primarily expressed in neurons and glial cells of the central nervous system (Klein et al., 
1990). Studies utilizing NGF and TrkA germline knockout animals indicated that NGF-
TrkA signaling is critical for the developmental survival of sympathetic neurons, as well 
as distinct subsets of nociceptive sensory neurons in the dorsal root ganglion (DRG) 
and trigeminal ganglion (TG)(Silos-Santiago et al., 1995; Smeyne et al., 1994a). These 
studies are well-mirrored by human patients with mutations in NTRK1, the human gene 
encoding TrkA, which results in hereditary sensory and autonomic neuropathy (HSAN 
type IV) characterized by an inability to sweat and feel pain (Pezet and McMahon, 
2006). In contrast, germline knockout studies analyzing TrkC-/- or NT-3-/- mice have 
found only modest effects on sympathetic neuron survival, with more pronounced 
deficits in placodally-derived cranial sensory ganglia as well as proprioceptive DRG 
neurons (Klein et al., 1994; Tessarollo et al., 1997). Within the central nervous system, 
Ngf-/- and TrkA-/- mice have modest deficits in hippocampal development (Chen et al., 
1997), while TrkB-/- mutant mice have much more severe deficits in hippocampal, 
cortical, striatal, and thalamic neurons, among others, and TrkB-/- mice rarely survive 
beyond three weeks of age (Gupta et al., 2013; Klein et al., 1993a).  
 
Trk Receptor Trafficking and Processing 
 Trk receptor synthesis occurs in the endoplasmic reticulum and undergoes post-
translational glycosylation of the extracellular domain in the Golgi apparatus. Trk 
receptors are transported to the cell surface by microtubule-dependent kinesins, often 
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traveling long distances beyond the cell body for localization in dendrites or axonal 
growth cones (Kuruvilla et al., 2004). Activation and signaling is in part governed by 
membrane localization, where sphingolipid and cholesterol-rich domains known as lipid 
rafts, rich with RTK adaptor proteins and other signaling regulators (Brown and London, 
1998), form important signaling hubs for Trk receptors. TrkA is concentrated in 
caveolae-containing lipid rafts prior to ligand engagement  (Spencer et al., 2017), while 
TrkB translocates to lipid rafts in response to BDNF-mediated activation (Pereira and 
Chao, 2007). 
 Following activation by neurotrophins, the internalization of Trk receptors is 
accomplished by either a clathrin and dynamin-dependent pathway, or an actin-
dependent process (Beattie et al., 2000; Kirkham and Parton, 2005; Nichols and 
Lippincott-Schwartz, 2001). Following internalization of the activated neurotrophin-Trk 
receptor complex, Trk receptors continue active signaling from early endosomes. While 
some endosomes are preferentially recycled and shuttled back to the cell surface to 
escape lysosomal or proteasomal degradation, others undergo degradation (Grimes et 
al., 1996; Ye et al., 2003). TrkA, for example, contains a recycling signal in its 
juxtamembrane domain that allows for preferential sorting towards the recycling 
pathway, while TrkB and TrkC are more frequently shuttled towards the degradative 
pathway (Chen et al., 2005b). When neurotrophin receptors are localized in the distal 
axons, the internalization of the ligand-receptor complex can give rise to a signaling 
endosome which is retrogradely transported to convey trophic signals to the cell body, 
activating PI3K and MAPK pathways while in transit from axons to cell soma and 
dendrites (Ginty and Segal, 2002).   
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p75 Neurotrophin Receptor 
p75, initially identified as a low-affinity receptor for NGF, is a member of the 
tumor necrosis factor (TNF) superfamily of death receptors, and is now recognized to 
bind all neurotrophins with similar affinity (Chao, 1994). Structurally, p75 is composed of 
four cysteine-rich domains comprising the extracellular domain, a transmembrane 
domain, and an intracellular domain containing two distinct regions: (1) the Chopper 
domain in the juxtamembrane region capable of inducing cell death; and (2) a C-
terminal region that shares homology with the death domains present in other TNF 
receptor family members, which also mediate apoptotic signal transduction (Bamji et al., 
1998; Charalampopoulos et al., 2012; Vilar et al., 2009b). Binding of the neurotrophins 
to p75 occurs via the cysteine-rich domains in its extracellular domain (He and Garcia, 
2004). p75 has been demonstrated to exist on the cell surface as a monomer, a dimer, 
and a trimer, depending on the mode of activation (Anastasia et al., 2015). Additionally, 
trafficking of p75 shares similarities with the Trk receptors, as p75 has been shown to 
concentrate to lipid rafts in response to neurotrophin binding, and upon activation, can 
be sorted into endosomal compartments that may be recycled or targeted for 
degradation (Hibbert et al., 2006; Spencer et al., 2017). Some evidence supports the 
notion that following its internalization, p75 also can form signaling endosomes that are 
retrogradely transported from distal axons to somal and dendritic compartments, 
prolonging its signaling (Curtis et al., 1995; Hibbert et al., 2006).  
While the functions of the Trk receptors are generally trophic in nature, the 
functions of p75 signaling are more complicated. While p75 is widely expressed 
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throughout neuronal and glial populations in both the PNS and CNS (Ibanez and Simi, 
2012), the requirement and specific functions of the enigmatic receptor depend heavily 
on the cellular context of activation (e.g. which other neurotrophic factor receptors are 
present), the co-receptors it complexes with, and the specific ligand promoting its 
activation. In some instances, p75 modulates neuronal survival (Barker and Shooter, 
1994; Wehner et al., 2016b), while in other contexts its activation leads to death 
receptor signaling culminating in apoptosis (Frade and Barde, 1999; Frade et al., 1996).  
The survival functions of p75 depend on its co-expression with the Trk receptors, 
where p75 can enhance the binding affinity between the neurotrophin ligands and their 
cognate Trk receptors, thereby promoting their pro-survival and growth functions 
(Hantzopoulos et al., 1994), although there is still debate about whether p75 does so by 
directly associating with the Trk receptors. The most striking phenotype observed in 
p75-/- mice is the deficit in sensory neuron survival (Lee et al., 1992a), reminiscent of the 
phenotype observed in TrkA and NGF germline knockout mice, further substantiating 
the role of p75 in augmenting Trk signaling. p75 is also known to complex with the 
Lingo-1 and Nogo receptors to regulate growth cone collapse, neurite retraction, and 
spine density in response to the myelin-derived ligands Nogo, MAG, and MOG 
(Kraemer et al., 2014; Vilar et al., 2009a).  
More recently p75 has come to be appreciated as the high affinity receptor for 
the unprocessed neurotrophins, or proneurotrophins, along with the proneurotrophin co-
receptors Sortilin or SorCS2 (Lee et al., 2001; Volosin et al., 2008). In the PNS and in 
cholinergic basal forebrain neurons, activation of p75 in by proneurotrophins, or by 
neurotrophins in the absence of the cognate Trk receptor, results in the activation of the 
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nuclear factor-κB (NF-κB) and c-Jun N-terminal kinase (JNK) pathways, resulting in cell 
death (Bamji et al., 1998; Kenchappa et al., 2010; Volosin et al., 2006). Neurotrophin or 
proneurotrophin binding initially leads to the recruitment of cytosolic adaptors such as 
NRAGE to the p75 intraceullar domain (ICD), resulting in the activation of JNK and a 
subsequent upregulation of p75 cleavage by the α-secretase TACE. TACE cleavage 
results in extracellular shedding of the ECD, thereby beginning the receptor 
intramembrane proteolysis process (Bertrand et al., 2008). Cleavage of the ECD allows 
for binding and further cleavage by the presenilin-dependent γ-secretase, liberating the 
intracellular domain (ICD) of p75 into the cytosol for signaling. In the cytosol, the p75 
ICD forms a bridging complex with neurotrophin receptor-interacting factor (NRIF) and 
the E3 ubiquitin ligase TRAF6, where TRAF6 ubiquitinates NRIF causing nuclear 
translocation and transcriptional activation and expression of pro-apoptotic mediators 
(Geetha et al., 2005; Kanning et al., 2003; Kenchappa et al., 2010)(Summarized in 
Figure 1.2). In support of this signaling model, the analysis of p75, TRAF6, NRIF, and 
JNK3 knockout mice have all revealed deficits in sympathetic neuron programmed cell 
death at birth. Interestingly, these deficits are eventually corrected by adulthood (Bamji 
et al., 1998; Kenchappa et al., 2006; Kraemer et al., 2014). 
 
The Neurotrophic Factor Hypothesis Revisited 
 The neurotrophic factor hypothesis posits that neurons are generated in excess 
during neural development, setting the stage for a competition between neurons for a 
limited supply of target-derived neurotrophic factor. Neurons receiving an adequate 
supply of trophic factor activate PI3K and MAPK-dependent pathways, and concurrently 
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downregulate pro-apoptotic pathways, ultimately leading to neuronal survival (Dudek et 
al., 1997; Yuen et al., 1996). Neurons failing to receive adequate trophic support 
undergo apoptosis and are subsequently eliminated. Despite a plethora of studies 
demonstrating the existence of active death receptor signaling mechanisms, such as 
that regulated by p75, the neurotrophic factor hypothesis remained unchallenged for 
nearly half a century. More recently Deppmann et al. (2010) drew from models of 
competition between axons at the neuromuscular junction and employed computational 
modeling approaches to demonstrate the likely existence of “competition factors” that 
were found to be neurotrophin ligands activating p75 in sympathetic neurons. In this 
model, in line with the neurotrophic factor hypothesis, “winning” sympathetic neurons – 
those receiving adequate quantities of NGF – upregulate TrkA through a positive 
feedback loop, while also upregulating the expression of BDNF for release from distal 
axon terminals. “Losing neurons” – those that fail to achieve adequate quantities of NGF 
fail to receive a survival signal, and are also not protected from activation of pro-
apoptotic signaling cascades. The local release of BDNF from “winning neurons” binds 
to p75 on distal axon terminals of the “losing neurons”, initiating an active death 
receptor signaling cascade, thereby accelerating the process of programmed cell death 
and shortening the window of nervous system refinement (Deppmann et al., 2008). 
Several additional competition factors have been subsequently proposed to mediate this 
process, including Semaphorin3A (Wehner et al., 2016a), amyloid precursor protein 
(APP) signaling through death receptor-6 (Nikolaev et al., 2009), TNFα (Barker et al., 
2001), and the proneurotrophins (Lee et al., 2001).  
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The GDNF family ligands 
The glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs) are a 
second family of neurotrophic factors, distantly related to the TGF-β superfamily, 
consisting of four homologous growth factors: GDNF, neurturin, artemin, and persephin. 
The GFLs exert their functions by first binding as homodimers to 
glycerophosphtidylinositol (GPI)-linked co-receptors known as GDNF family receptor-αs 
(GFRαs), which then engages the receptor tyrosine kinase Ret (Airaksinen and Saarma, 
2002). Each GFL has a preferred GFRα co-receptor, with GDNF preferentially binding 
to GFRα1 (Cacalano et al., 1998), neurturin to GFRα2 (Buj-Bello et al., 1997), artemin 
to GFRα3 (Baloh et al., 1998), and persephin to GFRα4 (Enokido et al., 1998)(Figure 
1.3), although some cross binding has been observed at high concentrations of ligand in 
in vitro systems (Creedon et al., 1997). Additionally, while the physiologic effects of the 
GFLs in the PNS and in non-neuronal tissues are mediated through GFRα-Ret 
signaling, some populations within the CNS such as the neocortex and hippocampus 
abundantly express the GFRα receptors but not Ret (Pozas and Ibanez, 2005), 
suggesting the existence of additional signal-transducing GFL receptors. In 
concordance with this hypothesis, alternative receptors such as neuronal cell adhesion 
molecule (NCAM) and syndecan-3 have been identified (Bespalov et al., 2011; 
Paratcha et al., 2003) and mediate some of the functions of the GFLs in the CNS.  
 As the founding member of the GFLs, GDNF was initially identified as a survival 
factor for rat embryonic midbrain dopaminergic neurons (Lin et al., 1993). Since its 
discovery, the functions of GDNF have been greatly expanded to include roles in kidney 
organogenesis, spermatogenesis, enteric nervous system development, sensory 
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neuron survival and differentiation, parasympathetic neuron migration and proliferation, 
and motor axon guidance (Buj-Bello et al., 1995; Enomoto et al., 2000; Golden et al., 
2010; Gould et al., 2008; Meng et al., 2000; Molliver et al., 1997a; Moore et al., 1996; 
Pichel et al., 1996; Sanchez et al., 1996). Despite the many roles in nervous system 
development, GDNF and GFRα1-deficient mice die at birth primarily due to kidney 
agenesis and the complete lack of the enteric nervous system.  
In the central nervous system, GDNF is expressed in neurons of the 
hypothalamus, hippocampus, cerebellum, and dopaminergic midbrain neurons (Golden 
et al., 1998), although substantial CNS deficits are not observed in animals lacking 
GDNF or GFRα1 despite the origins of its discovery (Tomac et al., 1995; Trupp et al., 
1997). While GDNF signaling may be dispensable for developmental survival of these 
neurons, reports suggest that the maintenance of adult midbrain dopaminergic neurons 
is dependent on GDNF, which has been demonstrated to modulate striatal dopamine 
homeostasis (Kopra et al., 2017; Kumar et al., 2015). Additionally, GDNF has been 
reported to protect dopaminergic neurons of the ventral tegmental area (VTA) against 
drugs of abuse (Barak et al., 2011). These studies have led to the development of 
therapeutic strategies employing GDNF for use in treating neuropsychiatric and 
neurodegenerative disorders. Several clinical trials involving GDNF protein infusion in 
patients with Parkinson’s Disease have been completed (Gill et al., 2003; Kordower, 
2003), with only modest benefits observed thus far. 
As the second member of the GFL family to be identified, neurturin (NRTN) was 
first identified as a survival factor for cultured sympathetic neurons (Kotzbauer et al., 
1996). NRTN is widely expressed in many neuronal and non-neuronal cell types in both 
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embryos and adults (Golden et al., 1998), and has been shown to have several distinct 
functions compared to GDNF. Nrtn-/- mice have deficits in developing parasympathetic, 
dorsal root, trigeminal, and nodose sensory ganglia, and like GDNF, plays an important 
role in the development of enteric neurons of the gut (Enomoto et al., 2000; Ernsberger, 
2008; Sasselli et al., 2012). In addition to its roles as a survival factor for neurons, 
NRTN has also been observed to regulate liver bud migration (Tatsumi et al., 2007), 
erythropoiesis, airway inflammation (Mauffray et al., 2015), and psoriasis (Sakai et al., 
2017). In the CNS, NRTN also protects midbrain dopaminergic neurons from 
degeneration in animal models of Parkinson’s Disease (PD)(Horger et al., 1998). Like 
GDNF, phase I and phase II clinical trials were performed utilizing NRTN as a treatment 
for PD, and in this case NRTN was introduced into the striatum using an adeno-
associated viral delivery scheme (Marks et al., 2016; Ramaswamy et al., 2009; Warren 
Olanow et al., 2015). To date, these trials have been inconclusive, but with promising 
early results suggestive of therapeutic efficacy in early stage PD patients (Bartus and 
Johnson, 2017). Current approaches are underway to improve NRTN expression and 
bioavailability following AAV-neurturin delivery.  
Artemin (ARTN), the third GFL to be identified through a database homology 
search, is expressed at relatively low levels in both the CNS and in peripheral tissues 
(Baloh et al., 1997). Ablating ARTN or GFRα3 in mice results in deficits in 
postganglionic sympathetic neurons due to a loss of sympathetic ganglion coalescence 
and migration, as well as reduced survival of nociceptive sensory neurons of the dorsal 
root ganglion (Baloh et al., 1998; Nishino et al., 1999). In adult mice, Fontana et. al. 
(2012) discovered Schwann cell-derived ARTN mediated a c-Jun-dependent increase in 
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axon regeneration and motoneuron survival (Fontana et al., 2012). Additionally, ARTN 
has been proposed to have both pro- and anti-nociceptive effects, depending on the 
model of pain utilized and the location of delivery. In the spinal nerve ligation (SNL) 
model of nerve injury, systemic delivery of ARTN was effective in reducing the injury-
induced decrease in paw withdrawal thresholds in response to both inflammatory and 
thermal stimuli, and also reduced capsaicin-dependent release of inflammatory 
nociceptive mediators (Gardell et al., 2003), leading the authors to propose that ARTN 
has antinociceptive roles in vivo. Interestingly, Cayhan et. al. found that ARTN was 
dramatically increased in human cancer cells and promoted cancer cell invasion in 
pancreatic ductal adenocarcinoma, although these changes were not correlated with 
increased pain (Ceyhan et al., 2010). Additional studies are necessary to determine the 
therapeutic efficacy of ARTN in pain pathologies.  
As the final member of the GFL family to be identified through homology cloning 
(Milbrandt et al., 1998), the physiological roles known for persephin (PSPN) are more 
limited. PSPN is expressed at very low levels in both the PNS and CNS of both rodents 
and primates (Golden et al., 1999). PSPN is the only GFL with no binding affinity for 
syndecan-3 (Bespalov et al., 2011). Like other GFLs, PSPN is neuroprotective to 
midbrain dopaminergic neurons in OHDA models of PD (Sidorova et al., 2010). Mice 
lacking PSPN have no known developmental or adult abnormalities, but are particularly 
sensitive to cerebral ischemia (Tomac et al., 2002). In sharp contrast to the other GFLs, 
PSPN does not promote migration, differentiation, or survival of peripheral ganglia, nor 
do PSPN-deficient mice display any overt phenotypic changes in the enteric nervous 
system development or in kidney morphogenesis (Milbrandt et al., 1998).  
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Biology of the GDNF Family Receptors    
GFL-mediated signal transduction occurs through a receptor complex consisting 
of two GFRα molecules and two Ret receptors (Durbec et al., 1996; Jing et al., 1996; 
Trupp et al., 1996). While each GFL ligand binds preferentially to a cognate GFRα 
receptor (as described in previous sections), some crosstalk exists wherein GDNF can 
also bind to GFRα2 to activate Ret, and NRTN can bind to GFRα1 (Baloh et al., 1997). 
Each GFRα co-receptor shares 30%-45% sequence identity, with many common 
structural features between them. All of the GFRαs have three cysteine-rich domains 
(CRD1, CRD2, and CRD3) with the exception of GFRα4 which lacks CRD1 (Enokido et 
al., 1998). Mutational analysis of each CRD has suggested that CRD2 and CRD3 are 
required for ligand interaction, while CRD1 acts only to stabilize the complex (Anders et 
al., 2001; Ibanez, 2013; Kjaer and Ibanez, 2003). Comparison of the crystal structures 
of complexed GDNF-GFRα1 and ARTN-GFRα3 reveals that the ligand-receptor binding 
site is highly conserved between GFL-GFRαs, while a hinge region linking CRD1 and 
CRD2 is more variable, likely explaining at least some of the observed preferential 
ligand-receptor pairing (Parkash and Goldman, 2009).   
The GFRα receptors are linked to the cell surface through a GPI-anchor, which 
selectively isolates these receptors to lipid raft domains, thereby facilitating signaling 
with nearby acylated and palmitoylated signaling effectors also localized to lipid rafts. 
Engagement of GFRα by the preferred GFL causes subsequent recruitment of Ret to 
lipid rafts, where signaling occurs (Tansey et al., 2000). Interestingly, when GFRα1 is 
excluded from lipid rafts through the creation of a knockin mouse wherein the GPI-
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anchor of GFRα1 was replaced with a transmembrane domain known to be excluded 
from lipid rafts, disruptions occur in kidney morphogenesis, motor axon guidance, and 
enteric nervous system development, thus mimicking the phenotypes observed in 
GFRα1 knockout mice (Tsui et al., 2015). Additionally, the creation of soluble GFRα 
receptors through phosphoinositide-specific phospholipase C (PI-PLC) cleavage, or the 
addition of recombinant soluble GFRα, can activate Ret in trans (Paratcha et al., 2001). 
However, transgenic mice expressing GFRα1 from the ret locus (in a GFRα1-/- 
background) had no observable phenotypes (Enomoto et al., 2004), making the 
physiological relevance of trans activation of Ret by GFRα1 uncertain. Both the 
expression pattern of the GFRα co-receptor and the observed phenotype of the null 
mice are generally similar to that of their cognate ligands (Airaksinen and Saarma, 
2002).  
In addition to the GFRα receptors, two related receptors exist: GDNF family 
receptor α-like (GFRAL) and growth arrest specific-1 (GAS-1) (Cabrera et al., 2006). A 
recent report demonstrated that GFRAL does not bind GDNF family members, but 
instead mediates the effects of growth differentiation factor-15 (GDF15) through 
activation of Ret to control food intake and animal body weight (Emmerson et al., 2017; 
Hsu et al., 2017; Mullican et al., 2017; Yang et al., 2017). 
To date, Ret is the only receptor tyrosine kinase that does not bind its ligands 
directly, but instead requires a co-receptor for activation. Ret is a single-pass, type 1 
transmembrane RTK that is conserved from humans to Drosophila melanogaster 
(Anders et al., 2001). The gene encoding Ret (Rearranged during Transfection) was 
initially described as a gene product activated by DNA rearrangement in a T cell 
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lymphoma (Iwamoto et al., 1993). The Ret gene consists of 20 exons and undergoes 
alternative splicing to generate to several unique splice variants (Ivanchuk et al., 1997; 
Tahira et al., 1990). Alternative splicing of intron 19 gives rise to three unique isoforms, 
Ret9, Ret51, and Ret43 (not present in rodents), which are identical except for their C-
terminal amino acid sequence. Surprisingly, this modest change in the C-terminal 
residues confers isoform-specific differences in their subcellular trafficking, signaling, 
and function (Lorenzo et al., 1995; Tsui-Pierchala et al., 2002a) (discussed later). 
Additionally, exon skipping in the 5’ region of the Ret gene gives rise to at least two 
isoforms of Ret, RetΔ3 and RetΔ345, the physiologic function of which is unknown (Le Hir 
et al., 2002, Gabreski et al. 2016).  
The structure of Ret differs from other RTKs in many key respects. First, while 
the ECDs of most RTKs are composed primarily of leucine-rich repeats, immunoglobulin 
domains, or fibronectin-like domains, the ECD of Ret is composed of 4 cadherin-like 
domains, with a calcium-binding site located between CLD2 and CLD3, as well as a 
cysteine-rich domain proximal to the membrane which is required for ligand binding 
(Anders et al., 2001). The presence of calcium is required for proper folding and cell 
surface localization of Ret (Knowles et al., 2006), while the unusual CLD motifs are 
thought to stabilize Ret dimers (Kjaer and Ibanez, 2003). The transmembrane domain of 
Ret is required for dimerization, although how this region promotes dimerization remains 
unclear (Ibanez, 2013). The intracellular aspect of Ret is composed of a long 
juxtamembrane domain, a highly conserved tyrosine kinase domain, and a C-terminal 
tail with multiple tyrosines (Tyr) capable of becoming phosphorylated upon dimerization 
and autophosphorylation of Ret. Phosphorylation of these tyrosines allow for the 
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interaction and docking of signaling molecules, promoting the subsequent activation of 
downstream signaling cascades (Airaksinen and Saarma, 2002). 
Ret is initially translated with a signal sequence targeting it to the endoplasmic 
reticulum, where it undergoes rapid glycosylation to produce an immature 150 kDa 
protein (Tsui-Pierchala et al., 2002b). Ret then undergoes further post-translational 
modification within the trans-Golgi network, resulting in a mature, fully glycosylated 170 
kDa membrane-localized protein. Unlike the neurotrophin receptors, inactive plasma-
membrane localized Ret is found outside lipid raft domains, and Ret is only recruited to 
rafts by the formation of the GFL-GFRα complex, thereby enabling association of Ret 
and raft-localized Src (Pierchala, 2006; Tansey et al., 2000). Activation of Ret results in 
clathrin-dependent internalization (Richardson et al., 2006), and important isoform-
specific differences exist in Ret degradation. While Ret51 is internalized more rapidly 
than Ret9, a greater proportion of Ret51 escapes degradation and undergoes Rab11+ 
recycling, while Ret9 is primarily targeted for degradation (Richardson et al., 2012; Tsui 
and Pierchala, 2010). The observed isoform-specific differences in Ret degradation at 
least partially explain why GDNF can promote retrograde survival of DRG sensory 
neurons, but not sympathetic neurons, as sensory neurons preferentially express Ret51 
(Tsui and Pierchala, 2010). 
The three major signaling pathways downstream of Ret activation are similar to 
those described for the Trk receptors: (1) the Ras-MAPK pathway, chiefly regulating 
neurite outgrowth and differentiation of neurons (Grimm et al., 2001); (2) the PI3K-AKT 
pathway, essential for neuronal survival (Hemmings, 1997); and (3) the PKC pathway, 
regulating proliferation, differentiation, and neurite outgrowth (Battaini, 2001). Each 
19 
 
pathway is controlled by the phosphorylation of specific Tyr residues, each recognized 
by different docking proteins with different binding affinities. 
The C-terminal splicing of Ret creating distinct Ret9 and Ret51 isoforms results 
in important differences in the intracellular domain of Ret, and thus, confers isoform-
specific differences in signaling properties. While Ret51 contains 18 tyrosine residues 
equipped for downstream signaling, the shorter Ret9 isoform only contains 16 residues 
(Tsui-Pierchala et al., 2002a). Of these, adaptor proteins have been identified for at 
least eight of these tyrosine residues: Tyr687, Tyr752, Tyr905, Tyr928, Tyr981, Tyr1015, 
Tyr1062, and Tyr1096, the last of which is present only in the longer Ret51 isoform 
(Encinas et al., 2004; Grimm et al., 2001; Ishiguro et al., 1999; Jain et al., 2006; 
Kurokawa et al., 2001; Melillo et al., 2001; Salvatore et al., 2000; Taraviras et al., 1999). 
Transgenic mice with a phenylalanine substitution for Tyr1062 have deficits in kidney 
morphogenesis. Interestingly, in monoisoformic mice selectively expressing either Ret9 
or Ret51, the phenotype resulting from Tyr1062 substitution was much more severe in 
Ret9-only mice, presumably because Ret51-only mice were able to compensate 
through signal transduction from Tyr1096 (Jain et al., 2006). 
With a few notable exceptions of GFL functions in the CNS mediated by NCAM 
or syndecan-3, the physiologic functions of Ret can be described as the collective 
addition of the functions of each GFL or GFRα co-receptor. In short, Ret is required for 
early induction, branching, and morphogenesis of the ureteric bud in the developing 
kidney (Schuchardt et al., 1994; Schuchardt et al., 1996), and mediates maintenance 
and self-renewal of spermatogonial stem cells in the testis (Meng et al., 2000).  
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In the nervous system, Ret signaling is critical for the development of 
sympathetic (Enomoto et al., 2001), motor (Gould et al., 2008), sensory (Golden et al., 
2010; Luo et al., 2009; Luo et al., 2007), and enteric nervous system development 
(Schuchardt et al., 1994; Schuchardt et al., 1996), as well as the postnatal maintenance 
of dopaminergic midbrain neurons (Kramer et al., 2007). In humans, loss-of-function 
mutations in ret are strongly associated with Hirschsprung’s disease, characterized by 
severe deficits in enteric neuron development, as well as patients with congenital 
abnormalities of the kidney and urinary tract (CAKUT) (Eng, 1996; Jain et al., 2004; Pan 
and Li, 2012). Gain of function mutations, on the other hand, lead to endocrine cancers, 
including multiple endocrine neoplasia type 2A and 2B (MEN2A and MEN2B), 
differentiated from one another by the presence of orofacial mucosal neuromas and 
gastrointestinal symptoms present in MEN2B (Eng, 1996). Patients with gain of function 
Ret mutations are also particular at risk for developing familial medullary thyroid 
carcinomas (Ball, 2011; Santoro et al., 1990).  
 
Summary 
 In this work, we utilize several peripheral nervous system populations to expand 
upon our knowledge of the molecular mechanisms governing Ret signal transduction, 
and the physiological functions of Ret. In chapter two, we identify a novel function for 
p75 in augmenting GFL-Ret signaling in nociceptive sensory neurons of the DRG, 
revealing a highly specific and surprising new function for p75 in postnatal sensory 
neuron differentiation (Chen et al., 2017). In chapter three, we again investigate the 
functions of this p75-Ret receptor complex, and discover a highly unusual, non-
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canonical Ret signaling pathway promoting p75-dependent programmed cell death of 
perinatal sympathetic neurons. Finally, in chapter four, we identify a novel biphasic role 
for GDNF-Ret signaling in geniculate ganglion neurons: the prenatal determination of 
chemosensory cell fate, and the postnatal specification of a unique population of lingual 
mechanoreceptors (Donnelly et al., 2018). Collectively, these studies broaden our 
knowledge of the physiological roles of Ret, and bring forth new concepts with important 
implications for the design of therapeutic regimens harnessing Ret signal transduction.   
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Figure 1.1: Neurotrophin signaling through the Trk and p75 receptors. 
All four neurotrophins, nerve growth factor (NGF), brain-derived neurotrophic factor 
(BDNF), neurotrophin-4 (NT-4), and neurotrophin-3 (NT-3) exert their trophic functions 
through the tropomyosine-related kinase (Trk) receptors, with NGF binding to TrkA, 
BDNF and NT-4 binding to TrkB, and NT-3 binding preferentially to TrkC. In addition, in 
the absence of the cognate Trk receptor, all four neurotrophins can also activate p75, a 
member of the tumor necrosis family of death receptors, to promote apoptosis (top). 
When both Trk and p75 receptors are present, p75 can enhance neurotrophin signaling 
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through the Trk receptor, enhancing survival (bottom). This figure was adopted from 
(Chao, 2004)  
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Figure 1.2: Mechanism of p75-mediated apoptosis in sympathetic neurons. 
Activation of p75 by proapoptotic ligands such as neurotrophins, proneurotrophins, or 
trophic factor withdrawal (1) initially leads to the recruitment of cytosolic adaptors such 
as NRAGE to the p75 ICD (2), resulting in the activation of JNK (3) and a subsequent 
upregulation of p75 cleavage by the α-secretase TACE (4). TACE cleavage (5) results 
in extracellular shedding of the ECD, thereby beginning the receptor intramembrane 
proteolysis process (Bertrand et al., 2008). Cleavage of the ECD allows for binding and 
further cleavage by the presenilin-dependent γ-secretase (6), liberating the intracellular 
domain (ICD) of p75 into the cytosol for signaling. In the cytosol, the p75 ICD forms a 
bridging complex with neurotrophin receptor-interacting factor (NRIF) and the E3 
ubiquitin ligase TRAF6, where TRAF6 ubiquitinates NRIF (7) causing nuclear 
translocation (8) and transcriptional activation and expression of pro-apoptotic 
mediators, ultimately leading to apoptotic cell death. This figure was adopted from 
Kenchappa et al. (2010).  
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Figure 1.3: The glial cell line-derived neurotrophic factor family ligands exert their 
trophic functions through the receptor tyrosine kinase Ret. 
(A) The GFLs, consisting of GDNF, neurturin (NRTN), artemin (ARTN), and persephin 
(PSPN) act as dimers, first binding to their respective GPI-anchored GDNF family 
Receptor-α co-receptor (GFRα1-4). (B) Formation of the GFL-GFRα complex leads to 
recruitment of Ret into lipid raft domains and formation of a GFL-GFRα-Ret complex, 
leading to Ret dimerization and autophosphorylation of the intracellular tyrosine kinase 
domain, allowing subsequent recruitment of phospho-specific signaling adapters. 
Importantly, Ret has several C-terminal splice variants, conferring isoform-specific 
signaling properties described in greater detail in Chapter 1. This figure was adopted 
from (Mulligan, 2014).  
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CHAPTER 2: A P75-RET SIGNALING COMPLEX REGULATES THE 
ESTABLISHMENT OF POSTNATAL SENSORY NEURON DIVERSITY 
 
Summary 
Producing the neuronal diversity required to adequately discriminate all elements of 
somatosensation is a complex task during organogenesis. The mechanisms guiding this 
process during dorsal root ganglion (DRG) sensory neuron specification remain poorly 
understood. Here we show that the p75 neurotrophin receptor interacts with Ret and its 
GFRα co-receptor upon stimulation with glial cell line-derived neurotrophic factor 
(GDNF). Furthermore, we demonstrate that p75 is required for GDNF-mediated Ret 
activation, survival, and cell surface localization of Ret in DRG neurons. In mice in 
which p75 is deleted specifically within sensory neurons beginning at E12.5, we observe 
that approximately 20% of neurons are lost between P14 and adulthood, and these 
losses selectively occur within a subpopulation of Ret+ nonpeptidergic nociceptors, with 
neurons expressing low levels of Ret impacted most heavily. These results suggest that 
p75 is required for the development of the nonpeptidergic nociceptor lineage by fine-
tuning Ret-mediated trophic support.  
 
Introduction 
 The generation of the diverse array of sensory neurons necessary for 
discriminating all aspects of somatosensation is critical for animals to interact and 
respond to their environment. Sensory neurons in the dorsal root ganglia (DRG) 
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innervate the peripheral tissues of the body below the neck and communicate sensory 
information to higher order neurons within the central nervous system. DRG neurons 
are greatly diversified with respect to their sensory functions, which is mirrored by their 
unique morphological, physiological, and molecular characteristics. Large, medium, and 
small diameter neurons carry proprioceptive stimuli (proprioceptors), tactile stimuli 
(mechanoreceptors) and nociceptive stimuli (nociceptors), respectively. Each of these 
morphologically distinct groups can be further subdivided based on their expression of 
different neurotrophic factor receptors, G protein coupled receptors, ion channels and 
transcription factors. Using these morphological and molecular properties, combined 
together with electrophysiological properties as well as distinctive central and peripheral 
innervation patterns, sensory neurons have been categorized into multiple 
subpopulations (Liu and Ma, 2011).  
In adult mice, nociceptors can be divided into two major populations. One 
population, the peptidergic nociceptors, expresses neuropeptides such as calcitonin 
gene-related peptide (CGRP) and substance P (SP), and the nerve growth factor (NGF) 
receptor, TrkA. CGRP- or SP-negative nonpeptidergic nociceptors, in contrast, express 
the tyrosine kinase Ret and the GFRα co-receptors for the GDNF family ligands. 
Interestingly, the Ret+ nociceptive population of neurons emerges from TrkA-expressing 
neurons in early postnatal development, and the deletion of TrkA results in the complete 
loss of Ret-expressing unmyelinated neurons (Molliver et al., 1997b; Silos-Santiago et 
al., 1995). This Ret-expressing population of nociceptors further differentiates into three 
subclasses of neurons that express specific Mas-related G protein-coupled receptors 
(Mrgpr), namely, neurons that express MrgprA3, MrgprB4 or MrgprD (Dong et al., 2001; 
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Liu et al., 2008).  Recent physiologic studies suggest that these three classes of 
neurons are responsive to pruritogens, the gentle stroking of hair, and noxious 
mechanical stimulation, respectively (Han et al., 2013; Liu et al., 2012; Liu et al., 2007; 
Zylka et al., 2005). One central question in developmental biology is how such neuronal 
diversity is developed and maintained throughout life.  
 The development of sensory neurons in the DRG is regulated by the interplay 
between neurotrophic factors and various transcription factors (Marmigere and Ernfors, 
2007). Recent studies indicate that the expression of transcription factors such as 
Runx1, Runx3, Er81, Shox2, and MafA play significant roles in the diversification of 
DRG neurons (Bourane et al., 2009; Chen et al., 2006; Inoue et al., 2007; Kramer et al., 
2006; Scott et al., 2011). Neurotrophin family members have been shown to support the 
survival of various types of DRG neurons during development. Previous loss–of–
function studies of neurotrophin family members Nerve Growth Factor (NGF), Brain 
Derived Neurotrophic Factor (BDNF), Neurotrophin 3 (NT3) and their respective high-
affinity receptors TrkA, TrkB and TrkC, demonstrated that different sensory neuron 
subtypes require different neurotrophins for their survival. For example, in Ngf-/- and 
TrkA-/- mice, nociceptors are lost (Crowley et al., 1994; Smeyne et al., 1994b), while 
Nt3-/- and TrkC-/- mice lose proprioceptors (Ernfors et al., 1994; Tessarollo et al., 1994), 
and TrkB-/- and Bdnf-/- mice lose mechanoreceptors (Jones et al., 1994; Klein et al., 
1993b).  
 In vitro studies have demonstrated that the GFLs promote the survival and 
axonal growth of various DRG neurons including nociceptive neurons (Molliver et al., 
1997b). In vivo loss–of–function studies on GFLs and GFRαs have shown that they are 
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necessary for the survival of DRG neurons, their proper peripheral projections and cell 
body size (Ernsberger, 2008; Lindfors et al., 2006). The analysis of three different 
conditional Ret mutant mice demonstrated that Ret signaling is important for several 
aspects of DRG neuron development such as cell survival, central and peripheral 
neuronal projection and expression of phenotypical markers (Franck et al., 2011; 
Golden et al., 2010; Luo et al., 2007).  
 The p75 neurotrophin receptor (p75) is a member of the tumor necrosis receptor 
superfamily. p75 binds members of the Trk receptor family and modulates the cell 
survival functions of neurotrophins (Ceni et al., 2014). p75 is highly expressed in 
migrating neural crest cells and most sensory neurons during development.  p75 null 
mice lose approximately 50% of DRG neurons across different sensory neuron 
subtypes, but the mechanism of these deficits is unclear in part due to expression of 
p75 in multiple cell types in the peripheral sensory system including neurons, Schwann 
cells and targets (Lee et al., 1992b). One hypothesis is that neuronal loss is due to an 
impairment in neurotrophin signaling.  Indeed, in vitro experiments have shown that 
sensory neurons isolated from p75 null mutant mice are 2-3 fold less sensitive to the 
survival promoting effect of NGF treatment (Davies et al., 1993b; Lee et al., 1994). In 
addition, in vitro experiments suggest that p75 prolongs the activation of TrkA receptors 
by preventing poly-ubiquitination and degradation of TrkA (Makkerh et al., 2005a). 
These results argue that p75 can serve as a modulator of the neuronal response to 
neurotrophins. Although the role of p75 for modulating neurotrophin signaling is clearly 
established, whether the DRG neuron loss in p75 null mutant mice is due to a lack of 
neurotrophin signaling still remains to be determined.  
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 Here we show that p75 is co-localized with GFRα1, GFRα2 and Ret in a subset 
of DRG neurons. p75 forms a complex with GFRα1, GFRα2 and Ret in vitro and in vivo. 
Removal of p75 from neurons reduced the survival effect of GDNF in vitro and impacted 
a subset of nonpeptidergic nociceptors in vivo, especially those that express low levels 
of Ret. Surprisingly, p75 deletion did not affect TrkA+ or TrkB+ populations of DRG 
neurons. p75, therefore, serves to augment GFL signaling and maintains the balance of 
cell specification and diversity during DRG neuron development.   
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Results 
p75 is expressed in a subset of Ret expressing nociceptive neurons 
 Ret expressing cells in the DRG encompass several neuronal populations 
mediating different sensory modalities. Previous studies have shown that small 
diameter nonpeptidergic nociceptors which mediate pain sensation up-regulate Ret 
expression and down-regulate TrkA expression postnatally. This process is not 
complete until 2-3 weeks after birth (Molliver et al., 1997b). p75 is expressed in a variety 
of DRG neuron subclasses, and germline deletion of p75 results in a 50% loss of DRG 
neurons across different neuronal types (Murray et al., 1999). To determine whether 
Ret-expressing nonpeptidergic nociceptive neurons express p75, immunostaining was 
performed on postnatal day 14 (P14) L4 DRG sections with antibodies against p75, Ret, 
GFRα1 and GFRα2. As shown in Figure 2.1B, 2.1E and 2.1H, small diameter 
nonpeptidergic nociceptors are Ret+ and most of them are also immunopositive for 
GFRα1 or GFRα2. p75 expression overlapped with some small diameter neurons that 
are immunopositive for Ret, GFRα1 or GFRα2 (Figures 2.1C, 2.1F, and 2.1I). When we 
counted neurons that were immunopositive for both p75 and Ret, we found that ~23.8% 
of small diameter Ret+ cells are also p75+ (Figure 2.1J). Previous studies have also 
shown that Ret+ nociceptive neurons have different levels of Ret expression and can be 
divided into groups that express a high level of Ret (Rethigh neurons) and a low level of 
Ret (Retlow neurons), each group with their own characteristic markers (Zylka et al., 
2003). When we investigated the co-localization of p75 with Ret in small diameter 
Rethigh (as indicated by arrows in Figure 2.1A-C) and Retlow neurons (as indicated by 
arrowheads in Figure 2.1A-C), we found that among Rethigh neurons, only 22.1% co-
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express p75, while 67.6% of Retlow neurons express p75 (Figure 2.1J). The specificity of 
Ret staining was confirmed by staining sensory neurons taken from tamoxifen (TMX)-
labeled Rosa26LSL-tdTomato/+; Ret-Cre/ERT2 mice (Figure 2.2). These results suggest that 
p75 is in position to regulate the development of a subset of Ret+ nociceptive neurons, 
and its role may be more significant in Retlow sensory neurons.  
 
p75 is a component of the GFRα/Ret receptor complex 
 To investigate potential interactions between p75 and the components of the 
GDNF receptor complex, namely GFRα1 and Ret, we stained primary cultures of 
dissociated DRG neurons with antibodies against p75 and GFRα1. As shown in Figure 
2.3A, punctate staining of p75 is often co-localized with GFRα1, although non-
overlapping labeling exists. Based on these findings, we next explored whether a 
functional interaction exists between p75 and GFRα1 and Ret. p75 was co-expressed 
with GFRα1 or Ret in HEK-293 cells and a co-immunoprecipitation assay was 
performed. As shown in Figures 2.3B and 2.3C, p75 co-immunoprecipitates with GFRα1 
and Ret. GDNF treatment enhanced the association of p75 with GFRα1. On the other 
hand, GDNF had no effect on the association of p75 with Ret when myc-tagged p75 
was co-expressed with Ret alone in HEK293 cells. Quantification of the western blot 
signals from 3 independent experiments showed that no statistically significant changes 
in the amount of normalized Ret in the immuoprecipitates in the presence of GDNF as 
compared to no GDNF pulled down by an anti-myc antibody (fold change +GDNF/-
GDNF=1.17, p=0.19) or an anti-p75 antibody (fold change +GDNF/-GDNF=1.08, 
p=0.58). The amount of normalized p75 in the immuoprecipitates pulled down by an 
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anti-Ret antibody is also unchanged with GDNF treatment (fold change +GDNF/-GDNF 
= 0.86, p=0.43). This is likely due to the lack of GFRα1 expression. To determine 
whether p75 forms a complex with GFRα1 under physiological conditions in vivo, co-
immunoprecipitation assays were performed using lysates from superior cervical 
ganglia (SCG). We found that p75 and GFRα1 were able to be co-immunoprecipitated 
regardless of which protein was isolated by IP (Figure 2.3D). To determine the time 
course of the interaction between p75 and Ret, primary DRG neuron cultures were 
generated from P0 rats and maintained in culture for 7-10 days. Importantly, DRG 
neurons cultured under similar conditions were previously shown to develop in a 
manner comparable to their in vivo development regarding the expression of ion 
channels and neurotrophic factor receptors (Molliver et al., 1997). 7-10 DIV DRG 
neurons were stimulated with GDNF for the indicated times, followed by 
immunoprecipitation of Ret and immunoblotting for p75 and Ret. Interestingly, we 
observed that GDNF led to a statistically significant increase in p75-Ret association at 
15 minutes, 1 hour, and 6 hours (Figure 2.3E-F) after stimulation.  These results 
suggest that p75 forms a complex with GFL receptor components that mediate GFL 
signaling. 
 
p75 augments GDNF-mediated Ret activation by increasing cell surface 
localization of Ret 
 To determine whether p75 modulates GDNF-induced Ret autophosphorylation, 
primary DRG neuron cultures were generated from p75 conditional knockout mice 
(p75F/F), followed by infection with HSV-expressing Cre to knockdown their expression 
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of p75, or with HSV-expressing GFP alone as a control. The cultures were then treated 
with GDNF, followed by immunoprecipitation to assess the level of phosphorylated Ret 
using an anti-phosphotyrosine antibody. As shown in Figure 2.4A, GDNF induces a 
rapid phosphorylation of Ret, which is sustained above baseline for at least 60 minutes. 
Transduction of primary DRG neurons with HSV-GFP-Cre resulted in successful 
knockdown of approximately 80% of p75 compared to HSV-GFP-transduced neurons 
(Figure 2.4A-B). Following knockdown of p75, GDNF-induced Ret phosphorylation is 
dramatically reduced at both 15 minutes and 60 minutes following GDNF treatment 
(Figure 2.4A, 3C). These results suggest that p75 augments GDNF-mediated Ret 
activation.  
 Given the striking loss of GDNF-mediated Ret activation, we hypothesized that 
loss of p75 may result in changes of cell surface localization of Ret. To explore this 
possibility, we first transfected NIH/3T3 cells with Ret9 or Ret51, with or without p75 co-
transfection. Cell surface proteins were biotinylated using NHS-LC-Biotin and 
precipitated using neutravidin. Interestingly, we observed that co-transfection of p75 
with Ret9 and Ret51 significantly enhanced cell surface levels of both isoforms (Figure 
2.4D). To test whether p75 plays a similar role in DRG neurons, we performed cell 
surface biotinylation experiments in HSV-treated p75F/F DRG neurons. We observed a 
striking reduction in the amount of total cell surface Ret using an antibody that detects 
both isoforms, as well as a reduction of both individual Ret9 and Ret51 isoforms in 
HSV-Cre treated neurons compared to HSV-GFP controls (Figure 2.4E, quantifications 
in 2.4F, 2.4G).  
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p75 is required for GFL-mediated survival of Ret+ nonpeptidergic nociceptors in 
vitro 
Given that p75 is required for GDNF-mediated Ret activation, we sought to 
determine whether the loss of p75 impacted GFL-mediated DRG neuron survival. 
Further, because TrkA+ peptidergic nociceptors selectively depend on NGF, while Ret+ 
nonpeptidergic nociceptors depend on GDNF and NRTN (Molliver et al., 1997b; Snider 
and Silos-Santiago, 1996), we hypothesized that p75 deletion would selectively impair 
GFL-mediated survival within the nonpeptidergic nociceptor population. To this end, we 
crossed p75F/F mice with UBC-Cre/ERT2 mice, in which a tamoxifen (TMX)-inducible Cre 
is driven by the ubiquitin C promoter expressed in all cells (generating p75-WT and p75-
cKO neurons) (Ruzankina et al., 2007), or Ret-Cre/ERT2 mice, in which TMX induces 
recombination selectively within Ret+ neurons (generating p75-WT and p75-RC 
neurons) (Luo et al., 2009). DRG neurons were cultured in the presence of NGF and 4-
hydroxy-TMX to induce recombination. Importantly, we observed a substantial 
knockdown of p75 in p75-cKO neurons compared to p75-WT (p < 0.0001; greater than 
98% reduction; Figures 2.5A-B). No changes were observed in the total amount of TrkA 
(Figure 2.5A, 2.5C) or Ret (Figure 2.5A, 2.5D) protein levels, further validating this 
system. Due to the difficulty of detecting GFRα1 and GFRα2 protein levels by western 
blotting in cultured DRG neurons, we performed immunostaining to determine whether 
loss of p75 alters the proportion of GFRα1 or GFRα2 neurons. While we observed no 
difference in the proportion of GFRα1+ neurons (p = 0.2723), a small but statistically 
significant reduction in the proportion of GFRα2+ neurons was observed (p = 0.0103; 
p75-WT: 80.12 ± 1.32 and p75-cKO: 66.76 ± 4.34%; Figure 2.6C-D).  
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To fully characterize how p75 deletion alters Ret and TrkA expression, we next 
treated 7-10 DIV, TMX-maintained p75-WT and p75-cKO DRG neurons with NGF, a 
NGF blocking antibody (αNGF), αNGF and GDNF, or αNGF and NRTN. 48 hours later, 
p75-WT and p75-cKO DRG neurons were fixed and immunostained for DAPI, TuJ1 (a 
pan-neuronal marker), Ret, and TrkA. The number of TrkA+/Ret- and Ret+/TrkA- neurons 
were quantified in each condition. As expected, we observed no genotype-dependent 
differences in the number of TrkA+ neurons regardless of treatment condition (Figure 
2.6A), although we did observe a significant reduction of TrkA+ neurons following NGF 
deprivation, as expected (Snider and Silos-Santiago, 1996). Interestingly, the proportion 
of Ret+ neurons was increased in p75-cKO compared to p75-WT neurons treated with 
αNGF, αNGF and GDNF, and αNGF and NRTN, but not in NGF-maintained neurons. 
Additionally, as expected, we observed a drastic increase in Ret+ neurons following 
NGF-deprivation regardless of genotype (p < 0.0001 for all genotypes) (Figure 2.6B). 
Collectively, these data indicate that removal of p75 does not substantially alter levels of 
TrkA, but enhances upregulation of Ret following NGF deprivation. 
To determine whether loss of p75 altered GFL-mediated survival of TrkA+ 
peptidergic or Ret+ nonpeptidergic neurons, p75-WT and p75-cKO neurons were 
treated as described above and the number of apoptotic Ret+ (Figure 2.5E) and TrkA+ 
(Figure 2.5F) neurons was quantified by counting pyknotic nuclei. As expected, NGF 
deprivation led to an increase in the number of apoptotic neurons (Figures 2.5E-F) 
regardless of genotype. GDNF and NRTN treatments were able to partially rescue Ret+ 
neurons from apoptosis (Figure 2.5E; p < 0.001 for each), and this rescue affect was 
substantially diminished in p75-cKO (p < 0.0001 for each). As expected, GDNF and 
64 
 
NRTN were not able to rescue TrkA+ neurons and loss of p75 had no effect (Figure 4F). 
To further substantiate these findings, these experiments were repeated using DRG 
neurons cultured from p75-RC, or p75-WT littermate mice. Interestingly, we observed 
that GDNF and NRTN were each able to rescue Ret+ neurons from apoptosis in p75-
WT (p < 0.0001), but not p75-RC neurons, with a corresponding increase in apoptosis 
observed in p75-RC neurons treated with αNGF and GDNF (p < 0.01), and αNGF and 
NRTN (p < 0.001) compared to p75-WT neurons (Figure 2.5G). Additionally, as 
expected, GFL treatment did not rescue TrkA+ neurons from apoptosis, and no 
genotype-dependent effects were observed in TrkA+ neurons (Figure 2.5H). 
Collectively, these results indicate that p75 functions specifically to augment the GFL-
mediated survival of Ret+ DRG neurons.  
 
 Removal of neuronal p75 expression induces a loss of 20% of adult DRG 
neurons  
 Based on our findings that p75 is necessary for GFL-mediated survival of DRG 
neurons in vitro, we asked whether it plays similar roles in vivo. Previous studies 
analyzing p75 germline knockout mice have demonstrated that 50% of DRG neurons 
are lost, and these losses occur across sensory modalities (Lee et al. 1992). It is 
unclear, however, whether this drastic phenotype reflects a cell-autonomous 
requirement for p75 within sensory neurons themselves. Thus, we generated p75F/F 
mice (described in Experimental Procedures, Figure 2.7) and crossed them with an 
Islet1-Cre driver that expresses Cre in spinal motor and sensory neurons at later stages 
(Srinivas et al., 2001). Grossly, Isl1-Cre+/-; p75F/F mice are indistinguishable from their 
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littermates. To determine at what age p75 is deleted in these animals, p75 
immunostaining was performed on E10.5, E12.5, and adult Isl1-Cre+/-; p75F/F mice 
(compared to p75F/F controls). We observed no reduction of p75 immunolabeling at 
E10.5 (Figure 2.8A, 2.8D), but a drastic loss of p75 by E12.5 (Figure 2.8B, 2.8E). At 
both E12.5 and adulthood (Figure 2.8C, 2.8F), the vast majority of neurons have lost 
p75 immunolabeling, with primarily non-neuronal cells expressing the residual p75. 
Therefore, Isl1-Cre+/-; p75F/F mice lose neuronal p75 expression between E10.5 and 
E12.5. To determine whether neuronal survival is altered in the Isl1-Cre+/-; p75F/F mice, 
we performed Nissl staining and counted total cell numbers in L4 DRGs from Isl1-Cre+/-; 
p75F/F (and p75F/F control) mice at P1, P14 or adulthood. As a control, we also analyzed 
L4 DRG counts in p75 germline knockout mice. As expected, we observed a 50% 
reduction in P1 p75-/- DRGs compared to p75+/+ controls (Figure 2.8G). Strikingly, given 
the drastic results observed in P1 p75-/- mice, we observed no difference in total L4 
DRG neuron numbers at P1 or P14 in Isl1-Cre+/-; p75F/F mice (Figure 2.8G). We did, 
however, observe that approximately 20% of DRG neurons were lost in adult Isl1-Cre+/-; 
p75F/F mice compared to p75F/F controls (Figure 2.8G). Collectively, these results 
indicate that neuron-specific deletion of p75 by E12.5 is insufficient to impact neuronal 
survival during embryogenesis, and suggest neuronal p75 functions postnatally in 
sensory neuron diversification. 
 
Removal of p75 does not alter the generation of Ret+ or Runx1+ neurons 
 Loss of NGF-TrkA signaling in a Bax-/- background (thereby preventing 
apoptosis) results in significantly reduced levels of Ret, as well as reduced levels of the 
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transcription factor Runx1 (Luo et al., 2007). Given that p75 has also been shown to 
enhance NGF signaling through TrkA, we tested whether the generation of Ret+ or 
Runx1+ neurons is affected in Isl1-Cre+/-; p75F/F mice. Upon immunostaining P14 DRG 
neurons for Ret or Runx1, we observed no differences in the intensity of 
immunostaining (Figure 2.8H-I, 2.8K-L) or in the total number of Runx1+ and Ret+ 
neurons in Isl1-Cre+/-; p75F/F compared to p75F/F control mice (Figure 2.8J, 2.8M), 
suggesting that the removal of p75 does not impact the NGF-TrkA-Runx1 signaling axis, 
thereby not altering subsequent Ret expression. We further characterized the 
expression level of TrkA, TrkB, GFRα1 and GFRα2 at P0, P14 and adult DRGs. There 
is no obvious difference in any of these markers between Isl1-Cre+/-; p75F/F mice and 
controls at P0 and P14 (Figures 2.9 and 2.10). These results suggest that loss of p75 in 
the Isl1-Cre+/-; p75F/F mice does not impact the expression level of TrkA, TrkB, or the 
relevant GFL co-receptors while Ret+ nonpeptidergic nociceptors are being generated.  
  
p75 is required for survival of a subset of nonpeptidergic nociceptors 
Given that we observed losses of approximately 20% of DRG neurons, and our 
in vitro findings linking p75 to GFL-Ret signaling, we hypothesized that nonpeptidergic 
nociceptors were selectively lost in adult Isl1-Cre+/-; p75F/F mice. To answer this 
question, adult p75F/F and Isl1-Cre+/-; p75F/F L4 DRG neurons were immunostained for 
NF200 (mechanoreceptors and proprioceptors), CGRP (peptidergic nociceptors), 
paravalbumin (proprioceptors), and IB4 (nonpeptidergic nociceptors). Interestingly, we 
observed no difference in the number of CGRP+ (Figure 2.11A, E), Parvalbumin+ 
(Figure 2.11B, F), or NF200+ (Figure 2.11D, H) neurons between Isl1-Cre+/-; p75F/F and 
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p75F/F mice (Figure 2.11O). In contrast, we observed a 35% decrease in IB4+ neurons 
(Figure 2.11C, 2.11G, 2.11O), indicating that p75 is selectively required for the survival 
of a subset of nonpeptidergic nociceptors. Given that the IB4+ immunolabeling may not 
sufficiently label all nonpeptidergic nociceptors, we sought to corroborate these results 
by performing co-immunostaining for peripherin and Ret to count the number of small 
diameter Ret+ nociceptors (Figure 2.11I-N). As shown in Figure 2.11-O, we observed a 
25% decrease in the total number of peripherin+/Ret+ neurons. We also observed ~30% 
decrease in the GFRα2+ population (Figure 2.10C, F and G) and ~50% decrease in 
small diameter GFRα1+ population (Figure 2.9J, M and N). Collectively, these results 
indicate that p75 is selectively required to promote the survival of nonpeptidergic Ret+ 
neurons, although we cannot rule out the possibility that p75 has additional functions in 
other unexplored subpopulations. 
 To further characterize the neuron loss within the IB4+ population, we performed 
in situ hybridization using probes against MrgA, MrgB, and MrgD on adult (6 month old) 
L4 DRG sections (Dong et al., 2001). Importantly, MrgA+ and MrgB+ neurons are known 
to express Ret weakly (Retlow), while MrgD+ neurons express Ret more strongly (Rethigh) 
(Zylka et al., 2003). Interestingly, compared to p75F/F mice, we observed that Isl1-Cre+/-; 
p75F/F DRGs had a greater than 50% reduction in MrgA+ (Figure 2.12A, D and G) and 
MrgB+ neurons (Figure 2.12B, E and H), while only 27% of MrgD+ neurons were lost 
(Figure 2.12C, F and I).  We cannot rule out the possibility that the loss of p75 in DRG 
neurons causes downregulation of Mrg family gene expression, as previous studies 
have shown a dependence on Ret signaling (Luo et al., 2007). Nonetheless, these data 
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are consistent with the model that the p75-dependence of Ret+ neurons is correlated 
with the level of p75 expression in the Retlow and Rethigh neurons.   
 
  
 
  
69 
 
Discussion 
 In this study, we demonstrate that p75 forms a GDNF-activated receptor complex 
with GFRα1 and Ret. Furthermore, knockdown of p75 levels within DRG neurons 
resulted in a drastic impairment in GDNF-mediated Ret activation, and a subsequent 
loss of cell surface localization of Ret, suggesting that p75 potentiates GDNF-Ret signal 
transduction through enhancing receptor availability to ligand, or by enhancing 
recycling. Correspondingly, p75 deletion results in a substantial reduction in GDNF and 
NRTN-mediated survival of Ret+ nonpeptidergic neurons, but not TrkA+ peptidergic 
neurons. Strikingly, especially when considering the 50% loss of DRG neurons during 
embryonic development in p75 germline null mutants, neuron-specific deletion of p75 by 
E12.5 resulted in no embryonic deficits. In these animals, 20% of neurons were lost 
postnatally, with losses occurring selectively within the IB4+/peripherin+/Ret+ class of 
nonpeptidergic nociceptors during the transition from P14 to adulthood. MrgA+ and 
MrgB+ neurons expressing the lowest levels of Ret had the highest degree of p75 
expression, and were more significantly affected than Retlow MrgD+ neurons. In light of 
these findings, we propose the following model to explain the role of p75 modulation of 
Ret signaling in the survival of adult DRG neurons (Figure 2.12J). The expression of 
p75 increases the level of Ret on the cell surface in p75F/F mice, increasing sensitivity of 
these neurons to GDNF, thereby potentiating GFL-induced Ret activation and 
downstream survival. Upon loss of p75 expression in Isl1-Cre+/-; p75F/F mice, the level of 
Ret on the cell surface is reduced. Rethigh MrgD+ neurons may be better able to 
compensate for the loss of p75, resulting in lower neuron losses. However, in Retlow 
MrgA+ or MrgB+ neurons, the loss of cell surface Ret cannot be adequately buffered, 
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leading to more substantial losses within the MrgA+ and MrgB+ neuron population. This 
model highlights the ability of p75 to fine-tune Ret signaling and maintain the balance of 
different types of DRG neurons in postnatal development. Our findings further expand 
the repertoire of receptor complexes that p75 modulates and the developmental 
processes that p75 impacts. 
 The developmental diversification of DRG neurons is an intricate process 
regulated by transcription factors and growth factors. Different types of sensory neurons 
rely on specific neurotrophic factors for their survival as they differentiate and mature. 
The p75 receptor can modulate both neurotrophin and GFL signaling pathways, playing 
a significant role in the development and maintenance of DRG neuron diversity. In p75 
knockout mice, 50% of lumbar DRG neurons are lost by the first week of postnatal life 
(Figure 5G) (Murray et al., 1999). This loss is across all DRG neuronal types and occurs 
early during embryonic DRG development. In Isl1-Cre+/-; p75F/F mice, p75 expression is 
removed at E12.5 specifically within nearly all sensory neurons, yet no neuronal deficits 
are observed before P14, and only 20% of the total neurons are lost in adult Isl1-Cre+/-; 
p75F/F mice. The striking disparity between neuronal losses in germline p75 knockout 
mice compared to Isl1-Cre+/-; p75F/F mice suggests that the early deficits in p75 
knockout mice may be due to its function in non-neuronal cells. For example, previous 
studies have indicated that p75 is expressed in neural crest stem cells, which give rise 
to DRG neurons, satellite cells in the DRG, and Schwann cells. Given that germline p75 
knockout animals lack p75 expression in all cell types from the onset of development, 
the previously observed loss of 50% of neurons across DRG subtypes may be due to 
defects in neural crest progenitors. Another possibility is that removing p75 from satellite 
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cells and Schwann cells may create a less supportive environment for the survival of 
DRG neurons. While we cannot rule out the possibility that the small amount of p75 
remaining following Islet1-Cre mediated deletion is responsible for the differences 
observed between germline p75 knockout mice and Isl1-Cre+/-; p75F/F mice, previous 
studies have also suggested a non-neuronal role for p75 early in sensory neuron 
development. For example, migration of p75-deficient Schwann cells is impaired and 
may thereby contribute to a reduced ability of developing sensory neurons to reach their 
proper target cells (Bentley and Lee, 2000). Nevertheless, the results reported here 
indicate that p75 has a postnatal function specifically serving to augment Ret signaling 
in nonpeptidergic nociceptors.  
Another unexpected finding of this study is that p75 expression is required for the 
survival of nonpeptidergic nociceptors, but not other neuronal populations. In our 
analysis of Isl1-Cre+/-; p75F/F mice, we observed no deficits in the number of CGRP+ 
peptidergic nociceptive neurons, nor is their survival impaired in vitro, despite the fact 
that p75 is expressed in the majority of CGRP+ neurons and p75 expression is removed 
in most CGRP+ neurons in Isl1-Cre+/-; p75F/F mice at a developmental period during 
which these neurons are highly dependent on NGF/TrkA signaling (Figure 2.13). In 
addition, we observed no deficits in numbers of TrkA+, Runx1+, Ret+, GFRα1+, or 
GFRα2+ neurons at P14. These results are surprising because p75 has been shown in 
many studies to enhance NGF signaling via TrkA through increased NGF binding 
affinity (Esposito et al., 2001; Hempstead et al., 1991), as well as through reduced 
ubiquitination and subsequent degradation of TrkA (Makkerh et al., 2005a). The pro-
survival function of p75 in sensory neurons has been proposed by many (Davies et al., 
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1993b; Lee et al., 1994) to be through modulation of NGF/TrkA signaling. Based on 
these results, we conclude that the intrinsic level of NGF signaling is sufficient to 
maintain their survival and, therefore, p75 is dispensable for NGF/TrkA-dependent 
survival of peptidergic neurons, although the trophic status of these neurons may still be 
impacted.  
 In conclusion, we have found that p75 physically associates with receptors in the 
GDNF family and plays a novel role in mediating the survival-promoting effects of the 
GFLs by enhancing cell surface localization of Ret, thereby augmenting GFL/GFRα/Ret 
signaling. Surprisingly, in vivo, deletion of p75 specifically within neurons resulted in no 
deficits until after P14, suggesting a potential early, non-neuronal role for p75 followed 
by a postnatal, neuron-specific function in nonpeptidergic nociceptors. Within the 
nonpeptidergic nociceptor population, neurons of the MrgA+ and MrgB+ subclasses 
demonstrate a greater dependence on p75 to potentiate Ret signaling compared to 
MrgD+ neurons. Thus, our data clarify the function of this enigmatic receptor in sensory 
neurons and identify a unique mechanism by which neurotrophic factor support can be 
fine-tuned to allow the selective survival of discrete subpopulations, ultimately 
expanding sensory neuron diversity. 
 
Experimental Procedures 
Animals 
 All experiments were carried out in compliance with the guidelines of the 
Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). 
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For the generation and characterization of p75F/F mice, one loxP site was inserted into 
the intron region between exon II and exon III of the p75 gene while the other loxP site 
was inserted into the intron region between exon III and exon IV, and is detailed further 
below (Figure 2.7). Detailed biochemical and anatomical analyses showed that p75F/F 
mice are a good model to study p75 function. For the in vitro studies investigating the 
role of p75 in Ret signaling in primary DRG neuron cultures, p75F/F mice generated and 
described by Bogenmann et al. were utilized. Characterization of these mice 
(Bogenmann et al., 2011a) indicates that they exhibit the same phenotypes as the 
p75F/F mice described above. Islet1-Cre mice were previously described and shown to 
induce Cre mediated recombination at around E12.5 (Srinivas et al., 2001). Ret-
Cre/ERT2 and UBC-Cre/ERT2 mice were previously characterized (Luo et al., 2007; 
Ruzankina et al., 2007). 
Staining of Sensory Neurons from Adult Rosa26LSL-tdTomato; Ret+/+ and Rosa26LSL-
tdTomato; Ret-Cre/ERT2 mice 
 For the experiments demonstrating the specificity of Ret immunostaining, 
tamoxifen (TMX; T5648, Sigma Aldrich, St. Louis, MO) was dissolved in corn oil and 
administered via intraperitoneal injection to adult mice of the indicated genotypes at a 
dose of 0.25 mg/g body weight for five consecutive days. Mice were then euthanized, 
perfused with 4% PFA, and trigeminal ganglia were collected, post fixed in 4% PFA for 
1 hour and cryoprotected with 30% sucrose overnight. 10μm cryosections were 
obtained and stained with a goat-anti-Ret (R&D, 1:50), rabbit anti-RFP (Rockland, 
1:200), and Tuj1 (Sigma, 1:200). As an additional control, staining using goat anti-Ret 
was conducted in the presence of a blocking peptide to ensure specificity (Alomone 
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Labs, 1:50). Donkey anti-mouse 488, donkey anti-rabbit 543, and donkey anti-goat 633 
secondary antibodies (Biotium, 1:200) were used.  
 
In situ Hybridization and Immunohistochemistry 
 In situ probes for MrgA1, MrgA3, MrgB4, MrgD and Ret were kindly provided by 
Dr. Xinzhong Dong (Johns Hopkins University). The in situ probe for p75 was provided 
by Mark Bothwell (University of Washington). Digoxigenin (DIG) and fluorescence-
labeled cRNA probes were used for in situ hybridization. For immunohistochemistry on 
cell culture and frozen DRG sections, the following antibodies were used: rabbit anti-
p75 (a gift from Dr. Moses Chao, 1:500), goat anti-GFRα1 (R&D, 1:100), goat anti-
GFRα2 (R&D, 1:100), Goat anti-Ret (R&D, 1:50), rabbit anti-Ret (Santa Cruz, 1:100), 
rabbit anti-Runx1 (1:1000, a gift from Dr. Tom Jessell), rabbit anti-CGRP (Immunostar, 
1:500), rabbit anti-parvalbumin (Swant, 1:1000), chicken anti-TrkB (1:500), rabbit anti-
peripherin (Novusbio 1:1000) and Rabbit anti-NF200 (Millipore, 1:500). Alexafluor-546 
and Alexafluor-488 conjugated secondary (Molecular Probes, 1:500) antibodies were 
used. For IB4 staining, FITC conjugated IB4 (Invitrogen, 1:100) was used. 
Generation of p75 Conditional Mutant Mice  
 The p75 floxed (p75F/F) mice were generated using standard methods. A 
targeting vector was constructed by introducing a loxP site into an EcoRV site in intron 2 
and a neomycin resistance marker (neo) flanked by loxP sites into an XbaI site in intron 
3. The targeting construct was electroporated into ES cells and G418 resistant ES 
clones were screened by Southern Blotting analysis. When the DNA was digested with 
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EcoRI, the probe hybridized to a 5kb band for the targeting allele (T) and a 14kb band 
for the wild type allele (+). ES cell clones containing the targeted (T) allele were isolated 
and transfected with plasmids expressing Cre recombinase under the control of the 
CMV promoter. ES cell clones in which the neor-cassette was removed but maintained 
two LoxP sites were isolated. This is called the floxed (F) allele. In the recombined allele 
(R), the neor-cassette and the third exon are removed and only one LoxP site is 
retained.  P75 floxed animals were crossed with a line of nestin-Cre transgenic mice. 
Brain DNA was isolated from P0 mice, digested with EcoR I and hybridized with the 
probe. Nearly complete recombination occurred in mice containing floxed alleles and 
the nestin-Cre transgene (F/R; Cre +).  Because the nestin-Cre transgenic mice used in 
this experiment have leaky Cre expression in the germ cells, germline recombination of 
the floxed allele can occur. Germline recombination only one allele (R) occurs in mice 
whose parents carry a floxed allele and the nestin-Cre transgene, even if they no longer 
express Cre (F/R; Cre -). No recombination of the floxed allele occurs in the absence of 
Cre expression (F/F; Cre -). Immunofluorescence staining of coronal sections of the 
septum with anti-p75 antibodies revealed that no p75 proteins are detected in mice 
containing the floxed allele and the nestin-Cre transgene (F/F, Cre +). To test if p75-s 
transcripts (spliced product of exon II to exon IV) described by von Shack et al. (von 
Schack et al., 2001) are present in the conditional mutant animals, reverse transcription 
coupled-PCR (RT-PCR) was used to assay the mRNA isolated from mice containing 
recombined alleles (R/R), alleles with neo-cassette insertions into exon III of original 
p75 mutants  (-/-) (Lee et al., 1992b), floxed alleles (F/F) or wild type alleles (+/+). No 
p75-s transcripts were detected using primers and PCR conditions previously described 
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by von Shack et al. (von Schack et al., 2001). Because the 5’ primer used by von Shack 
et al. is consisted of two 10-neucleotides complimentary to the end of exon II and the 
beginning of exon IV, respectively, the primer presumably only detected the spliced 
product of exon II to exon IV. However, we found that the primer set used by von Shack 
et al. was able to detect any transcripts containing axon IV, including the full-length 
cDNA. Although we do not know the basis for the lack of specificity, we noticed that the 
primer set is highly GC-rich. It is worth mentioning that Paul et al. recently demonstrated 
that the mutated p75 allele created by von Shack et al. gave rise to an alternatively 
spiced transcript (Paul et al., 2004), but not in the p75 mutants we generated previously. 
Over-expression of this spliced product increases cell death (Paul et al., 2004) and may 
contribute to the phenotype observed in that line of mutant mice. Isl1-Cre mice were a 
generous gift from Dr. Thomas Jessell. 
 
Cell Counts 
 Animals at the indicated ages were perfused with 4% PFA and L4 DRGs were 
isolated, postfixed in 4% PFA for 1 hour and then followed by cryprotection in 30% 
sucrose overnight. 10μm serial cryosections were made through the entire DRG. For 
total neuron counts, sections were stained with 0.5% cresyl violet and cells with visible 
nucleoli were counted as neurons. 
 
Cell Culture and Transfection of Immortalized Cell Lines 
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 NIH/3T3 cells were maintained in DMEM supplemented with 10% fetal bovine 
serum (FBS), 2 mM glutamine, and 1% penicillin-streptomycin (Invitrogen, Carlsbad, 
CA). HEK293 cells were maintained in DMEM supplemented with 10% FBS and 1% 
penicillin-streptomycin (Cellgro). For all biochemistry experiments, cells were plated 
onto 6-well tissue culture plates and allowed to proliferate to a density of 50% 
confluence prior to transfection. Transfections of NIH/3T3 cells were performed using 
Lipofectamine 2000 according to the manufacturer’s instructions (Invitrogen). In all 
NIH/3T3 transfection experiments, a total of 5 μg plasmid DNA was added per well, 
using a plasmid encoding GFP to keep the total amount of DNA constant between 
treatments. In all HEK293 transfection experiments, a total of 2μg of DNA was added 
per well, using a plasmid encoding GFP to keep the total amount of DNA constant. The 
mammalian expression plasmid encoding p75 was generously provided by Phil Barker.  
 
Production of Dorsal Root Ganglion Neuron Cultures and Neuron Survival Assays 
 Primary cultures of DRG neurons were produced as described previously (Tsui 
and Pierchala, 2010).  Briefly, DRG neurons were isolated from E19-P1 Sprague-
Dawley rats (Charles River, Portage, MI) and P0 p75F/F mice (Bogenmann et al., 2011a) 
crossed to the Cre strains described throughout. DRGs were enzymatically dissociated 
via incubation with collagenase (Worthington) followed by TrypLE (Invitrogen). Neurons 
were plated on gas-plasma treated 35 mm2 dishes (Harrick Plasma; Ithaca, NY) coated 
with 20% growth factor-reduced matrigel in DMEM (BD Biosciences, San Jose, CA). For 
all biochemical experiments, neurons were plated as mass cultures at a density of 40-
50 ganglia per plate. For death assays, neurons were plated as a droplet at a density of 
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10-15 ganglia per plate. Neurons were maintained in minimum essential medium (MEM) 
containing 50 ng/ml NGF (Harlan), 10% (FBS), the antimitotic agents 3.3 μg/ml 
aphidicolin and 5-fluoro-2-deoxyuridine (20 μM; Sigma, St. Louis, MO), 2 mM glutamine, 
and 1% penicillin-streptomycin (Invitrogen, Carlsbad, CA). For death assays, neurons 
were treated as described in the figure legends, fixed 48 hours post-treatment in 4% 
paraformaldehyde, and coverslipped with DAPI-fluoromount-G. GFP+ neurons were 
analyzed to identify pyknotic nuclei, a known morphological feature of apoptotic cell 
death. For the experiments utilizing TMX-dependent Cre drivers, both control and Cre+ 
neurons were maintained in the presence of 0.5 µg/ml 4-OH-TMX (Sigma). 
 
Immunoprecipitation and Quantitative Immunoblotting 
 Cells were treated as indicated in the figure legends. Following treatment, the 
dishes were placed on ice, gently washed with PBS, pH 7.4, and lysed with 
immunoprecipitation buffer (Tris-buffered saline (TBS), pH 7.4, 1% Nonidet P-40, 10% 
glycerol, 500 µM sodium vanadate, and protease inhibitors) as described previously 
(Tsui and Pierchala, 2010). Anti-Ret51 and/or anti-Ret9 antibodies were added (8 µL; C-
20 and C-19-G, respectively; Santa Cruz Biotechnology) to cleared extracts along with 
protein A and protein G (Invitrogen, Carlsbad, CA) and incubated overnight at 4°C with 
gentle agitation.  Immunoprecipitates were then washed three times with IP buffer and 
the complexes were prepared for sodium dodecyl sulfate-polyacrylate gel 
electrophoresis (SDS-PAGE) by adding 2X sample buffer (TBS, pH 6.8, 10% glycerol, 
4% SDS, 10% -mercaptoethanol and 0.02% bromophenol blue) and boiling the 
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samples for 10 minutes. Immunoblotting was performed as described in the 
Supplementary Experimental Procedures.  
 
Cell Surface Biotinylation Assays 
 Cell surface biotin labeling was used to distinguish cell surface proteins from 
intracellular proteins. Cells were treated as described in the figure legends and then 
cooled to 4°C to stop membrane traffic. Cells were washed thrice with ice-cold PBS and 
labeled with 2 mM EZ-Link NHS-LC-Biotin (in PBS; Pierce, Rockville, IL) for 20 minutes, 
followed by a second 20 minute incubation with fresh biotinylation reagent. The cells 
were then washed, and any remaining NHS-LC-Biotin was inactivated with two 20-
minute incubations in TBS.  Cells were then washed again with PBS and detergent 
extracted using a modified RIPA buffer (Tris, pH 7.4, 100 mM NaCl, 10% glycerol, 1% 
Triton X-100, 0.1% SDS, protease inhibitors, and 500 µmol/L sodium vanadate).  
Biotinylated proteins were precipitated with immobilized Neutravidin (Pierce) in an 
identical manner as the immunoprecipitations described above, and immunoprecipitates 
and supernatants (containing intracellular proteins) were then prepared for SDS-PAGE 
and immunoblotting. 
 
Statistics: 
 Statistical tests were carried out by using GraphPad Prism (GraphPad Software); 
statistical tests used are indicated throughout the results section. A student’s t-test was 
used to assessing statistical significance between two conditions, while one-way 
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ANOVA was utilized when multiple variables were compared. All data are reported as 
the mean ± s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001, ****p <0.0001. 
 
Cell Counts on Immunofluorescently Stained DRGs 
For neurons expressing various markers, sections were immunofluorescently stained 
with various antibodies and double stained with DAPI. Immunopositive cells with intact 
nuclei were counted. To count Rethigh and Retlow neurons, images of Ret 
immunofluorescence staining of DRG sections were taken using the same camera 
parameters and batch processed using Photoshop. Then the fluorescence intensity of 
Ret staining was surveyed by looking at the brightness reading of the cell bodies using 
Photoshop and compared with the Ret negative cells in the same section. After the 
survey of all the pictures, we found the fluorescence signal for Ret negative cells in the 
same section was around 100. Thus, a criterion was set to classify any cells with 
brightness reading higher than 150 (Maximum is 256) in any part of the cell body as 
Rethigh neurons; brightness reading between 100 and 150 as Retlow neurons; and 
brightness reading below 100 as no expression. To count small and large diameter 
GFRα1+ neurons, the size of GFRα1+ neurons was measured using ImageJ by 
manually tracing the cell body and measure the area of the selection. By comparing the 
size of GFRa1+ neurons and the GFRa2+ neuronal populations and assuming small 
diameter GFRa1+ neurons should have similar size as the majority of GFRa2+ neurons 
(as they both belong to the nonpeptidergic nociceptors), a criteria was set to classify 
any neurons with area less than 4400 pixel2 as small diameter neurons.   
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Co-localization Staining of DRG Neurons 
P14 DRG neurons were cultured as previously described. Briefly, DRG neurons were 
dissected from P14 mice and digested with collagenase and trypsin. They were then 
dissociated with fire polished Pasteur pipettes. The dissociated DRG neurons were 
cultured on acid-washed glass coverslips coated with laminin for 36 hours before being 
stained with an anti-p75 and an anti-GFRα1 antibody. The cells were incubated in 
primary antibodies for 1 hour at 4°C in HEPES-buffered DMEM and then incubated in 
secondary antibodies for 30 minutes in 4°C. Afterward, the cells were fixed with ice cold 
95% ethanol.      
 
Transduction of Dorsal Root Ganglion Neurons 
 Neurons were infected with herpes simplex viruses encoding either GFP (HSV-
GFP; GFP was driven by the CMV reporter), or GFP and Cre (HSV-GFP-Cre; GFP was 
driven by the CMV reporter and Cre was driven by the IE4/5 promoter) 24 hours after 
plating. The recombinant viruses (MIT Viral Core Facility, McGovern Institute, Boston, 
MA) were used at a MOI of approximately 8-10.  In all experiments, 48 hours post-
transduction the neurons were visualized for GFP fluorescence, which was observed in 
greater than 90% of neurons, to confirm efficient transduction and, thus, co-expression 
of Cre recombinase. 
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Quantitative Immunoblotting 
Protein samples were subjected to SDS-PAGE followed by electroblotting onto PVDF 
membranes (Immobilin P; Millipore).  Blots were blocked in 3-5% BSA in Tris-buffered 
saline containing 0.1% Tween-20, and Western blot analysis was performed using the 
following antibodies at the indicated concentrations: Ret51 (C-20, Santa Cruz, 1:500-
1:1000), Ret9 (C19R, Santa Cruz, 1:1000), phospho-tyrosine (4G10, Millipore, 1:2000-
1:3000), p75 (Promega, 1:3000), actin (JLA-20, Iowa Hybridoma Bank, 1:2000), TrkA 
(C-14, Santa Cruz, 1:1000), and transferrin (T2027, Sigma, 1:2000).  Blots were 
developed using a chemiluminescent substrate (Supersignal, Pierce, Rockford, IL). For 
quantifications, scanned images of X-ray films were imported into ImageJ (National 
Institutes of Health) and processed using the gel analysis tool.  Integrated density 
values obtained from immunoblotting were reported as mean values ± SEM, with 
arbitrary units on the vertical axis.  All immunoblot quantifications were normalized to 
the appropriate control: for co-immunoprecipitation studies, values were normalized to 
the precipitated protein; for phospho-specific signaling effectors, values were 
normalized to total levels of these effectors; and values were normalized to actin (used 
as a loading control) for all other samples. All biochemical experiments were performed 
independently at least 3 times with similar results, with sample sizes for individual 
experiments indicated in the figure legends. 
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Figures: 
 
Figure 2.1. p75 is co-expressed with GFRα1, GFRα2 and Ret in DRG neurons. 
Immunofluorescence staining of p14 DRG sections with anti-p75 (panel A, D, G), anti-
Ret (panel B), anti-GFRα1 (panel E), or anti-GFRα2 (panel H) antibodies.  The 
quantitation of co-localization is presented in panel J. Arrows in panel A-C indicate 
examples of Rethigh cells and arrowheads indicate examples of Retlow cells. Scale bar, 
100μm 
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Figure 2.2. Staining of sensory neurons from adult Rosa26LSL-tdTomato; Ret+/+ and 
Rosa26LSL-tdTomato; Ret-Cre/ERT2 mice 
Rosa26LSL-tdTomato; Ret+/+ mice (A-D) or Rosa26LSL-tdTomato; RetCre-ERT2/+ mice were treated 
with tamoxifin (TMX) for 5 days (E-L). Trigeminal ganglia were stained with an antibody 
to detect RFP (A, E, I), Ret (B, F), TuJ1(C, G, K), or the Ret antibody in the presence of 
the antibody blocking peptide (J). We observed Ret-Cre/ERT2 induced tdTomato 
fluorescent protein expression in Ret+ trigeminal neurons (E, I). The tdTomato labeling 
was absent without Ret-Cre/ERT2 (A). The goat anti-Ret antibody staining co-localized 
with Tuj1 staining (D, H, L) and with tdTomato fluorescent protein expression (H). In the 
presence of a blocking peptide for the goat anti-Ret antibody, the Ret staining was 
greatly diminished (J, L). These results demonstrate that the anti-Ret antibody 
selectively and specifically labels Ret+ neurons. Scale bar = 100μm.  
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Figure 2.3. p75 forms a receptor complex with GFRα1 and Ret. 
(A) Primary DRG neurons were cultured from P14 mice and immunostained with anti-
GFRα1 and anti-p75 antibodies without fixation. Images in the second row are 
magnified regions from the rectangles from images in the first row. Scale bar, 100μm 
(only for the top panels). (B) Immunoprecipitation assay of HEK293 cells co-transfected 
with GFRα1 and p75. When GFRα1 and p75 are co-expressed in HEK293 cells, they 
can be co-immunoprecipitated with an anti-GFRα1 antibody or an anti-p75 antibody. 
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Quantification of the GFR1 and p75 signals in co-IP experiments indicates GFR1 
and p75 association increased with GDNF treatments. (C) Immunoprecipitation assay of 
HEK-293 cells co-transfected with Ret and a myc tagged p75. Ret and p75 can be co-
immunoprecipitated with a myc antibody, a rabbit p75 antibody or a goat Ret antibody. 
Treating the cells with GDNF did not increase the association between p75 and Ret. 
Normal rabbit (rab) or goat IgG was used as a negative control. (D) Immunoprecipitation 
assay of P1-2 SCG. GFRα1 can be co-immunoprecipitated with p75 using a rabbit anti-
p75 antibody or a goat anti-GFRα1 antibody. Normal rabbit (rab) or goat IgG was used 
as control. (E) Primary DRG neurons were cultured from E18-P0 rats in the presence of 
50 ng/ml NGF. After 7-10 DIV, the neurons were stimulated with medium alone or with 
GDNF for the indicated times. Ret receptor complexes were immunoprecipitated and 
immunoblotted for p75 (top panel; left), followed by Ret51 (middle; left). Lysates were 
immunoblotted for p75, Ret, and for actin (as a loading control). (F) Quantification of 
p75 co-immunoprecipitating with Ret at each timepoint. 
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Figure 2.4. p75 augments GDNF-Ret signaling by increasing the cell surface 
localization of Ret 
(A) DRG neurons were cultured from P0 p75F/F mice in the presence of 50 ng/ml NGF. 
After two days, neurons were exposed to HSV-GFP or HSV-GFP-Cre viruses overnight 
(indicated above the blots). Neurons were maintained in culture until 7 DIV, followed by 
stimulation with medium alone or with 50 ng/ml GDNF for 15 minutes or 1 hour. Ret was 
immunoprecipitated and its level of activation was determined by phosphotyrosine 
immunoblotting. p75 immunoblotting confirmed that p75 protein levels were 
substantially reduced upon Cre expression. Actin immunoblotting of the supernatants 
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served as a loading control. (B) Quantifications of p75 levels in 10 separate experiments 
demonstrate that approximately 80% of p75 is removed following treatment with HSV-
GFP-Cre compared to HSV-GFP alone (*** p < 0.001). (C) Quantification of the mean 
proportion of phospho-Ret (pRet) over total Ret ± the standard error (5 experiments 
were quantified; * p < 0.05). (D) NIH/3T3 cells were transfected with GFP, Ret9, Ret51, 
p75, p75 and Ret9, or p75 and Ret51. After 24-36 hours, the cells were surface 
biotinylated using NHS-LC-Biotin in PBS (or treated with PBS alone as a control).  The 
cells were then subjected to neutravidin precipitation. Precipitated cell surface proteins 
and supernatants (containing intracellular proteins) were then immunoblotted for Ret9, 
Ret51, and p75. Actin immunoblotting served as a loading control. (E) DRG neurons 
were cultured from P0 p75F/F mice and treated as described in A. Neurons were 
subsequently surface biotinylated as in D followed by neutravidin immunoprecipitation.  
Precipitated cell surface proteins (left) and supernatants (right; containing intracellular 
proteins) were analyzed by immunoblotting for pan-Ret (upper), Ret9 (2nd panel), and 
Ret51 (3rd panel). Actin immunoblotting served as a loading control. p75 
immunoblotting confirmed efficient knockdown of greater than 70% of p75. (F) 
Quantifications of the cell surface levels of Ret9 (*** p < 0.001) and (G) Ret51 (** p < 
0.01) indicate a highly significant difference in HSV-GFP-Cre treated neurons compared 
to HSV-GFP controls. IP, immunoprecipitation; W, western blot.   
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Figure 2.5. p75 mediated Ret-mediated survival of nonpeptidergic nociceptors in 
vitro 
 (A) Primary DRG neuron cultures were generated from P0 p75F/F; UBC-Cre/ERT2 (p75-
cKO) or p75F/F control mice (p75-WT) and maintained in the presence of 50 ng/ml NGF 
and 4-OH-TMX. 7 DIV neurons were lysed and immunoblotted for p75 (top panel) to 
confirm efficacy of deletion, pan-Ret, TrkA, and actin (as a loading control). (B) 
Quantification of normalized p75 levels indicated a highly significant reduction of p75 
levels in p75-cKO neurons (n=10) compared to p75-WT neurons (n=8; **** p < 0.0001). 
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(C) No difference was observed in total levels of TrkA (n=5 p75-WT and n=7 p75-cKO; 
p = 0.6982) or (D) Ret protein levels (p=0.6737). (E, F) 7 DIV neurons were treated as 
described in A and subsequently treated with NGF, an anti-NGF blocking antibody 
(αNGF), αNGF with GDNF, or αNGF with NRTN (as indicated on the horizontal axis). 48 
hours post-treatment, neurons were fixed and stained with Ret, TrkA, and DAPI (to 
determine nuclear pyknosis, indicating apoptosis) The number of apoptotic Ret+/TrkA- 
(E) or Ret-/TrkA+ neurons (F) was quantified for each treatment group (n=5 for p75-WT 
and n=3 for p75-cKO for each condition), with all statistical differences noted. GDNF 
and NRTN treatment was sufficient to recue Ret+, but not TrkA+ neurons from apoptosis 
in p75-WT, but not p75-cKO neurons. (G, H) DRG neuron cultures were generated from 
P0 p75F/F (p75-WT) and p75F/F; Ret-Cre/ERT2 (p75-RC) mice and treated, 
immunostained, and quantified as in E and F (treatments indicated on the horizontal 
axis).  The number of apoptotic Ret+/TrkA- (G) or Ret-/TrkA+ neurons (H) was quantified 
for each treatment group (n=6 for p75-WT and n=5 for p75-RC for each condition). 
Similar results were noted as in E and F, with GFL treatment able to selectively rescue 
Ret+ neurons from apoptosis in p75-WT, but not p75-RC neurons.  
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Figure 2.6. Characterization of neurotrophic factor receptor expression in p75-
deleted DRG neurons in vitro. 
 (A, B) Primary DRG neuron cultures were generated from P0 p75F/F (p75-WT; n=5) and 
p75F/F; UBC-Cre/ERT2 (p75-cKO; n=3) mice and subsequently maintained in the 
presence of 50 ng/ml NGF and 0.5 µg/ml 4-OH-TMX. To fully characterize how p75 
deletion, NGF deprivation, and GFL treatments impacted TrkA and Ret expression, 7 
DIV neurons were treated with NGF, an anti-NGF blocking antibody (αNGF), αNGF with 
GDNF, or αNGF with NRTN (as indicated on the horizontal axis). 48 hours post-
treatment, neurons were fixed and stained with anti-Ret, anti-TrkA, and DAPI (to 
determine nuclear pyknosis, indicating apoptosis). (A) We observed a significant 
reduction in TrkA expression following NGF deprivation regardless of genotype. (B) 
NGF deprivation (regardless of GFL treatment) led to a significant increase in Ret 
expression. p75-cKO neurons had a significantly larger increase in Ret upregulation 
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compared to p75-WT neurons following NGF deprivation. (C, D) 7 DIV p75-WT and 
p75-cKO DRG neurons maintained in NGF and 4-OH-TMX (as described in A) were 
fixed, immunostained for TuJ1 and GFRα1 or GFRα2, and the number of GFRα1+ (C) or 
GFRα2+ (D) neurons was quantified. While no significant differences were observed for 
GFRα1 (p = 0.2723), a small but statistically significant reduction in the number of 
GFRα2+ neurons (p = 0.103) was observed in p75-cKO neurons compared to p75-WT 
neurons.  
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Figure 2.7. Generation of the p75 floxed (p75F/F) mice 
(A) Diagram of the strategy in generating the floxed p75 allele. The targeting vector was 
constructed by introducing a lox P site into an EcoR V site in intron 2 and a neomycin 
resistance marker (neo) flanked by loxP sites was introduced into an Xba I site in intron 
3. The targeting construct was electroporated into ES cells and selected with antibiotic 
G418. G418 resistant ES cell clones were screened by Southern blotting analysis. 
When the DNA was digested with EcoR I, the probe hybridized to a 5.0 kb band for the 
T allele and a 14.0 kb band for the wild type allele (+) (Panel B).   ES cell clones 
95 
 
containing the targeted (T) allele were isolated and transfected with plasmids 
expressing Cre recombinase under the control of the CMV promoter. ES cell clones in 
which the neor-cassette was removed but maintained two LoxP sites were isolated. This 
is called the floxed (F) allele. In the recombined allele (R), the neor-cassette and the 
third exon are removed and only one LoxP site is retained (Panel C).  (D) P75 floxed 
animals were crossed with a line of nestin-Cre transgenic mice. Brain DNA was isolated 
from P0 mice, digested with EcoR I and hybridized with the probe. Nearly complete 
recombination occurred in mice containing floxed alleles and the nestin-Cre transgene 
(F/R; Cre +).  Because the nestin-Cre transgenic mice used in this experiment have 
leaky Cre expression in the germ cells, germline recombination of the floxed allele can 
occur. Germline recombination only one allele (R) occurs in mice whose parents carry a 
floxed allele and the nestin-Cre transgene, even if they no longer express Cre (F/R; Cre 
-). No recombination of the floxed allele occurs in the absence of Cre expression (F/F; 
Cre -). (E) Immunofluorescence staining of coronal sections of the septum with anti-p75 
antibodies revealed that no p75 proteins are detected in mice containing the floxed 
allele and the nestin-Cre transgene (F/F, Cre +). (F) To test if p75-s transcripts (spliced 
product of exon II to exon IV) described by von Schack et al. (von Schack et al., 2001) 
are present in the conditional mutant animals, reverse transcription coupled-PCR (RT-
PCR) was used to assay the mRNA isolated from mice containing recombined alleles 
(R/R), alleles with neo-casset insertions into exon III of original p75 mutants  (-/-) (Lee et 
al., 1992b), floxed alleles (F/F) or wild type alleles (+/+). No p75-s transcripts were 
detected using primers and PCR conditions previously described by von Shack et al. 
(von Schack et al., 2001). Because the 5’ primer used by von Shack et al. is consisted 
of two 10-neucleotides complimentary to the end of exon II and the beginning of exon 
IV, respectively, the primer presumably only detected the spliced product of exon II to 
exon IV. However, we found that the primer set used by von Shack et al. was able to 
detect any transcripts containing axon IV, including the full-length cDNA. Although we 
do not know the basis for the lack of specificity, we noticed that the primer set is highly 
GC-rich. It is worth mentioning that Paul et al. demonstrated that the mutated p75 allele 
created by von Shack et al. gave rise to an alternatively spiced transcript (Paul et al., 
2004), but not in the p75 mutants we generated previously. Over-expression of this 
spliced product increases cell death (Paul et al., 2004) and may contribute to the 
phenotype observed in that line of mutant mice. (G) To further test if p75-s splice variant 
exists in the conditional p75 mutation animals, RT-PCR was used to analyze mRNA 
isolated from controls (+/+) and the mice with recombinant alleles (R/R) using primers 
from exons I and VI that encompass the full-length mRNA sequence. The full-length p75 
transcript (p75-FL) will give rise to PCR products with the size of 1.3 kb. The p75-s 
transcript (p75-s, p75-2/4) will yield PCR products with the size of 0.9 kb.  No 0.9 kb 
product was detectable. Instead, a 0.8 kb alternative splice variant was present. DNA 
sequencing of this 0.8 kb product revealed that this variant is a result of RNA splicing 
from exon I to exon IV (p75-1/4). Importantly, this splice variant is out of reading frame 
and thus will not produce functional proteins.  Taken together, these results indicate that 
the recombined allele (R) does not generate transcripts that produce functional p75 
proteins.  
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Figure 2.8. Isl1-Cre+/-; p75F/F mice lose 20% of DRG neurons 
 (A-F) p75 immunofluorescence staining of DRG sections from E10.5, E12.5 and adult 
p75F/F and Isl1-Cre+/-; p75F/F mice is shown in A-F. As shown in panel D, p75 
immunoreactivity in DRG sensory neurons is not reduced at E10.5 in Isl1-Cre+/-; p75F/F 
mice. However, the number of p75-immunoreactive neurons is markedly reduced in 
E12.5 (panel E) and adult animals (panel F). The immunoreactivity observed in adult 
DRG is likely coming predominantly from satellite cells, which normally express p75. 
Scale bar, 100μm. (G) Total neuron numbers in L4 DRGs from p75F/F mice were 
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compared to Isl1-Cre+/-; p75F/F mice at different postnatal ages. Adult Isl1-Cre+/-; p75F/F 
mice lose approximately 20% of DRG neurons. In contrast, p75-/- mice lose 50% of DRG 
neurons at P1 (* p < 0.05). At p14, Runx1 expression in p75F/F mice (H) is similar to Isl1-
Cre+/-; p75F/F mice (I). The Ret expression level is also not changed between p75F/F (K) 
and Isl1-Cre+/-; p75F/F (L) mice. There is no change in the number of Runx1+ neurons (J) 
or Ret+ neurons (M) at p14 in Isl1-cre+/-; p75F/F mice compared to p75F/F mice (n=3).   
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Figure 2.9. Level of TrkA and, GFRα1 expression at P1, p14 and adult DRG 
P0, P14, and adult lumbar DRGs from p75F/F and Isl1-Cre+/- ; p75F/F mice are sectioned 
and stained with an anti-TrkA and an antiGFRα1 antibody. All images were taken using 
the same exposure. For TrkA, at P0 (panel A, D), P14 (panel B, E) and adult (panel C, 
F) stages, no gross differences in immunofluorescence staining were observed between 
p75F/F (panel A, B and C) and Isl1-Cre+/- ; p75F/F (panel D, E and F) mice. Quantitation 
of TrkA+ neurons indicates that there is no difference between p75F/F and Isl1-Cre+/- ; 
p75F/F mice for all stages analyzed (panel G). For GFRα1, at P0 (panel H, K), P14 
(panel I, L) and adult (panel J, M) stages, no gross difference in immunofluorescence 
staining was observed between p75F/F (panel H, I and J) and Isl1-Cre+/- ; p75F/F (panel 
K, L and M) mice. Quantitation of GFRα1+ neurons indicates that there is no difference 
between p75F/F and Isl1-Cre+/- ; p75F/F mice at P0 and P14 ages. In adult DRG there is a 
significant reduction in small diameter GFRα1+ neurons in Isl1-Cre+/- ; p75F/F mice, 
however, the large diameter GFRa1+ neurons are unchanged (panel N). Scale bar: 
100µm. Arrows indicate small diameter GFRa1+ neurons. For panel G and N, value is 
expressed as mean ± SEM, n=3 for all data points. ** p<0.01 
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Figure 2.10. Level of GFRα2, Ret and TrkB expression at P0, p14 and adult DRG 
P0, P14, and adult lumbar DRGs from p75F/F and Isl1-Cre+/- ; p75F/F mice are sectioned 
and stained with an anti-GFRα2 antibody. P0 lumbar DRGs from p75F/F and Isl1-Cre+/- ; 
p75F/F mice are sectioned and stained with an anti-Ret or anti-TrkB antibody. All images 
were taken using the same exposure. For GFRα2, At P0 (panel A, D), P14 (panel B, E) 
and adult (panel C, F) stages, no gross difference in immunofluorescence staining was 
observed between p75F/F (panel A, B and C) and Isl1-Cre+/- ; p75F/F (panel D, E and F) 
mice. Quantitation of GFRα2+ neurons indicates that, at P0 and P14 ages, there is no 
difference between p75F/F and Isl1-Cre+/- ; p75F/F mice. In adult DRG there is a ~30% 
decrease in the Isl1-Cre+/- ; p75F/F mice, which correlates with the loss of IB4+ neurons 
and the Ret+ /peripherin+ neurons (panel G). For Ret, there is no gross difference in 
immunofluorescence staining between p75F/F (panel H) and Isl1-Cre+/- ; p75F/F (panel I) 
mice at P0. Quantitation of Ret+ neurons indicates there is no difference between p75F/F 
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and Isl1-Cre+/- ; p75F/F mice at P0 (panel L). For TrkB, there is no gross difference in 
immunofluorescence staining between p75F/F (panel J) and Isl1-Cre+/- ; p75F/F (panel K) 
mice at P0. Quantitation of TrkB+ neurons indicates there is no difference between 
p75F/F and Isl1-Cre+/- ; p75F/F mice at P0 (panel M). Scale bar: 100µm. For panel G, L, 
M, value is expressed as mean ± SEM, n=3 for all data points. * p < 0.05. NS, no 
statistical difference. 
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Figure 2.11. IB4+ nonpeptidergic nociceptors are selectively lost in Isl1-Cre+/-; 
p75F/F mice 
 (A-N) Immunofluorescence staining of adult L4 DRG with anti-CGRP (panel A and E), 
anti-Parvalbumin (panel B and F), anti-NF200 (panel D and H) antibody, IB4 (panel C 
and G) or a combination of anti-peripherin (I, L) and anti-Ret (J, M) antibodies from 
p75F/F (panel A-D, I-K) and Isl1-Cre+/-; p75F/F (panel E-H, L-N) mice. Scale bar for A-C, 
E-G, 200μm (located in panel A), Scale bar for D, H-N 100μm (located in panel D). (O) 
The quantification of CGRP+, Parvalbumin+, IB4+, Peripherin+/Ret+ and NF200+ neurons 
in adult L4 DRGs from p75F/F and Isl1-Cre+/-; p75F/F mice. Only the IB4+ and 
Peripherin+/Ret+ neurons were significantly reduced in the Isl1-Cre+/-; p75F/F mice. 
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Values are expressed as mean ± SEM, * p<0.05. N indicates the number of animals 
being counted (each animal provides two DRGs).   
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Figure 2.12. Nonpeptidergic neuron deficits in Isl1-Cre+/-; p75F/F mice correlates 
with level of p75-Ret co-expression 
In situ hybridization of adult (6 months old) L4 DRG with MrgA (panel A and D), MrgB 
(panel B and E) and MrgD (panel C and F) in situ probes from p75F/F mice (panel A-C) 
and Isl1-Cre+/-; p75F/F (panel D-F). Scale bar, 100μm. Quantification of MrgA+ (panel G), 
MrgB+ (panel H) and MrgD+ (panel I) neurons showed that in Isl1-Cre+/-; p75F/F mice, 
over 50% of MrgA+ and MrgB+ neurons were lost, while approximately 20% of MrgD+ 
neurons were lost. Importantly, MrgA+ and MrgB+ neurons were shown to express low 
level of Ret while MrgD+ neurons express high level of Ret. The value is expressed as 
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mean ± SEM (n=3 for each data point, * p<0.05, ** p<0.01). (J) The expression of p75 
increases the level of Ret on the cell surface in p75F/F mice and potentiates GFL-
induced Ret phosphorylation and its downstream survival effects. When p75 expression 
is lost in Isl1-Cre+/-; p75F/F mice, the level of Ret on the cell surface is reduced. For 
neurons that express high levels of Ret (MrgD+), the high level of Ret expression may 
compensate for the loss of p75 and results in more modest deficits. In neurons that 
express low levels of Ret (MrgA+ and MrgB+), however, the loss of Ret on the cell 
surface cannot be compensated for, leading to substantial cell loss.    
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Figure 2.13. p75 is effectively deleted from the CGRP+ neurons in Isl1-Cre+/-; 
p75F/F mice 
Immunofluorescent staining of adult L4 DRG with anti-CGRP (panel A, D,) or anti-p75 
(panel B, E) from p75F/F mice (panel A, B, C) and Isl1-Cre+/-; p75F/F mice (Panel D, E, 
F). Panel C is a merged image of panel A and B; panel F is a merged image of panel D 
and E. Scale bar: 200μm. G. Quantification of the percentage of p75+/CGRP+ dual-
labeled neurons. In Isl1-cre+/-; p75F/F mice, p75 expression is effectively removed from 
the vast majority of CGRP+ neurons. Value is expressed as mean ± SEM, n=3 for each 
data point. **** P<0.0001. 
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CHAPTER 3: A P75-RET SIGNALING COMPLEX MEDIATES PROGRAMMED CELL 
DEATH IN DEVELOPING SYMPATHETIC NEURONS 
 
Summary: 
Programmed cell death (PCD) is an evolutionarily-conserved process critical in 
sculpting many organ systems, yet many of the underlying mechanisms remain poorly 
understood. We investigated the interactions of pro-survival and pro-apoptotic receptors 
in PCD using the sympathetic nervous system as a model. We demonstrate that Ret, a 
receptor tyrosine kinase required for the survival of many neuronal populations, is 
restricted to a subset of degenerating neurons that rapidly undergo apoptosis. Pro-
apoptotic conditions induce Ret to associate with the death receptor p75. Genetic 
deletion of p75 within Ret+ neurons, and deletion of Ret during PCD, inhibits apoptosis 
both in vitro and in vivo. Mechanistically, Ret inhibits nerve growth factor (NGF)-
mediated survival and downstream signaling that is necessary for sympathetic neuron 
survival. Additionally, Ret deletion significantly impairs p75 regulated-intramembranous 
proteolytic (RIP) cleavage, leading to reduced activation of downstream apoptotic 
effectors. Collectively, these results indicate that Ret acts non-canonically to augment 
p75-mediated apoptosis. 
 
Introduction: 
Apoptosis is a fundamental developmental process during organogenesis. In the 
nervous system developmental cell death, also known as programmed cell death 
(PCD), is an evolutionarily conserved process that allows an organism to match the size 
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of the neuronal population with the size of its target tissue. In the peripheral nervous 
system there is a widespread overproduction of neurons, with most populations 
producing twice the number of neurons that are present in adulthood (Oppenheim, 
1991). Neurons project to their targets and compete for a limited supply of neurotrophic 
factors. Neurons that make appropriate or sufficiently extensive connections receive an 
adequate amount of target-derived neurotrophic factors and survive, while those that do 
not are eliminated through apoptotic signaling cascades (Levi-Montalcini, 1987; 
Oppenheim, 1991). Importantly, the mechanisms underlying PCD can be reactivated 
during nervous system injuries and neurodegenerative diseases (Ibanez and Simi, 
2012), underscoring the importance of understanding of these molecular mechanisms in 
detail. 
 PCD in the nervous system is perhaps best understood in sympathetic neurons 
of the superior cervical ganglion (SCG). Perinatally these neurons are wholly dependent 
on target-derived nerve growth factor (NGF) for their survival (Levi-Montalcini, 1987; 
Smeyne et al., 1994a). NGF is the founding member of the neurotrophin family, also 
consisting of brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and 
neurotrophin-4 (NT-4)(Chao, 2003). NGF exerts its pro-survival functions through the 
receptor tyrosine kinase, TrkA, which is ubiquitously expressed in sympathetic neurons. 
TrkB and TrkC, the cognate receptors for BDNF/NT-4 and NT-3, respectively, are not 
expressed in the SCG, and as such, these neurotrophins are dispensable for the 
survival of developing sympathetic neurons (Bamji et al., 1998). 
 In addition to the competition for survival factors, evidence also points to the 
presence of active pro-apoptotic signaling mechanisms through various death receptors 
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within the TNF superfamily, including the p75 neurotrophin receptor and TNFR1 (Bamji 
et al., 1998; Barker et al., 2001). p75 is a promiscuous receptor that regulates several 
cellular functions through its interactions with other co-receptors. p75 can bind to all four 
neurotrophins (Gentry et al., 2004), and acts collaboratively with sortilin as the high 
affinity receptor for the proneurotrophins (Nykjaer et al., 2004). In the SCG, p75 has 
been reported to have both pro-survival and pro-apoptotic functions (Gentry et al., 2004; 
Kraemer et al., 2014). p75 inhibits ligand-induced TrkA ubiquitination and subsequent 
internalization and degradation, thereby potentiating NGF-TrkA signaling (Makkerh et 
al., 2005b). However, in the absence of NGF, or the presence of BDNF or proBDNF, 
p75 activation triggers apoptosis (Bamji et al., 1998; Kenchappa et al., 2010; Lee et al., 
2001). Consistent with these studies, in p75-/- mice, the number of sympathetic neurons 
is greatly increased, and the rate of apoptosis following NGF deprivation is strongly 
diminished (Bamji et al., 1998; Deppmann et al., 2008). Furthermore, coincident 
knockout of p75 in TrkA-/- sympathetic neurons largely rescues neurons from apoptosis, 
consistent with a role for p75 in apoptosis following NGF withdrawal (Majdan et al., 
2001). These and other studies have led to the proposal that there is competition 
between neurons during PCD. “Winning” neurons – those that receive adequate 
amounts of target-derived NGF, and are themselves protected from cell death, 
upregulate and release pro-apoptotic p75 ligands such as BDNF, which induce 
apoptosis in nearby unprotected “losing” neurons (Deppmann et al., 2008). Although it 
remains unclear to what extent NGF withdrawal, pro-apoptotic competition, or a 
combination of both, ultimately accounts for apoptosis mediated by p75 in the 
sympathetic nervous system, it is clear that multiple stimuli can induce p75-mediated 
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apoptosis.  
 Ret is expressed in the SCG during the period of PCD, but its role has not been 
examined. Ret signaling has been shown to be critical for survival in a number of 
neuronal populations including subpopulations of sensory neurons of the dorsal root 
ganglia (DRG), enteric neurons and spinal γ-motor neurons (Airaksinen and Saarma, 
2002; Enomoto et al., 2001; Luo et al., 2009; Luo et al., 2007).  Moreover, Ret signaling 
is required for sympathetic chain ganglia migration, coalescence of the ganglia and 
early axon pathfinding (Enomoto et al., 2001). These functions result in early and 
severe morphologic deficits in the SCG prior to the period of PCD in Ret-/- mice, limiting 
investigation of the function of Ret in this process.  
 In this study we investigated the function of Ret in PCD. We demonstrate that 
Ret expression is restricted to a subpopulation of apoptotic neurons that are rapidly 
eliminated. Ret and p75 form a molecular complex induced by pro-apoptotic stimuli, and 
Ret is required for p75-mediated apoptosis induced by multiple stimuli in vitro. 
Importantly, p75 deletion specifically within Ret-expressing neurons, and Ret deletion 
specifically during PCD, results in a significant abrogation in programmed cell death in 
vivo. These studies revealed a surprising non-canonical function of Ret in augmenting 
apoptotic signaling through p75 during PCD in vivo.   
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Results  
Ret expression is limited to a subpopulation of neurons that are rapidly 
eliminated during programmed cell death 
  Studies analyzing Ret expression in the developing sympathetic nervous system 
using either a RetGFP/+ reporter line or in situ hybridization demonstrated that Ret 
expression is nearly ubiquitous throughout the ganglion by E11.5-E12.5, but then 
declines significantly by E14.5-E15.5, correlating with its role in sympathetic neuron 
migration and coalescence of the sympathetic chain ganglia. Curiously, Ret expression 
then re-emerges by E16.5, corresponding to the onset of PCD (Enomoto et al., 2001; 
Nishino et al., 1999). While Ret was expressed in many neurons perinatally, very few 
neurons expressed the GFRα co-receptors, which is surprising given that GFL signaling 
through Ret requires GFRα receptors. To determine the functional significance of Ret 
expression during PCD, we performed a tamoxifen (TMX) pulse experiment using a 
Cre-inducible tomato reporter line (Rosa26LSL-tdTomato) crossed to Ret-Cre/ERT2 mice 
(Luo et al., 2009). This experimental strategy (Figure 3.1A) enabled us to permanently 
mark the population of neurons expressing Ret at E16.5, thereby allowing the 
determination of the fate of these cells during PCD. Embryos were collected at E17.5, 
E19.5, and P3. Strikingly, there was a significant 76.4% reduction in the number of Ret+ 
neurons present at E19.5 compared to E17.5 (Figure 3.1B-3.1C, quantifications in 1E; 
952.4 ± 49.1 vs. 224.3 ± 20.0 neurons, p<0.0001), with a further loss of neurons by P3 
(Figure 3.1D; 13.5 ± 2.3 neurons). These data indicate that the Ret+ neurons present at 
E16.5 are rapidly eliminated, and the number of Ret+ neurons labeled is strikingly 
similar to the number of apoptotic SCG neurons reported in previous studies 
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investigating PCD in the SCG (Aloyz et al., 1998; Majdan et al., 2001). Additionally, we 
observed many examples of Ret+ neurons appearing atrophic (arrows in 3.1B, 3.1C), a 
characteristic associated with PCD in sympathetic neurons (Deckwerth and Johnson, 
1993).  
Given the well-established role of p75 in PCD in the SCG, we sought to 
determine whether Ret expression coincides with p75 expression during PCD. To this 
end, SCGs from Ret-Cre/ERT2; Rosa26LSL-tdTomato mice were immunolabeled for p75 and 
RFP (tomato). As a control for the specificity of p75 immunolabeling, SCGs were taken 
from p75-/- mice at P0 and immunolabeled for p75, which demonstrated a complete lack 
of staining (Figure 3.2). p75 and RFP co-immunolabeling revealed that p75 is widely 
expressed throughout the SCG, while Ret expression is restricted to a subpopulation of 
SCG neurons, all of which express p75 (Figure 3.1B-3.2C). These results indicate that 
Ret is expressed within a subpopulation of p75-expressing neurons, and that Ret+ 
neurons undergo apoptosis during the period of PCD. 
 
Ret and p75 associate in vitro and in vivo 
To investigate whether there is a functional interaction between p75 and Ret, we 
utilized the NIH/3T3 cell line, which does not express Ret9 or Ret51 and expresses only 
low levels of p75 (Calco et al., 2014). As shown in Figure 3.3A, co-transfection of Ret9 
or Ret51 with p75 leads to robust formation of Ret9-p75 and Ret51-p75 receptor 
complexes, regardless of whether Ret or p75 immunoprecipitation was used. To 
demonstrate that this interaction is both specific and relevant in neurons in vivo, Retfx/fx 
mice were mated with UBC-Cre/ERT2 mice, a TMX inducible Cre line driven by the 
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ubiquitously-expressed Ubiquitin C promotor (Ruzankina et al., 2007), allowing for 
temporally controlled deletion of Ret. Retfx/fx; UBC-Cre/ERT2 mice were administered 
TMX (0.25 mg/g body weight) from E14.5-E18.5 and euthanized at E19.5 to collect 
embryos. Spinal cords were then dissected, lysed, and detergent extracted, followed by 
immunoprecipitation of Ret. Ret deletion was highly efficient, and this led to a 
corresponding loss in p75 that co-immunoprecipitated with Ret antibodies (Figure 3.3B-
D). These findings were further confirmed through proximity ligation assays conducted 
on NIH/3T3 cells transfected with p75 and Ret51, or p75 and Ret51-HA. As expected, 
we observed strong co-localization of p75 and HA-tagged Ret when staining using anti-
p75 and anti-HA antibodies, but not with untagged Ret (Figure 3.3E). These results 
indicate that this Ret-p75 interaction is present under physiological conditions in vitro 
and in vivo.   
 
Pro-apoptotic p75 ligands enhance the interaction between p75 and Ret  
 To test the hypothesis that p75-Ret association may be enhanced by pro-
apoptotic p75 stimuli including NGF withdrawal, BDNF, and proBDNF, primary 
sympathetic neurons were generated from E18.5 rat embryos and cultured in the 
presence of 50 ng/ml NGF. After 2 days, NGF was removed and neurons were rinsed 
with medium twice, followed by the addition of an anti-NGF (αNGF) blocking antibody 
for the indicated times. The neurons were then washed, detergent extracted and Ret 
immunoprecipitations were performed. Although a basal level of association typically 
existed, blocking NGF signaling led to a striking increase in the interaction between p75 
and Ret, which was statistically significant at all time points analyzed following NGF 
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deprivation (Figure 3.4A, B). BDNF treatment led to a significant increase in p75-Ret 
association by 12 hours as compared to low NGF (p < 0.01), although the extent of this 
interaction was smaller compared to NGF deprivation (Figure 3.4C, D). Similar to 
BDNF, stimulation with an uncleavable form of proBDNF (10 ng/ml) led to a striking 
increase in p75-Ret association by 6 hours, and this increase was sustained for at least 
24 hours (Figure 3.4E, F). Despite the robust induction of p75-Ret association following 
stimulation with proBDNF, we were unable to detect co-immunoprecipitation of the 
proneurotrophin co-receptor, Sortilin, with Ret, despite reliable detection of sortilin in the 
immunoprecipitation supernatants (Figure 3.4E). These data suggest a potential sortilin-
independent proBDNF induction of p75-Ret complex formation, although it cannot be 
ruled out that proBDNF cleavage occurs in vitro, or that the Ret antibodies used for the 
immunoprecipitation preclude sortilin co-immunoprecipitation is some manner.  
 To determine whether pro-apoptotic conditions could induce the formation of this 
receptor complex in vivo, Retfx/fx; UBC-Cre/ERT2 mice were used to ensure specificity of 
immunoprecipitation of the Ret-p75 complex. P0 mice were given tamoxifen (TMX) from 
P0-P4, followed by injection of vehicle (as a negative control) or a NGF-blocking 
antibody, as we have done previously (Tsui-Pierchala et al., 2002c). SCGs were then 
collected, lysed, and subjected to Ret immunoprecipitation and immunoblotting. Ret 
immunoblotting verified efficient knockdown following TMX administration. Interestingly, 
we observed that anti-NGF administration led to a significant increase in Ret compared 
to vehicle-treated mice, with a corresponding increase in co-immunoprecipitating p75 
(Figure 3.4G-3.4I). Collectively, these data suggest pro-apoptotic stimuli increase p75-
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Ret association, and suggest that Ret is upregulated following exposure to pro-apoptotic 
stimuli in vivo.  
 
p75 enhances TrkA signaling in the presence of NGF, but inhibits canonical 
GDNF-Ret signaling in sympathetic neurons 
Given previous studies indicating that p75 is able to enhance NGF/TrkA signaling 
in sympathetic and sensory neurons (Lee et al., 1992a), as well as our demonstration of 
a novel interaction between p75 and Ret, we hypothesized that p75 may be able to 
modulate canonical Ret signaling. To this end, SCG cultures were generated from P0 
p75fx/fx; UBC-Cre/ERT2 mice (Bogenmann et al., 2011b). Neurons were maintained in 
the presence of NGF (50 ng/ml) as well as 4-OH-TMX (to induce Cre-mediated 
recombination; 5 μg/ml) for 5 days. To first assess whether TrkA activation was affected 
by deletion of p75 as previously reported (Makkerh et al., 2005b), p75fx/fx and p75fx/fx; 
UBC-Cre/ERT2 SCG neurons were lysed, detergent extracted, and immunoprecipitated 
for TrkA. Immunoblotting was performed for pTrkA, TrkA, p75, and actin, and levels of 
pTrkA/TrkA/Actin were quantified. As displayed in Figure 3.5, p75 deletion was highly 
effective and led to a significant reduction in pTrkA (p < 0.05). These data confirm 
previous studies indicating that p75 enhances signaling through TrkA in the presence of 
NGF. To determine whether deletion of p75 altered canonical GFL-Ret signaling, p75fx/fx 
and p75fx/fx; UBC-Cre/ERT2 SCG neurons were maintained in NGF (50 ng/ml) and 4-
OH-TMX for 5 days. The neurons were then stimulated with GDNF (50 ng/ml) for 15 
minutes or 1 hour, followed by detergent extraction and Ret immunoprecipitation. 
Immunoblotting was performed for phospho-tyrosine, Ret, p75, and actin. Surprisingly, 
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deletion of p75 led to a striking increase in Ret activation within 1 hour (p < 0.05; Figure 
3.6A, B). Given that p75 is expressed ubiquitously throughout the SCG, these data 
indicate that p75 inhibits canonical GFL activation of Ret. 
 
p75 is a mediator of programmed cell death following NGF deprivation. 
p75-mediated apoptosis requires the function of a number of downstream 
signaling effectors, including early binding of TRAF6 and NRIF to full length p75 shortly 
after activation, an early wave of JNK/c-Jun pathway activation, cleavage of the p75-
ECD by the TACE complex, liberation of the p75-ICD by the gamma secretase complex, 
and a late wave of activation of the JNK/c-Jun pathway, ultimately leading to terminal 
activation of executioner caspases. These final events lead to morphological and 
nuclear changes such as DNA fragmentation, chromosome condensation, and nuclear 
blebbing, all characteristic signs of apoptosis (Kraemer et al., 2014). 
 To confirm previous studies indicating that p75 is involved in apoptosis in 
sympathetic neurons, we cultured E18.5-P0 SCG neurons from p75-/- mice and p75+/+ 
mice (Bogenmann et al., 2011b). These neurons were deprived of NGF (or maintained 
in NGF, as a control) for 12 hours. Importantly, apoptosis-related nuclear morphological 
changes (pyknosis) do not begin to become evident until approximately 20 hours 
following NGF deprivation (Deckwerth and Johnson, 1993). 12 hours following these 
treatments, neurons were fixed, stained for phospho-c-Jun (p-c-Jun), and the number of 
neurons with nuclear p-c-Jun accumulation was quantified to assess the extent initiation 
of apoptosis. Numerous studies investigating PCD in the SCG describe p-c-Jun as one 
of the earliest molecular events that trigger apoptosis, detectable prior to caspase 
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activation and nuclear pyknosis (Bamji et al., 1998; Deshmukh and Johnson, 1997; 
Werth et al., 2000). As demonstrated in 3.7A, there were fewer p75-/- neurons displaying 
phosphorylated c-Jun compared to p75+/- controls. As a later indicator of apoptosis, 
apoptotic neurons were quantified by counting pyknotic nuclei. To this end, sympathetic 
neurons were deprived of NGF for either 24 or 48 hours. Similar to the p-c-Jun data, 
p75-/- neurons had reduced apoptosis at 24 hours, but not 48 hours, when compared to 
p75+/+ neurons (Figure 3.7B). These data are consistent with previous reports indicating 
that redundant death receptor signaling mechanisms are present and can mediate 
apoptosis after extended periods of NGF withdrawal in p75-deleted neurons 
(Deppmann et al., 2008; Kraemer et al., 2014).  
 
Ret is required for programmed cell death in primary sympathetic neurons.  
To test the hypothesis that Ret augments p75-mediated apoptosis, primary SCG 
neurons were produced and transfected with siRNA targeted against Ret, or a non-
targeting scrambled siRNA as a control. In addition, for all experiments, a non-targeting 
siGLO siRNA was included to verify transfection efficiency, which demonstrated that 
greater than 90% of neurons were transfected. 48 hours following siRNA transfection, 
neurons were lysed followed by immunoblotting to determine the efficacy of siRNA-
mediated knockdown of Ret. Transfection with Ret siRNA, but not scrambled siRNA, 
was effective in reducing Ret levels by greater than 65% (p < 0.05; Figure 3.8A, B). To 
assess whether Ret is required for p75-mediated apoptosis, 48 hours post transfection, 
scrambled and Ret-siRNA-transfected neurons were subjected to four conditions for 12 
hours: high NGF (100 ng/ml), low NGF (1 ng/ml), BDNF (200 ng/ml) in the presence of 
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low NGF (1 ng/ml), or αNGF. Neurons were then fixed, and the number of neurons with 
nuclear p-c-Jun accumulation was assessed (Figure 3.8D-K) and quantified (Figure 
3.8C). We observed very few examples of nuclear p-c-Jun accumulation in high NGF 
(Figure 3.8D, 3.8E) or low NGF-treated conditions (Figure 3.8F, 3.8G), regardless of 
siRNA or Ret-siRNA transfection. As expected, BDNF and αNGF treatment led to 
increased nuclear accumulation of p-c-Jun in scrambled siRNA-treated neurons, with 
NGF deprivation producing more robust effects (Figure 3.8H, 3.8J). In marked contrast, 
Ret siRNA-treated neurons had significantly reduced p-c-Jun+ nuclei for both treatment 
groups (3.8I, 3.8K). Quantifications indicated that statistically significant reductions were 
observed between scrambled siRNA and Ret siRNA neurons treated with BDNF (Figure 
3.8C; 46.42% reduction; 31.76 ±1.877 vs. 17.02 ± 1.84 percent; p < 0.05) and αNGF 
(38.24% reduction; 67.95 ± 4.75 vs. 41.97 ± 6.11 percent; p < 0.0001). These results 
demonstrate that Ret is required for p75-mediated apoptotic signaling mediated by both 
ligand stimulation (BDNF) and trophic factor deprivation (αNGF).  
 
 
Ret antagonizes NGF-TrkA signaling and survival 
While these results indicate that Ret augments early p75-mediated activation of 
the pro-apoptotic signaling cascade, we sought to determine whether there is a specific 
threshold of NGF deprivation required to trigger apoptotic p75-Ret signaling by 
performing a NGF dose response curve. Due to the limited window of transfection 
efficacy via the siRNA knockdown approach, we utilized a permanent means of deleting 
Ret by using P0 Retfx/fx and Retfx/fx; UBC-Cre/ERT2 SCG neurons maintained in the 
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presence of NGF and 4-OH-TMX. Following Cre-mediated deletion of Ret, Ret-WT and 
Ret-cKO neurons were treated for 24 hours with concentrations of NGF ranging from 0-
100 ng/ml. Neuronal apoptosis was then assessed by the presence of pyknotic nuclei. 
As expected, and consistent with previous 24-hour death assays investigating NGF-
mediated survival under similar culture conditions (Putcha et al., 2001), we observed 
fewer than 50% of Ret-WT neurons were able to survive 24 hours following complete 
deprivation of NGF (Figure 3.9A), with increasing concentrations of NGF improving 
survival of these neurons in a dose-dependent manner (Figures 3.9C, 3.9E, 3.9G, 3.9I). 
In contrast, Ret-cKO neurons had fewer apoptotic profiles with complete NGF 
deprivation (Figure 3.9B, p < 0.01) and 0.1 ng/ml NGF (Figure 3.9D, p < 0.05), but had 
statistically similar numbers of pyknotic nuclei at higher doses (1, 10, 100 ng/ml NGF; 
Figures 3.9F, 3.9H, 3.9J, 3.9K). Immunoblotting confirmed effective deletion of Ret in 
Retfx/fx; UBC-Cre/ERT2 (Ret-cKO) compared to Retfx/fx mice (Ret-WT) (>95%; Figure 
3.9L-M). These data suggest that Ret antagonizes NGF signaling through TrkA, and 
that Ret is required for p75-mediated apoptosis induced by NGF withdrawal in a dose-
dependent manner. 
To further confirm the role of Ret in p75-mediated apoptosis, BDNF and 
proBDNF death assays were conducted in several different culture models: (1) Retfx/fx; 
UBC-Cre/ERT2 (Ret-cKO) neurons (Retfx/fx as a control), where Ret is deleted as above; 
(2) p75fx/fx; Ret-Cre/ERT2 (p75-RC) neurons (neurons from littermate p75fx/fx mice as a 
control), where p75 is deleted specifically within Ret+ neurons; (3) and p75fx/fx; UBC-
Cre/ERT2 (p75-cKO) neurons (neurons from littermate p75fx/fx mice as a control), where 
p75 is deleted in all neurons. Neurons were cultured from the above mice at E18-P0 
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and maintained for 5 days in the presence of NGF (50 ng/ml) and 4-OH-TMX (5 ug/ml), 
rinsed, and treated with low NGF (1 ng/ml), or low NGF in the presence of BDNF (200 
ng/ml) or proBDNF (10 ng/ml). Neurons were fixed and analyzed for nuclear pyknosis 
as described above 48 hours after stimulation (Figure 3.9N). Interestingly, both BDNF 
and proBDNF stimulation led to a substantial increase in apoptosis in control neurons, 
and this effect was significantly reduced in all cKO models analyzed (p > 0.0001; Figure 
3.9N). 
 
Deletion of p75 specifically within Ret-expressing neurons impairs programmed 
cell death in vitro and in vivo 
To determine the extent to which p75 is required for apoptotic signaling initiated 
by NGF deprivation, P0 p75fx/fx (p75-WT) and p75fx/fx; Ret-Cre/ERT2 (p75-RC) neurons 
were maintained for 5 days in the presence of NGF (50 ng/ml) and 4-OH-TMX (5 ug/ml). 
Neurons were then rinsed and treated with NGF or deprived of NGF for 12 hours to 
assess p75-mediated p-c-Jun activation. Neurons were then fixed, stained, and the 
number of neurons with nuclear p-c-Jun accumulation was quantified (Figure 3.10A, B). 
While nuclear p-c-Jun was only rarely present in NGF treated neurons for either p75-
WT or p75-RC neurons, NGF deprivation led to a substantial increase in the number of 
p-c-Jun+ nuclei in p75-WT neurons. αNGF treated p75-RC neurons, in contrast, had 
significantly fewer p-c-Jun+ nuclei (68.6% reduction; 59.45±8.73 vs. 18.70±2.05 
percent; p < 0.0001).  
 Given that only a subset of sympathetic neurons express Ret during PCD, and 
that these in vitro data indicate that p75-mediated apoptosis appears to be augmented 
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by Ret, we hypothesized that deletion of p75 within Ret+ neurons would be sufficient to 
impair PCD. To test the requirement of p75 in Ret+ neurons during PCD in vivo, we 
utilized p75fx/fx; Ret-Cre/ERT2 mice (or p75fx/fx mice as a control; Figure 3.10C). Briefly, 
mice were given TMX (0.25 mg/g body weight) once per day for 4 days, beginning at 
E14.5, at which time Ret-dependent SCG migration and coalescence is largely 
complete (Enomoto et al., 2001). Immunoblotting of the spinal cords from E19.5 mice 
confirmed the successful deletion of p75 from Ret+ neurons using this TMX dosing 
regimen (Figure 3.10D, E). SCGs were then stained for cleaved caspase-3, βIII-Tubulin 
(TuJ1), tyrosine hydroxylase (TH), and DAPI to quantify the number of apoptotic SCG 
neurons (Figures 3.10F, G). Because caspase-3 is an irreversible executioner caspase, 
cleaved caspase-3 staining is a highly sensitive marker of neurons undergoing 
apoptosis. Interestingly, we observed a statistically significant reduction in cleaved 
caspase-3+ neurons in p75-RC SCGs, compared to the SCGs of p75-WT mice (Figure 
3.10G, 50.1% reduction; 96.04 ± 12.84 vs. 48.18 ± 12.77 cc3+ cc3+/mm3; p < 0.05).  
 
Ret is required for p75-mediated apoptosis in vivo 
To examine whether Ret is directly involved in p75-mediated PCD in vivo, we 
utilized Retfx/fx; UBC-Cre/ERT2 mice with the TMX dosing strategy described previously 
(Figure 3.10C) in order to avoid the deleterious effects of Ret deletion during SCG 
coalescence, while also avoiding perinatal lethality described by other studies involving 
perturbations of Ret signaling (Uesaka and Enomoto, 2010; Uesaka et al., 2007). SCGs 
were immunostained for cleaved caspase-3, TH, and DAPI, and the number of cleaved 
caspase-3+ cells was quantified to compare apoptosis in Retfx/fx (Ret-WT) and Retfx/fx; 
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UBC-Cre/ERT2 (Ret-cKO) mice. Ret-cKO mice had significantly fewer cleaved caspase-
3+ neurons compared to Ret-WT mice (Figure 3.10H, I; 34.2% reduction; 268.62 vs. 
176.85 cc3+/mm3, p < 0.05). Interestingly, this reduction compares similarly to the 
reduction observed in p75-RC mice. Immunoblotting of spinal cord lysates from Ret-WT 
and Ret-cKO mice confirmed the efficacy of Ret deletion (Figure 3.10J). To further 
confirm these findings, total cell counts were performed on SCGs collected from E19.5 
Ret-cKO and p75-RC mice administered tamoxifen as described in Figure 3.10C. We 
observed a significant increase in total cell counts in Ret-cKO (compared to Ret-WT) 
and p75-RC (compared to p75-WT) SCGs regardless of whether counts were 
determined using TuJ1 (left side) or TH (right side) as neuronal markers (Figure 3.10K). 
The magnitude of the increase in neuron numbers was similar in Ret-cKO and p75-RC 
SCGs (14.51% increase in TuJ1+ counts in Ret-cKO mice compared to 15.55% in p75-
RC SCGs; 20.01% increase in TH+ counts in Ret-cKO SCGs compared to 17.79% in 
p75-RC SCGs). When taken together with the in vitro functional assays, these data 
provide compelling in vivo evidence suggesting that Ret augments p75-mediated 
apoptosis during PCD.  
 
Ret is critical for p75-mediated activation of apoptotic effectors due to inhibition 
of p75 cleavage. 
Having established that Ret augments p75-mediated apoptosis, we examined 
whether Ret deletion altered p75 enhancement of NGF/TrkA signaling, p75-mediated 
activation of apoptotic effectors, or both. To this end, primary neurons were cultured 
from P0 Ret-WT and Ret-cKO mice maintained in NGF and 4-OH-TMX. Neurons were 
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then maintained in NGF (50 ng/ml), or deprived of NGF for 12 hours, followed by 
detergent extraction and immunoblotting for Ret. This confirmed that the deletion 
efficacy using this strategy was greater than 90% for both treatment groups (Figure 
3.11A, B). To explore the possibility that Ret deletion results in a reduction of total levels 
of p75, immunoblotting was performed for p75 (p75 full length; p75-FL; Figure 3.11A, 
C). NGF-maintained Ret-WT neurons had a significant reduction in p75 following NGF 
deprivation (Figure 3.11C, p < 0.05), likely as a result of regulated intramembrane 
proteolysis (RIP) cleavage of p75. Interestingly, there was no significant difference in 
p75 levels in NGF vs. αNGF-treated Ret-cKO neurons (Figure 3.11A, C). To determine 
directly whether Ret deletion impairs p75 cleavage, thereby impairing downstream 
apoptotic signaling, Ret-WT and Ret-cKO neurons were treated with NGF or were 
deprived of NGF for 12 hours in the presence of the degradation pathway inhibitors MG-
132 (5 µM) and epoximicin (5 µM). These inhibitors are necessary to prevent the rapid 
degradation of the p75-CTF generated by RIP cleavage (Kanning et al., 2003). Neurons 
were then lysed, and p75 cleavage was assessed using an antibody against the p75-
CTF, which detects both uncleaved p75 (p75-FL) and the 28 kDa p75-CTF. In this 
culture system, only the p75-CTF fragment was observed, and we were not able to 
detect the p75-ICD fragment. Interestingly, deletion of Ret led to a drastic reduction in 
the amount of p75 cleavage induced by NGF deprivation in Ret-cKO neurons compared 
to Ret-WT neurons (Figure 3.11D-E). Importantly, the antibody used to detect the p75 
cleavage fragments (Promega) has epitopes outside of the CTF as well, thereby likely 
making binding affinity of the antibody to the p75-FL and p-75-CTF dissimilar. Thus, 
direct comparison of these p75 fragments is not possible. Finally, to determine whether 
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this effect was secondary to a reduction in the amount of TACE or Presenilin-1 (PSN-1), 
immunoblotting was performed and their levels were quantified. As shown in Figure 
3.12A-C, no statistically significant differences were observed in TACE or PSN-1 in Ret-
cKO neurons as compared to Ret-WT neurons.  
To determine whether downstream apoptotic signaling was altered, we 
performed immunoblotting for p-c-Jun, pJNK, total JNK, and actin in neurons that were 
either maintained in NGF or deprived of NGF. As expected, NGF deprivation led to a 
significant activation of p-c-Jun in Ret-WT neurons compared to neurons maintained in 
NGF. However, in Ret-cKO neurons, this activation of p-c-Jun following NGF 
deprivation was impaired, and αNGF treated Ret-cKO neurons had significantly lower 
levels of p-c-Jun compared to Ret-WT neurons (Figure 3.11F, G; p < 0.01). 
Correspondingly, a similar reduction in pJNK/JNK levels was observed as well (Figure 
3.11F, H; p < 0.0001).  
A previous study demonstrated that p75-mediated apoptosis requires interaction 
with TRAF6 (Kanning et al., 2003). To examine whether TRAF6/p75 association was 
altered in the absence of Ret, p75 was immunoprecipitated from Ret-WT and Ret-cKO 
neurons treated with NGF or αNGF, and TRAF6 immunoblotting was performed. No 
significant differences were observed in TRAF6 association with p75 in any of the 
conditions examined (Figure 3.12D-E). Taken together, these data suggest that Ret 
augments apoptotic signaling by facilitating RIP cleavage of p75. 
 
Deletion of Ret prolongs TrkA activation following NGF deprivation by delaying 
TrkA receptor ubiquitination 
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Because Ret antagonizes NGF-mediated survival in a dose-dependent manner, we 
sought to test the hypothesis that Ret antagonizes NGF/TrkA signaling. Ret-WT and 
Ret-cKO neurons were treated as indicated and immunoblotting was performed for 
pTrkA, TrkA, and actin (as a loading control). When analyzing the effects of Ret deletion 
on TrkA signaling, we observed that total levels of TrkA (TrkA/actin) were not affected 
by either genotype or by the experimental treatment (Figure 3.11I, J). Ret-WT and Ret-
cKO neurons maintained in NGF displayed no significant differences in their levels of 
activated TrkA (pTrkA/TrkA/actin), but Ret-WT neurons had significantly reduced levels 
of activated TrkA following the removal of NGF (Figure 3.11I, K). Surprisingly, Ret-cKO 
neurons deprived of NGF for 12 hours did not have a significant reduction in activated 
TrkA when compared to NGF-maintained neurons (Figure 3.11I, K). Additionally, there 
was a significantly greater amount of activated TrkA in αNGF-treated Ret-cKO neurons 
compared to Ret-WT neurons (p < 0.05). Based on these findings, we hypothesized that 
removal of Ret potentiates NGF-TrkA signaling by altering activation-induced TrkA 
degradation. To test this hypothesis, Ret-WT and Ret-cKO neurons were deprived of 
NGF overnight, followed by treatment with NGF as indicated. Lysosomal and 
proteasomal degradative pathways were inhibited by using concanamycin and 
epoxomycin, respectively, to inhibit the rapid loss of ubiquitinated receptors, explaining 
why TrkA levels did not change in these experiments. As expected, NGF treatment led 
to a significant increase in TrkA ubiquitination in Ret-WT neurons by 15 minutes, which 
was significantly impaired in Ret-cKO neurons (p > 0.01). These data indicate that Ret 
deletion prolongs TrkA signaling following NGF deprivation by potentially delaying TrkA 
ubiquitination, thereby enhancing NGF-TrkA signaling, ultimately leading to increased 
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neuronal survival. Collectively, these data suggest that during PCD Ret pushes SCG 
neurons towards apoptosis both by inhibiting pro-survival signaling through TrkA and 
enhancing p75-mediated apoptosis.  
 
Discussion 
In this study we identified Ret as a novel component of the cell death machinery 
in sympathetic neurons that acts in concert with p75 during programmed cell death. Ret 
expression is restricted to neurons that are rapidly eliminated through apoptosis, and 
pro-apoptotic stimuli induce formation of a Ret-p75 complex. Ret potentiates p75-
mediated activation of downstream signaling effectors in response to apoptotic cues, 
and acts to augment p75-mediated apoptosis in a dose-dependent manner following 
NGF withdrawal. The removal of p75 specifically within Ret+ neurons is sufficient to 
diminish PCD, and this is mirrored following deletion of Ret in vivo. Ret potentiates 
apoptosis through two unique mechanisms that are ultimately connected by p75. First, 
Ret inhibits TrkA activation by promoting receptor ubiquitination, thereby reducing 
survival signaling. Second, Ret directly enhances RIP cleavage of p75 in response to 
pro-apoptotic cues, thereby inducing the late activation of the JNK/c-jun pathway that is 
necessary for downstream activation of pro-apoptotic effectors. Given the functions of 
Ret in developing neurons to date have been exclusively trophic in nature, these 
findings raise a number of important future questions. 
 
Ret as a Mediator of p75-Dependent Apoptosis 
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 The in vitro and in vivo data presented here support the notion that Ret, acting 
with p75, augments programmed cell death in the developing SCG. Several lines of 
evidence support this assertion. We demonstrate that knockdown of Ret in vitro reduces 
apoptosis in response to apoptotic cues, and does so in a dose-dependent manner in 
the case of NGF withdrawal (Figures 3.8 and 3.9). Additionally, and most critically, 
deletion of p75 specifically within Ret+ neurons is sufficient to diminish apoptotic 
signaling (Figures 3.9 and 3.10), and deletion of Ret in vivo quantitatively duplicates this 
result (Figure 3.10H, J), suggesting that Ret mediates the majority of p75-dependent 
apoptosis in SCG neurons. Also lending support to this model, we show that Ret 
expression in the SCG is limited to a subpopulation of neurons that are rapidly 
eliminated during the window of PCD (Figure 3.1). While this Ret+ subpopulation of 
neurons is relatively small when a single TMX pulse is performed (approximately 1,000 
neurons), these numbers quantitatively compare with the proportion of SCG neurons 
undergoing apoptosis at any given time during PCD (Aloyz et al., 1998; Majdan et al., 
2001, Wehner et al., 2016). Additionally, our data suggest that in vivo, trophic factor 
withdrawal induces the upregulation of Ret (Figure 3.4G-I). Lastly, it is important to 
consider that completion of PCD within the SCG occurs over a period of weeks 
(Deppmann et al., 2008), and thus, the proportion of neurons undergoing apoptosis at 
any specific age is a snapshot of the overall PCD process. 
It remains unclear precisely which pro-apoptotic stimulus chiefly drives 
programmed cell death through p75, and to what extent p75 accounts for programmed 
cell death in the SCG. In this study, we observed that deletion of p75 and Ret resulted 
in substantially impaired apoptosis (Figures 3.8, 3.9 and 3.10), but deletion of neither 
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receptor fully blocked apoptosis. These data are consistent with previous reports 
analyzing apoptosis in the SCG in p75-/- mice, as well as the in vivo data presented 
here, with p75-RC and Ret-cKO mice having an incomplete loss of cleaved caspase-3+ 
neurons (Figure 3.10). Furthermore, the deletion of p75 inhibited apoptosis induced by 
NGF withdrawal at 12 hours and 24 hours, but not by 48 hours (Figure 3.7). Collectively, 
these data indicate that p75-mediated apoptosis only represents a portion of the PCD 
occurring in sympathetic neurons, suggesting that other death receptors, or other 
apoptotic pathways, must play a significant role. Thus, while p75 may represent a 
critical conduit for sympathetic neurons to undergo PCD, prolonged atrophic or pro-
apoptotic conditions may bring forth additional death receptor mechanisms or other pro-
apoptotic mediators. Furthermore, our data provide compelling evidence that Ret 
augments p75-mediated apoptosis. However, it is unclear whether Ret-dependent, and 
Ret-independent, p75-mediated apoptotic mechanisms may both exist.  
Although receptor tyrosine kinases (RTKs) have not been demonstrated to have 
a role in naturally occurring cell death in vivo, previous reports studying pediatric neural 
tumor cells indicated that TrkA can induce cell death through its interaction with CCM2 
(Harel et al., 2009). These findings bear some similarity to those of this study through 
the indication that TrkA and Ret cannot alone induce apoptosis, but can activate or 
augment the activity of other pro-apoptotic proteins. The finding that, in developing 
sympathetic neurons, Ret augments p75-mediated apoptosis implies a highly unusual 
non-canonical function for Ret. Several neurotrophic factor receptors have been 
suggested to serve as dependence receptors, whereby in the absence of ligand a pro-
apoptotic signal is generated by default. Utilizing transfected cell lines in vitro, Bordeaux 
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et al. reported that Ret expression causes increased apoptosis through a signaling 
pathway involving caspase cleavage of full length Ret (Bordeaux et al., 2000). 
Additionally, these investigators found that the addition of GDNF ameliorated apoptosis 
of cells transfected with Ret, thereby suggesting that Ret acts as a dependence 
receptor. While these data should be interpreted cautiously due to the exclusive use of 
transfected cell lines, a method known to cause cellular toxicity, the premise warrants 
further investigation. Importantly, we did not find evidence of Ret cleavage in response 
to pro-apoptotic stimuli, nor do we find evidence for a dependence-receptor mechanism 
of cell death via Ret. Furthermore, in multiple cell lines, transient transfection of Ret 
does not induce cell death (data not shown). The pro-apoptotic function of Ret 
described here, supported by both in vitro and in vivo evidence in neurons, argues for a 
non-canonical enhancement of p75-mediated apoptosis by Ret reliant exclusively on the 
presence of apoptotic cues that trigger the activation of p75, and does not involve 
deprivation of GDNF or other GFLs. Regardless, the investigation of whether this 
receptor complex serves as a dependence receptor in the absence of GFLs in other 
neuronal systems represents an interesting future direction. 
 
Context-Dependent Cues Dictate Neuron Survival in Programmed Cell Death 
In sympathetic neurons, the functions of p75 can be divided into two main 
categories: the trophic function of p75 in potentiating NGF/TrkA signaling, and the 
degenerative functions of p75. Given these opposing functions, a key question that 
emerges is how p75 can promote both survival and apoptosis. As p75 and TrkA are 
both ubiquitously expressed throughout the developing SCG, how do individual neurons 
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determine whether p75 will potentiate TrkA signaling or to actively promote apoptosis? It 
is possible that Ret acts as one such determinant, whereby upon its expression, p75 is 
pushed towards a pro-apoptotic signaling role, while also acting to dampen NGF/TrkA 
pro-survival signaling. To this end, Deppmann et al. (2008) demonstrated that a series 
of feedback loops regulate PCD in sympathetic neurons: high levels of NGF/TrkA 
signaling in “winning neurons” reinforces TrkA expression, while also inducing 
upregulation of pro-apoptotic p75 ligands. These trophically-supported neurons then 
release these factors to act on neighboring atrophic neurons, which have 
downregulated TrkA, activating p75 death signaling (Deppmann et al., 2008). In this 
model, it is likely that Ret is positioned to support this feedback mechanism, whereby 
expression of Ret antagonizes TrkA activation, expediting its downregulation, while also 
creating a highly active death receptor complex with p75, ultimately enhancing p75 
cleavage and downstream activation by apoptotic effectors.   
Based on the co-expression of p75 and Ret in many neuronal populations, we 
speculate that the proapoptotic p75-Ret receptor complex discovered here may be of 
physiological significance in other populations, and may have varied functions 
depending on the cell type. For example, p75 acts to enhance GFL-Ret signaling in 
subpopulations of DRG sensory neurons, leading to the emergence of nonpeptidergic 
nociceptors (Chen et al., 2017).  Additionally, while Ret has been assumed to function 
as a pro-survival, pro-growth RTK, this non-canonical function of Ret in augmenting 
p75-mediated cell death may be of importance in the pathophysiology of nervous 
system injuries and neurodegenerative diseases.  
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Experimental Procedures  
 
Animals 
All experiments were carried out in compliance with the guidelines of the Association for 
Assessment and Accreditation of Laboratory Animal Care International (AAALAC) and 
were approved by the Institutional Animal Care and Use Committee (IACUC) of the 
University of Michigan.  
 
Production of Embryos and Tamoxifen Delivery 
UBC-Cre/ERT2 (Ruzankina et al., 2007), Retfx/fx (Luo et al., 2007), p75fx/f and p75-/- 
(Bogenmann et al., 2011b), Ret-/- (Schuchardt et al., 1994), Ret-Cre/ERT2 (Luo et al., 
2009), and Rosa26LSL-tdTomato mice (Madisen et al., 2010) have all been previously 
described, and all mice were maintained in mixed genetic backgrounds, except for 
Rosa26LSL-tdTomato which was maintained in a C57BL/6J background.  For timed matings, 
noon of the day on which a vaginal plug was detected was considered as E0.5. For the 
experiments tracing Ret expression, Rosa26LSL-tdTomato mice were crossed to Ret-
Cre/ERT2 mice and given one intraperitoneal (i.p.) injection of TMX (0.25 mg/g body 
weight) at E16.5 and euthanized for analysis at E17.5, E19.5, or P3.  Additionally, 
Retfx/fx; UBC-Cre/ERT2 or p75fx/fx; Ret-Cre/ERT2   were given i.p. injections of TMX (0.25 
mg/g body weight) consecutively for four days beginning at E14.5 and euthanized at 
E19.5. 
 
In Vivo Administration of NGF Blocking Antibody 
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Retfx/fx or Retfx/fx; UBC-Cre/ERT2 mice were directly administered TMX (0.40 mg/g body 
weight with maximum volume of 50 μl) via i.p. injection daily for 5 days beginning at P0. 
At P5, mice were delivered 50 μl of vehicle alone (PBS) or 50 μl of function blocking 
anti-NGF serum, as described previously (Tsui-Pierchala 2002). Mice received 4 doses 
of PBS or αNGF once every 12 hours. At P7 the mice were euthanized, and the SCGs 
were collected and pooled from two mice of identical genotypes per condition. The 
SCGs were then lysed, detergent extracted, and subjected to Ret immunoprecipitation 
and immunoblotting. 
 
Detergent Extraction and Immunoprecipitation from Whole Tissues 
Spinal cords were harvested separately from P0 Retfx/fx; UBC-Cre/ERT2 mice, and then 
placed in a 2.0 mL tube with 250 μL IP Buffer lacking NP-40, along with a steel grinding 
ball (5mm, Qiagen, Valencia, CA). The spinal cords were then mechanically 
homogenized using the TissueLyzer II (Qiagen). The homogenates were mixed with 
250 μL of 2% NP-40-containing IP buffer and incubated for 1 hour at 4°C under gentle 
agitation. Homogenates were centrifuged for 10 minutes at 16,100xg and subjected to 
an initial pre-clearing step with protein A and protein G alone at 4°C for 2 hours under 
gentle agitation, followed by pre-clearing with protein A, protein G, and a species-
matched nonspecific control IgG for 2 hours under gentle agitation. Following pre-
clearing, immunoprecipitations were performed as described in a following section.  
 
Culture and Transfection of Immortalized Cell Lines and Proximity Ligation 
Assays 
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NIH/3T3 cells were maintained in DMEM supplemented with 10% fetal bovine serum 
(FBS), 2 mM glutamine, and 1% penicillin-streptomycin (Invitrogen, Carlsbad, CA). Cells 
were plated on 6-well tissue culture plates (Falcon) and allowed to proliferate until an 
approximate density of 50% confluence was obtained prior to transfection. 
Transfections were performed using Lipofectamine 2000 according to the 
manufacturer’s instructions (Invitrogen). A total of 5 μg plasmid DNA was added per 
well, using a plasmid encoding eGFP to keep the total amount of DNA constant 
between treatments. The plasmid encoding p75 was generously provided by Phil 
Barker. For proximity ligation assays [PLA], the DuoLink Proximity Ligation Assay 
(Sigma, Carlsbad, CA) was utilized according to the manufacturer instructions. NIH/3T3 
cells were transfected with p75 and Ret51, or p75 and HA-tagged Ret51. Antibodies 
used for PLA were p75 (Advanced Targeting Systems, 1:500) and HA (Sigma, 1:500), 
with DuoLink In Situ Orange Mouse/Rabbit Kit used for secondary antibody and 
amplification. DAPI was used for nuclear localization.  
 
Production of Primary Superior Cervical Ganglion Neurons 
Superior cervical ganglia (SCGs) were surgically dissected from E19 Sprague-Dawley 
rats (Charles River, Portage, MI) or P0 Retfx/fx or p75fx/fx mice, and enzymatically 
dissociated via incubation in type I collagenase (Worthington) and a 1:1 ratio of HBSS: 
TrypLE (Invitrogen). Neurons were plated on gas-plasma treated 35 mm2 dishes 
(Harrick Plasma; Ithaca, NY) coated with type I collagen (BD Biosciences, San Jose, 
CA). For all biochemical experiments using rat neurons, cells were plated as mass 
cultures at a density of 3 ganglia per plate, while experiments using mouse neurons 
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were plated at a density of two ganglia (one animal) per plate. For death assays, 
neurons were plated as a droplet at a density of 1 ganglion per plate. Neurons were 
maintained in minimum essential medium (MEM) containing 50 ng/ml NGF (Harlan), 
10% (FBS), anti-mitotic agents aphidicolin (3.3 μg/ml) and 5-fluoro-2-deoxyuridine (20 
μM; Sigma, St. Louis, MO), 2 mM glutamine, and 1% penicillin-streptomycin (Invitrogen, 
Carlsbad, CA). Neurons were maintained at 37°C with 8% CO2 with medium changes 
every 3-4 days until experimental treatment. Treatments with growth factors and 
pharmacological agents were performed as described in the figure legends. 
 
siRNA-Mediated Gene Silencing in Sympathetic Neurons  
Neurons (2 DIV) were transfected with small interfering RNA (siRNA) using a scrambled 
control (siGENOME Non-Targeting siRNA Pool #1, Dharmacon, Lafayette, CO) or Ret 
(ON-TARGETplus SMARTpool, Dharmacon) siRNA at a concentration of 100 nM via i-
Fect (Neuromics, Minneapolis, MN) according to the manufacturer’s instructions. 
Transfection efficiency was determined in all experiments by the cotransfection of a 
fluorescently labeled nontargeting control siRNA (siGLO RISC-free siRNA; Dharmacon). 
48 hours post-transfection, at which time expression of siGLO was maximal, neurons 
were treated as described in the figure legends.  
 
Immunoprecipitations and Quantitative Immunoblotting 
Cells were stimulated as indicated in the figure legends. Following stimulation, dishes 
were placed on ice, gently washed with PBS and lysed with immunoprecipitation buffer 
(Tris-buffered saline, pH 7.4, 1% Nonidet P-40, 10% glycerol, 500 µM sodium vanadate, 
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and protease inhibitors) as described previously (Tsui and Pierchala, 2008). Antibodies 
for α-p75 (5 μl; 07-476, Millipore, Billerica, MA), α-Trk (8 μl; C-14, Santa Cruz), α-Ret51 
and/or α-Ret9 (8 µL; C-20 and C-19-G, respectively; Santa Cruz Biotechnology) were 
added along with protein A and protein G (Invitrogen, Carlsbad, CA) and incubated 
overnight at 4°C under gentle agitation. Immunoprecipitates were then washed three 
times with IP buffer and prepared for sodium dodecyl sulfate-polyacrylate gel 
electrophoresis (SDS-PAGE) by adding 2X sample buffer (tris-buffered saline, pH 6.8, 
20% glycerol, 10% β-mercaptoethanol, 0.1% bromophenol blue and 4% SDS) and 
boiling the samples for 10 minutes.  
Samples for western blotting were subjected to SDS-PAGE followed by 
electroblotting onto polyvinylidene difluoride membranes (Immobilin P; Millipore). 
Western blot analysis was performed using the following antibodies at the indicated 
concentrations: α-Ret51 (C-20, Santa Cruz, 1:500-1:1000), α-Ret9 (C19R, Santa Cruz, 
1:1000), α-Ret (AF482, R&D, 1:1000), α-phospho-tyrosine (4G10, Millipore, 1:2000-
1:3000), α-p75 (Advanced Targeting Systems, 1:1000, or Promega, 1:2000), α-actin 
(JLA-20, Iowa Hybridoma, 1:2000), pTrkA (9141, 1:1000, Cell Signaling), α-TrkA (C-14, 
Santa Cruz, 1:1000), α-phospho-c-Jun (9261, Cell Signaling, 1:300), α-phospho-JNK 
(9251, Cell Signaling, 1:1000), α-JNK (9252, Cell Signaling, 1:1000), α-Sortilin 
(ab16640, Abcam, 1:1000), TRAF6 (HPA020599, Sigma, 1:1000), α-TACE (sc-6416, 
Santa Cruz, 1:1000), α-Presenilin-1 (sc-7860, Santa Cruz, 1:1000). Blots were 
developed using a chemiluminescent substrate (Supersignal, ThermoFisher). For 
quantifications, scanned images of X-ray films were imported into ImageJ (National 
Institutes of Health) and processed using the gel analysis tool. Integrated density values 
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obtained from immunoblots were reported as mean values ± SEM, with arbitrary units 
on the vertical axis. Values were normalized to the appropriate control: for co-
immunoprecipitation studies, values were normalized to the precipitated protein; for 
phospho-specific signaling effectors, values were normalized to total levels of these 
effectors; and values were normalized to actin (used as a loading control) for all other 
samples. All biochemical experiments were performed at least three times with similar 
results. 
 
Statistics and Data Analysis 
All results are expressed as the mean ± s.e.m. All statistical tests were performed using 
two-tailed parameters with a significance level of p ≤ 0.05 to test for statistical 
significance. For all statistical tests involving more than two variables, a two-way 
ANOVA with multiple comparisons was utilized with a Tukey post-hoc test to adjust for 
multiple comparisons. A two-tailed student’s t-test was utilized for all comparisons 
between two treatment groups.  A two-tailed student’s t-test was also utilized to 
compare each time course treatment group with the corresponding NGF-maintained 
control for that experiment. The data were originally entered into Excel and imported 
into GraphPad Prism, which was used for all statistical tests. The presence of asterisks 
indicates statistical significance. * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 
0.0001. The sample sizes are indicated in the figure legends. No sample sizes of less 
than 3 independent experiments were utilized. For the SCG counts, when possible, 
each animal represents the average count of two SCGs to increase statistical accuracy.  
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Fixation, Sectioning and Immunostaining of Superior Cervical Ganglia 
Superior cervical ganglia (SCG) were fixed with 4% paraformaldehyde at 4ºC for 2-3 
hours, washed in PBS three times for 10 minutes, and cryoprotected at 4ºC in 1X PBS 
containing 30% sucrose overnight.  Tissues were embedded in OCT (Tissue Tek), 
frozen and stored at -80ºC until use.  SCGs were serially sectioned at 7 µM on a 
cryostat (CM1950, Leica Biosystems, Germany). Tissue sections were washed with 
PBS and blocked with 5% normal goat serum in PBS-T (0.1% Triton X-100 in 1X PBS) 
for 1 hour, followed by incubation with primary antibody (diluted in blocking solution) in a 
humidified chamber overnight at 4ºC. Sections were washed with PBS-T, and incubated 
with secondary antibody (1:500) diluted in blocking solution for 2 hours.  Sections were 
washed again with PBS-T and mounted in fluoromount-G with DAPI (Southern Biotech).  
Images were taken using an inverted fluorescence microscope (Axiovert 200M, Zeiss 
Microsystems, Germany). Antibodies used include α-cleaved caspase-3 (1:300, Cell 
Signaling), α-tyrosine hydroxylase (1:1000, Millipore), α-βIII-tubulin [TuJ1] (1:200, 
Sigma), and α-p75 [NGFr] (1:200, Advanced Targeting Systems).  The number of 
cleaved caspase-3 positive neurons was counted on every third section by an observer 
naïve to the genotypes of the mice. Area measurements of SCGs were performed in the 
AxioVision software (Zeiss) using the “Outline” function. For total cell counts, SCGs 
were serially sectioned at a thickness of 30 µM, stained for TuJ1, TH, and DAPI, and all 
neurons were quantified using either TuJ1 or TH as a surrogate marker as described in 
the figure legend.     
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Figure 3.1. Ret+ neurons are eliminated during programmed cell death. 
(A) Experimental strategy for fate determination of sympathetic neurons expressing Ret 
at E16.5 throughout the period of programmed cell death. Ret-Cre/ERT2; tomato mice 
were administered TMX at E16.5, a timepoint by which SCG coalescence and migration 
is largely complete. Ganglia were then collected at E17.5, E19.5, and P3, and the total 
number of RFP+ neurons was quantified to ascertain the number of neurons expressing 
Ret. Immunostaining of SCGs for TH (blue; left-most panel) and RFP (red; indicates Ret 
expression) was performed at E17.5 (B), E19.5 (C), and P3 (D), with the area indicated 
in the dotted box magnified in the right-most panel. Yellow arrowheads indicate neurons 
with atrophic profiles, as indicated by reduced somal diameter, atypical shape, and 
weak RFP expression. (E) Quantification of total RFP+ neurons per ganglion at each 
time point. Scale bar, 200 µm. 
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Figure 3.2. Validation of p75 immunostaining. 
(A) p75 immunostaining in SCGs taken from p75+/+ mice. Nuclei are stained with DAPI 
(blue) and p75 is shown in green. The merged image (panel 3) indicates widespread 
expression throughout the SCG. (B) p75-/- SCGs mice lack p75 immunoreactivity. These 
experiments were performed on animals at P0 (n=3 per genotype). Scale bars: 100 µM. 
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(C) p75 immunostaining in E18.5 SCGs dissected from Ret-Cre/ERT2; tomato mice. 
Neurons are stained for p75 (green), RFP (labeled Ret+ cells; red), and merged with 
DAPI to visualize the entire SCG. While p75 staining was observed in most cells 
throughout the SCG, RFP+ cells were restricted to a subpopulation of highly p75+ 
neurons. Scale bar: 100 µM. These immunofluorescent labeling experiments were 
performed at least 3 independent times. 
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Figure 3.3. p75 and Ret interact in vitro and in vivo. 
(A) NIH/3T3 cells were transfected as indicated with GFP, Ret9, Ret51, p75, Ret9/p75, 
or Ret51/p75 (5 µg total DNA per lane). 36 hours following transfection, cells were lysed 
and immunoprecipitated for Ret (left 6 lanes) or p75 (right 6 lanes). Immunoprecipitates 
were run side-by-side to verify validity of protein detection, with immunoblotting for Ret9, 
Ret51, p75, and actin, as a loading control. These experiments were repeated 5 
independent times with similar results. (B) Retfx/fx mice with or without UBC-Cre/ERT2 
were administered tamoxifen (TMX) as indicated above the figure. Spinal cords were 
then lysed, detergent extracted, and subjected to Ret immunoprecipitation followed by 
immunoblotting for Ret, p75, and actin. (C) Quantification of Ret (normalized to actin) 
indicated Retfx/fx; UBC-Cre/ERT2 mice had significantly reduced levels of Ret (p < 0.05; 
n=6; two-tailed t-test). (D) Quantification of p75 (normalized to actin) indicated that 
deletion of Ret led to a corresponding loss of co-immunoprecipitating p75 (p < 0.05; 
n=6; two-tailed t-test), indicating that this interaction is specific and occurs in vivo. (E) 
NIH/3T3 cells were transfected as indicated (Ret51 and p75 [left] or HA-tagged Ret51 
and p75 [right], with higher magnification panels displayed on bottom) followed by brief 
fixation. DuoLink proximity ligation assays were conducted per manufacturer 
instructions utilizing α-p75 and α-HA primary antibodies. Red staining indicates the 
colocalization pattern observed in 3T3 cells transfected with HA-Ret51 and p75 
compared to Ret51 and p75 transfected 3T3 cells. These assays were performed three 
independent times with similar results.  
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Figure 3.4. Pro-apoptotic stimuli induce p75-Ret complex formation. 
(A) Primary sympathetic neurons were cultured in NGF for 2 days, followed by NGF 
deprivation for 0, 3, 6, 12, or 24 hours as indicated. Ret was immunoprecipitated, 
followed by immunoblotting for p75, Ret, and actin. (B) Quantifications of panel A. NGF 
deprivation led to a significant increase in the amount of p75 associated with Ret at all 
time points analyzed (n=5-7). (C) Primary sympathetic neurons were treated with 200 
ng/ml BDNF for 3, 6, 12, and 24 hours followed by immunoprecipitation and 
immunoblotting as described in A. (D) Quantification of these results indicate that BDNF 
treatment increases p75-Ret association at 12 hours (p < 0.01; n=4) and 24 hours (p < 
0.01; n=4). (E) Primary sympathetic neurons were treated with 10 ng/ml of a cleavage-
resistant recombinant proBDNF (Alomone Labs), followed by immunoprecipitation and 
immunoblotting as described in A. Sortilin immunoblotting was conducted and detected 
in supernatants, but not immunoprecipitates. (F) Quantification of these results indicates 
that proBDNF treatment increases p75-Ret association at 6 hours (p < 0.01; n=5), 12 
hours (p < 0.05, n=5), and 24 hours (p < 0.001, n=3). (G) Retfx/fx mice with or without 
UBC-Cre/ERT2 were administered TMX via i.p. injection once per day for 4 days, 
followed by administration of a blocking antibody against NGF (αNGF), or vehicle as a 
control, every 12 hours for 2 days. SCGs were then isolated, detergent extracted, and 
Ret was immunoprecipitated. These immunoprecipitates were immunoblotted for Ret, 
p75, and actin. (H) Quantification of immunoprecipitated p75 demonstrated that 
administration of control mice with αNGF led to a significant increase in p75-Ret 
association (p < 0.05; ANOVA; n=7 per genotype/treatment condition). (I) Quantification 
of Ret demonstrates that TMX delivery was effective at deleting Ret in UBC-Cre/ERT2 
animals (p < 0.01; ANOVA, n=7 per condition). Additionally, a significant increase in Ret 
was observed in Retfx/fx animals administered αNGF compared to vehicle-treated mice 
(p < 0.05; n=7). For the experiments in A-F, significance was determined using a two-
tailed t-test comparing each treatment variable to the 50 ng/ml NGF maintained 
treatment. All quantifications are normalized to a loading control (actin). Due to 
variability between experiments, both individual data points from each experiment as 
well as bar graphs indicating the averages with error bars (mean ± s.e.m.) are displayed 
for the time course experiments in A-F.  
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Figure 3.5: p75 potentiates NGF-TrkA signaling in sympathetic neurons. 
(A) TrkA immunoprecipitations from p75fx/fx and p75fx/fx; UBC-Cre/ERT2 primary 
sympathetic neurons treated with 4-OH-TMX were subjected to western blotting for 
pTrkA and TrkA to determine the ratio of activated TrkA. Actin immunoblotting of the 
supernatants was performed as a loading control, while p75 immunoblotting was 
performed to ensure effective knockdown in p75-cKO mice. Two independent 
experiments are shown side-by-side. (B) Quantification of p75 normalized to actin levels 
demonstrates efficient knockdown of p75 in p75fx/fx; UBC-Cre/ERT2 neurons (n=3; p < 
0.05). (C) Quantification of the ratio of activated TrkA (pTrkA/TrkA, normalized to actin) 
indicates that p75fx/fx; UBC-Cre/ERT2 mice have significantly reduced activation of TrkA 
(n=3; p < 0.05). (D) Quantification of TrkA levels indicates no difference between 
genotypes. All experiments display the mean ± s.e.m. (n=3 independent experiments). 
Two-tailed t-test with a significance level of p ≤ 0.05 was used to test significance.  
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Figure 3.6. p75 inhibits canonical Ret signaling. 
(A) p75fx/fx (p75-WT) and p75fx/fx; UBC-Cre/ERT2 (p75-cKO) primary sympathetic 
neurons were treated with 4-OH-TMX and maintained in NGF. Neurons were then 
treated with medium alone, or with GDNF (50 ng/ml) for 15 minutes or one hour (as 
indicated in the figure) and subjected to Ret immunoprecipitation followed by 
immunoblotting for pTyr and Ret to determine the proportion of activated Ret. Actin and 
p75 immunoblotting of supernatants were performed as a control. (B) Quantification of 
activated Ret (pRet/Ret, normalized to actin) are displayed. GDNF-mediated Ret 
activation at 1 hour, but not 15 minutes, was significantly enhanced in p75-cKO neurons 
(p < 0.05; Two-way ANOVA). (C) Quantification of total Ret levels indicated that deletion 
of p75 did not significantly alter Ret levels. All experiments display the mean ± s.e.m., 
with n=4-7 per treatment. Two-way ANOVA with a significance level of p ≤ 0.05 was 
used to test significance. 
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Figure 3.7. p75 promotes sympathetic neuron apoptosis through a p-cJun 
dependent pathway. 
 
(A) Primary sympathetic neurons were cultured from P0 p75+/- and p75-/- mice in the 
presence of NGF. 2 days after plating, neurons were either maintained in high NGF (50 
ng/ml) or deprived of NGF and treated with an anti-NGF blocking antibody. 12 hours 
post-treatment, the percent of neurons with phospho-c-Jun+ (p-cJun) nuclei were 
quantified. p75-/- neurons had significantly fewer p-cJun+ nuclei compared to p75+/- (p < 
0.0001), suggesting that initiation of apoptosis was impaired in the absence of p75. 
Significance was tested between all groups using a two-way ANOVA (n=3 p75+/- and 
n=7 p75-/-). (B) p75+/- and p75-/- neurons were cultured as in panel A and deprived of 
NGF for 24 or 48 hours, followed by quantification of the number of pyknotic nuclei to 
ascertain the number of apoptotic neurons. Loss of p75 led to a significant decrease in 
apoptosis by 24 hours following NGF deprivation (p < 0.0001), but no significant 
differences were observed by 48 hours.  
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Figure 3.8: Ret knockdown blocks p75-mediated p-cJun activation. 
(A) Primary E18-P0 rat sympathetic neurons were cultured and transfected with 
scrambled (left two lanes) or Ret siRNA (right two lanes). 48 hours following 
transfection, neurons were lysed and immunoblotted for Ret and actin. (B) 
Quantification of Ret indicates a significant reduction of Ret following siRNA knockdown 
compared to scrambled control (65%; p < 0.01; n=4). (C) Neurons transfected with 
scrambled or Ret siRNA were treated with high NGF (50 ng/ml), low NGF (1 ng/ml), low 
NGF (1 ng/ml) with BDNF (200 ng/ml), or αNGF for 12 hours, followed by quantification 
of the number of p-cJun+ nuclei as described in Supplemental Figure 2. Ret knockdown 
significantly reduced p-cJun+ nuclei in BDNF (p < 0.05) and αNGF (p < 0.0001) treated 
neurons. (D-K) Examples of images of each treatment. TuJ1 (pan-neuronal marker) is 
displayed in red, nuclei are displayed in blue, and p-cJun is displayed in green. For 
each treatment, the left-most column displays p-cJun alone. Importantly, rarely were p-
cJun+ nuclei observed in NGF-maintained neurons (D-G), while BDNF and αNGF 
treatment led to significant phosphorylation of cJun (H, J), which was inhibited in Ret 
siRNA-treated neurons (I, K). Statistical significance was determined using a two-way 
ANOVA with multiple comparisons, n=4 per condition. Scale bar, 100 µm. 
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Figure 3.9: Ret deletion enhances NGF-mediated survival. 
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Retfx/fx (Ret-WT) and Retfx/fx; UBC-Cre/ERT2 (Ret-cKO) primary sympathetic neurons 
were treated with 4-OH-TMX and maintained in NGF. Neurons were then treated for 24 
hours with complete NGF deprivation using an anti-NGF blocking antibody (αNGF; 
panels A, B), 0.1 ng/ml NGF (panels C, D), 1.0 ng/ml NGF (panels E, F), 10 ng/ml NGF 
(panels G, H), or 100 ng/ml NGF (panels I, J). DAPI alone (left) and DAPI/Phase 
merged images (right) are displayed. Red arrows indicate apoptotic neurons with 
pyknotic nuclei. Scale bar represents 100 µM. As expected, increasing concentrations 
led to a dose-dependent reduction in the number of apoptotic nuclear profiles. (K) 
Quantification of survival counts. Ret-cKO mice had increased survival in a dose-
dependent manner compared to Ret-WT neurons, with significant differences observed 
with αNGF (p < 0.01; n=4 per treatment group) and 0.1 ng/ml (p < 0.05; n =3) 
treatments. Statistical significance was determined using a two-way ANOVA with 
multiple comparisons, n=3-6 per treatment group. (L) Immunoblot demonstrating the 
efficacy of Ret knockdown using the 4-OH-TMX system. (M) Quantification of Ret 
knockdown indicated that greater than 90% of Ret was deleted in Ret-cKO compared to 
Ret-WT neurons (p < 0.0001; two-tailed t-test; n =11-13 per treatment group). (N) 
Neurons were cultured from animals of the indicated genotypes and maintained as 
above, followed by treatment with low (1 ng/ml) NGF, or low NGF in the presence of 
200 ng/ml BDNF or 10 ng/ml proBDNF. Neurons were fixed after 48 hours, followed by 
quantification of nuclear pyknosis to ascertain neuronal apoptosis. BDNF and proBDNF 
induced a significant increase in apoptosis compared to low NGF-maintained neurons, 
which was significantly reduced in Ret cKO (compared to Ret-WT, n=4 per genotype 
and treatment group), p75-RC (compared to p75-WT, n=5-6 per genotype and 
treatment group), and p75-cKO (compared to p75-WT, n=4 per genotype and treatment 
group) neurons. Quantifications are displayed as the mean percent of apoptotic neurons 
± s.e.m. More than 300 neurons were quantified for each treatment. Scale bar, 100 µm. 
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Figure 3.10: Ret collaborates with p75 to mediate sympathetic neuron apoptosis 
in vivo.  
(A) p75fx/fx (p75-WT) and p75fx/fx; Ret-Cre/ERT2 (p75-RC) primary sympathetic neurons 
maintained in NGF were treated with 4-OH-TMX to induce recombination. Neurons 
were then maintained in NGF or deprived of NGF for 24 hours as indicated. Neurons 
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were stained for TuJ1 (red) or p-c-Jun (green). αNGF application led to robust activation 
of p-c-Jun in p75-WT neurons, and this activation was significantly abrogated in p75-RC 
neurons. Scale bar, 25 µm. (B) Quantifications of (A) indicate a highly significant 
difference in NGF deprivation-induced p-cJun activation. (C) Experimental strategy for 
cell autonomous deletion of p75 within Ret+ neurons using p75fx/fx; Ret-Cre/ERT2 mice 
as well as global deletion of Ret utilizing Retfx/fx; UBC-Cre/ERT2 (Ret-cKO) mice. The 
delivery of TMX between E14.5-E18.5 was employed to avoid the deleterious effects of 
Ret deletion on early SCG neuron migration and coalescence.  Cleaved caspase-3 
immunolabeling was conducted to ascertain apoptosis (indicated as green cells). (D) 
Western blot demonstrating efficacy of p75 deletion using the Ret-Cre/ERT2 driver and 
the deletion strategy in (C). (E) Quantification of p75 levels immunoprecipitating with 
Ret normalized to actin. p75-RC mice have significantly reduced p75 compared to p75-
WT mice. (F) Immunolabeling of TH (red) and cleaved caspase-3 (cc3; green) in p75-
WT and p75-RC SCGs. Large panels indicate overall cc3 activity throughout the 
ganglion, with the two indicated areas shown (upper is white, lower is blue) at larger 
magnification. Scale bar, 100 m. (G) Quantification of the number of cc3+ neurons 
normalized to ganglion area indicated that p75-RC mice have significantly reduced 
apoptosis (two-tailed t-test; p < 0.05; n=4 p75-WT and n=7 p75-RC). (H) Ret-WT and 
Ret-cKO SCGs were stained for DAPI and cc3 to ascertain the number of apoptotic 
neurons. For each genotype, panels on left represent sections of whole ganglia with 
increased magnification around the selected area displayed to the right. Ret-WT SCGs 
had fewer cc3+ neurons compared to p75-WT mice (two-tailed t-test; p < 0.05; n=5 per 
genotype), which was quantified in (I). Scale bar, 200 µm. (J) Immunoblotting of spinal 
cords taken from Ret-WT and Ret-cKO mice demonstrate the efficacy of Ret deletion 
using the experimental paradigm outlined in (C). (K.) SCGs were isolated from Ret-WT 
(n=4), Ret-cKO (n=6), p75-WT (n=3), and p75-cKO (n=5) mice, followed by serial 
sectioning and quantification of total cell counts using TuJ1 (left 4 bars) or TH (right 4 
bars). A significant increase in total neuron numbers was observed in Ret-cKO SCGs 
compared to Ret-WT controls (p > 0.05 for TuJ1; p > 0.001 for TH) and in p75-RC 
SCGs compared to p75-WT controls (p > 0.001 for TuJ1; p > 0.01 for TH; two-way 
ANOVA).  
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Figure 3.11: Ret inhibits pro-survival TrkA signaling and augments pro-apoptotic 
p75 cleavage and downstream signaling. 
(A) Retfx/fx (Ret-WT) and Retfx/fx; UBC-Cre/ERT2 (Ret-cKO) primary sympathetic neurons 
maintained in NGF were treated with 4-OH-TMX to induce recombination. Neurons 
were then maintained in NGF or deprived of NGF for 12 hours as indicated. Neurons 
were then lysed, detergent extracted, and immunoblotting was conducted for p75, Ret 
to verify deletion, and actin. (B) Ret-cKO neurons had drastically reduced levels of Ret 
(>90%) compared to Ret-WT controls, confirming efficacy of deletion (n=6-7 per 
treatment group) (C) Ret-WT neurons deprived of NGF had significantly reduced levels 
of full length p75 (p75-FL), consistent with NGF deprivation-induced cleavage (p < 0.05; 
n=3). This reduction in p75-FL was not observed in Ret-cKO neurons, indicating Ret is 
involved in the cleavage of p75. (D) Ret-WT and Ret-cKO SCG neurons were 
generated and treated as indicated in A, with the addition of the degradation inhibitors 
MG-132 and epoximicin to allow detection of the p75-CTF cleavage product. Samples 
were immunoblotted for full length p75 (p75-FL) and the C-terminal fragment cleavage 
product of p75 (p75-CTF), as well as actin. In our culture system, the p75-ICD is not 
detected. (E) Quantification of p75 cleavage (p75-CTF/p75-FL, normalized to actin). As 
expected, Ret-WT neurons, but not Ret-cKO neurons, had a highly statistically 
significant increase in p75 cleavage (p < 0.0001, n=3). NGF-deprived Ret-cKO neurons 
also had a highly significant decrease in p75 cleavage compared to NGF-deprived Ret-
WT neurons (p < 0.0001, n=3). (F) Neurons were treated and samples prepared as 
described in A. Immunoblotting was performed for activated c-Jun (p-c-Jun), activated 
JNK (pJNK), total JNK, and actin. (G) Quantification of p-cJun, normalized to actin. In 
Ret-WT neurons, but not Ret-cKO neurons, a statistically significant increase was 
observed in p-c-Jun following NGF deprivation (p < 0.05, n=7 per treatment group). 
Following NGF deprivation, Ret-cKO neurons also displayed a significant decrease in p-
c-Jun activation compared to Ret-WT neurons (p < 0.001, n=7 per treatment group). (H) 
Quantification of 46 kDa pJNK, normalized to total JNK and actin (pJNK/JNK/Actin).  
Following NGF deprivation, we observed a statistically significant decrease in activation 
of pJNK in Ret-cKO neurons compared with Ret-WT neurons (p < 0.0001, n=7). (I) 
Neurons were treated and samples prepared as described in A. Immunoblotting was 
performed for pTrkA, total TrkA, and actin. (J) Total levels of TrkA were not altered by 
deletion of Ret or by NGF deprivation after 12 hours (n=6 per treatment group) (K) As 
expected, deprivation of NGF led to a significant decrease in the proportion of activated 
TrkA (pTrkA/TrkA, normalized to actin) in Ret-WT neurons (p < 0.05, n=6 per treatment 
group), but not Ret-cKO neurons. Ret-cKO neurons also had a significant increase in 
the ratio of activated TrkA compared to Ret-WT neurons (p < 0.05, n=6 per treatment 
group). (L) Ret-WT or Ret-cKO neurons treated as described in (A) were deprived of 
NGF overnight to reduce TrkA activation. Neurons were then stimulated with 50 ng/ml 
NGF for 15 minutes, 1 hour, or 6 hours, following by TrkA immunoprecipitation and 
immunoblotting for ubiquitin, which is quantified in (M). As expected, robust 
ubiquitination of TrkA was observed in Ret-WT neurons at 15 minutes, as compared to 
later time points (p > 0.0001; n=4 for all treatments). Ret-cKO neurons had significantly 
reduced TrkA ubiquitination compared to Ret-WT neurons at 15 minutes (p > 0.01; 
n=4), and no significant differences were observed between TrkA-ubiquitination levels at 
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1 or 6 hours of NGF stimulation for Ret-cKO neurons compared to Ret-WT neurons. 
Data are represented as the mean ubiquitinated TrkA normalized to total TrkA ± s.e.m. 
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Figure 3.12: Removal of Ret does not alter TRAF6 association with p75 or 
upregulation of the p75 cleavage enzymes Presenilin-1 and TACE. 
(A) Retfx/fx (Ret-WT) and Retfx/fx; UBC-Cre/ERT2 (Ret-cKO) primary SCG neurons 
maintained in NGF were treated with 4-OH-TMX to induce recombination. Neurons 
were then maintained in NGF or deprived of NGF for 12 hours as indicated. Neurons 
were then lysed, detergent extracted, and immunoblotting was performed for TACE and 
presenilin-1, two enzymes required for regulated intramembrane proteolysis cleavage of 
p75. (B) Quantification of presenilin (PSN-1) normalized to actin and (C) TACE 
normalized to actin. No statistical differences were observed in any of the treatment 
groups. (D) Neurons were treated as described in A. Neurons were then lysed, 
detergent extracted, and immunoprecipitated for p75 followed by immunoblotting for 
TRAF6, p75, Ret (to confirm deletion), and actin, as a loading control. (E) Quantification 
of TRAF6 normalized to p75. No statistical differences were observed in any of the 
treatment groups (n=6-7 per treatment group). 
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CHAPTER 4: BIPHASIC FUNCTIONS OF THE GDNF-RET SIGNALING PATHWAY IN 
CHEMOSENSORY NEURON DEVELOPMENT AND DIVERSIFICATION 
 
Summary: 
The development of the taste system relies on the coordinated regulation of cues that 
direct the simultaneous development of both peripheral taste organs and innervating 
sensory ganglia, but the underlying mechanisms remain poorly understood. In this study 
we describe a novel, biphasic function for glial cell line-derived neurotrophic factor 
(GDNF) in the development and subsequent diversification of chemosensory neurons 
within the geniculate ganglion (GG). GDNF, acting through the receptor tyrosine kinase, 
Ret, regulates the expression of the chemosensory fate determinant Phox2b early in 
GG development. Ret-/- mice, but not Retfx/fx; Phox2b-Cre mice, display a profound loss 
of Phox2b expression with subsequent chemosensory innervation deficits, indicating 
that Ret is required for the initial amplification of Phox2b expression, but not its 
maintenance. Ret expression is extinguished perinatally, but re-emerges postnatally in a 
subpopulation of large-diameter GG neurons expressing the mechanoreceptor marker 
NF200 and the GDNF co-receptor GFRα1. Intriguingly, we observed that ablation of 
these neurons in adult Ret-Cre/ERT2; Rosa26LSL-DTA mice caused a specific loss of 
tactile, but not chemical or thermal, electrophysiological responses. Overall, the GDNF-
Ret pathway exerts two critical and distinct functions in the peripheral taste system: 
embryonic chemosensory cell fate determination and the specification of lingual 
mechanoreceptors.  
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Introduction: 
Creating the neuronal diversity required to appropriately discriminate different kinds of 
sensory stimuli, including all aspects of somatosensory, taste, visual, auditory, and 
olfactory stimuli, is a complex task during vertebrate development. Following 
neurogenesis, one means of differentiating and specifying unique sensory neuron 
subpopulations is by selective expression of transcription factors and neurotrophic 
factor receptors (Liu and Ma, 2011). These signaling pathways regulate the expression 
of additional transcription factors, ion channels, neurotransmitter receptors, and 
neuropeptides that define the molecular and functional characteristics of different 
classes of sensory neurons (Lallemend and Ernfors, 2012). The selective expression of 
distinct neurotrophic factor receptors is one potential means of delineating functionally 
distinct populations of somatosensory neurons within the dorsal root ganglion (DRG) 
and trigeminal ganglion (TG). For example, while TrkB+ large diameter 
mechanoreceptive neurons afferently innervate Merkel cells and lanceolate endings 
producing BDNF (Li et al., 2011), TrkA+ small and medium-diameter neurons mediating 
pain sensation project free nerve endings to the skin where NGF is produced (Chen et 
al., 2006). Because heterogenous sensory neurons responsive to temperature, touch, 
and all five taste qualities cohabitate within the peripheral taste ganglia (Boudreau et al., 
1971; Lundy and Contreras, 1999; Yokota and Bradley, 2016), this system is well suited 
to explore the underlying molecular mechanisms regulating sensory neuron 
diversification and physiology. The geniculate ganglion (GG) houses soma for taste and 
thermal afferents to lingual taste buds (TBs) in the fungiform papillae, projecting via the 
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chorda tympani (CT) nerve. Although a major taste ganglion for the anterior tongue, the 
GG also includes neurons innervating TBs on the soft palate, as well as somatosensory 
neurons projecting to the external ear (Krimm, 2007). This major ganglion for orofacial 
sensation is complex and multi-modal, containing soma for taste, touch, and lingual 
temperature reception (Boudreau et al., 1971; Lundy and Contreras, 1999; Yokota and 
Bradley, 2016). However, our knowledge of the molecular mechanisms dictating GG 
chemosensory neuron development and postnatal heterogeneity remain poorly 
understood, especially compared to primary sensory afferent neurons in the DRG and 
TG.   
 
Previous studies have focused on the role of the neurotrophins in chemosensory GG 
development and maintenance, with NT-4 and BDNF emerging as the principal 
regulators of GG axon guidance (Patel and Krimm, 2012), GG neuron survival (Ma et 
al., 2009), and CT nerve regeneration (Meng et al., 2017). Despite these advances in 
our understanding of the development and postnatal maintenance of the peripheral 
taste system, our knowledge of the roles of other inductive cues involved in sensory 
neuron specification and diversity remains rudimentary. Additionally, although there is 
some evidence supporting the presence of molecularly and functionally distinct 
subpopulations of GG neurons, our knowledge as to the signaling pathways or markers 
that shape the multi-modal nature of GG neurons is lacking. 
 
Another family of neurotrophic factors, the glial cell line-derived neurotrophic factor 
(GDNF) family ligands (GFLs), consisting of GDNF, neurturin (NRTN), artemin (ARTN), 
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and persephin (PSPN), are four homologous growth factors critical for the development 
of several populations of peripheral neurons, including autonomic neurons (Enomoto et 
al., 2001), rapidly adapting mechanoreceptors (Luo et al., 2009) and nonpeptidergic 
nociceptor populations (Luo et al., 2007) within the DRG sensory system. The receptor 
tyrosine kinase, Ret, conveys the trophic functions of the GFLs (Airaksinen and 
Saarma, 2002). Importantly, Ret is highly expressed in the GG early in embryonic 
development (D'Autreaux et al., 2011), and stimulation of early embryonic GG neurons 
with GDNF promotes axon outgrowth (Rochlin et al., 2000), indicating that the GDNF 
receptor components are present and poised to exert trophic effects in developing GG 
sensory neurons.  
 
In this study, we investigated the function of the GDNF-Ret signaling pathway in the 
development and subsequent postnatal diversification of chemosensory neurons within 
the GG. To discern the developmental requirement, as well as the molecular and 
neurophysiological signatures for GG cells and GG/CT afferents, we used expression 
analyses, genetic models, pharmacologic inhibitors, and neurophysiological 
approaches. Collectively, we identify a novel, biphasic function for GDNF-Ret signaling 
in the peripheral taste system, initially acting to promote the chemosensory phenotype 
of all GG neurons, while acting postnatally to define a unique subpopulation of lingual 
mechanoreceptors. These data significantly broaden our understanding of the cues 
responsible for taste neuron development, and bring to light new concepts for 
understanding GG biology and peripheral sensory circuits of the tongue.  
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Results 
 
Ret is widely expressed by geniculate chemosensory neurons at E13.5, but 
expression is extinguished perinatally 
A previous study describing the transcriptional profile of GG neurons indicated that a 
combinatorial expression pattern of Tlx3+/Islet+/Phox2b+/Phox2a+/Brn3a- coincides with 
a chemosensory neuronal fate, while a Tlx3+/Islet+/Phox2b-/Phox2a-/Brn3a+ 
transcriptional code coincides with somatosensory fate (D'Autreaux et al., 2011). In this 
study, Phox2b was discovered to serve in sensory neurons as a master regulator 
commanding a visceral, chemosensory fate, while repressing a somatosensory fate. In 
this way, the geniculate ganglion exerts a strong polarity between the distal 
chemosensory neurons innervating the anterior two-thirds of the tongue, and the 
proximal somatosensory neurons innervating the external ear. Curiously, upon 
qualitative analysis using in situ hybridization, the authors also found strong Ret 
expression which was correlated with a Phox2b+/Brn3a- chemosensory transcriptional 
profile as early as E11.5 (D'Autreaux et al., 2011). Importantly, these data suggest that 
Ret is one of the earliest growth factor receptors expressed by GG neurons, and may 
be selectively functioning within chemosensory neurons. We quantified the proportion of 
chemosensory and somatosensory neurons expressing Ret during embryonic 
development of the GG. For these purposes, chemosensory neurons were defined as 
TuJ1+ neurons expressing Phox2b, while somatosensory neurons were those lacking 
Phox2b expression. To validate the use of Phox2b as a specific marker of 
chemosensory neurons (Dauger et al., 2003b), we conducted immunolabeling of 
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Phox2b, RFP (detects the tdTomato protein), and TuJ1 (a pan-neuronal marker) in GG 
and TG from P0 Rosa26LSL-tdTomato/+; Phox2b-Cretg/+ mice. The TG, known to be Phox2b-
/Brn3a+, was analyzed as a negative control (Fode et al., 1998). For the specificity of 
RFP immunolabeling, Rosa26LSL-tdTomato/+; Phox2b-Cre+/+ mice were also analyzed. We 
observed that 98.84% of neurons immunoreactive for Phox2b were also RFP+, 
indicating a high reliability of this Phox2b antibody in labeling chemosensory neurons 
(98.84 ± 0.11%; Figure 4.1A). Further validating the use of Phox2b as a marker of 
chemosensory neurons, we found that 0.03% of TG neurons exhibited labeling for 
Phox2b, and in all cases, these neurons were RFP+ (Figure 4.1B). The majority of 
RFP+ immunolabeling in the TG was restricted to axons, likely due to labeling of 
trigeminal motor axons passing through the ganglion. These data confirm the high 
fidelity of Phox2b immunolabeling of chemosensory neurons and validate the use of the 
Phox2b-Cretg/+ line.   
To determine the spatiotemporal expression pattern of Ret in the GG, we 
performed a tamoxifen (TMX) pulse labeling experiment using a Cre-inducible tomato 
reporter line (Rosa26LSL-tdTomato) crossed to Ret-Cre/ERT2 mice (Luo et al., 2009). 
Importantly, we used this reporter strategy to avoid limitations in specificity occasionally 
observed with Ret immunostaining. Two time periods were analyzed (outlined in Figure 
4.2A): 4 daily TMX injections from E9.5-E12.5, with analysis performed at E13.5; or 4 
daily TMX injections from E14.5-E17.5, with analysis conducted at E18.5. Notably, 
analysis of these early and late embryonic timepoints allowed an examination into Ret 
expression during periods corresponding with transcriptional diversification and target 
innervation, respectively (Krimm, 2007; Mistretta and Liu, 2006). Ganglia were 
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immunolabeled for TuJ1, Phox2b, and RFP, and total numbers of chemosensory 
(Figure 4.2B) and somatosensory (Figure 4.2C) neurons expressing Ret were 
quantified. Coinciding with previous studies, we found that the majority of 
chemosensory neurons were Ret+ at E13.5 (69.41 ± 4.35%), but expression was 
greatly reduced by E18.5 (3.38 ± 0.42%; Figure 4.2B-F). Additionally, very few 
somatosensory neurons expressed Ret at either timepoint analyzed (Figure 4.2B-F).  
Given that Ret is highly expressed by chemosensory GG neurons prior to lingual 
innervation, we hypothesized that the Ret ligand GDNF is present locally, acting on 
Ret+ chemosensory neurons. To test this hypothesis, we used a TMX pulse labeling 
experiment using Rosa26LSL-tdTomato; GDNF-IRES-Cre/ERT2 (GDNFCre/+) mice (Cebrian 
et al., 2014), and analyzed the previously described timepoints (Figure 4.2A). Ganglia 
were collected from E13.5 and E18.5 labeled mice and immunolabeling was again 
performed for TuJ1, Phox2b, and RFP (to label GDNF+ cells).  Surprisingly, GDNF 
expression was restricted to GG neurons themselves, rather than the surrounding 
tissues (Figure 4.3). Similar to the Ret expression quantifications, we observed that 
many chemosensory neurons express GDNF at E13.5 (27.14 ± 0.85%), but expression 
is virtually lost by E18.5 (4.31 ± 0.22%; Figure 4.3A, C). Additionally, few 
somatosensory neurons express GDNF at E13.5 (0.43 ± 0.06%) or E18.5 (8.62 ± 
1.45%; Figure 4.3B, 4.3C). Collectively, these data suggest that a GDNF-Ret paracrine 
signaling pathway exists in chemosensory GG neurons early in development. 
 
Ret is required for expression of the chemosensory fate determinant Phox2b, but 
not Brn3a or TrkB 
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Sensory neuron diversification relies on differential transcriptional activities that induce 
and maintain expression of required growth factor receptors, and these receptors in turn 
serve activator or repressor functions (Lallemend and Ernfors, 2012). The expression of 
Ret within the E9.5-E12.5 developmental window, but not within E14.5-E17.5, suggests 
an early role in chemosensory fate determination. It is during this embryonic period that 
GG neurons begin their initial transcriptional fate acquisition (D'Autreaux et al., 2011) 
and initial axon outgrowth, but they do not reach their final targets until at least one day 
later (Krimm, 2007). Given this timeline, we hypothesized that Ret is unlikely to be 
involved in target innervation, but rather, may play a role in early transcriptional 
diversification. Therefore, we analyzed total GG neuron numbers and the proportion of 
Phox2b+ neurons in Ret-/- mice or Ret+/+ mice, as a control (Schuchardt et al., 1994) 
(Figure 4.4A-C). Strikingly, although no difference was observed in the total number of 
neurons (Ret+/+: 767.63 ± 29.35 neurons vs. Ret-/-: 761.35 ± 35.33 neurons; p = 0.9014; 
Figure 4.4A, 4.4B), we observed a significant reduction in the proportion of neurons with 
detectable Phox2b immunolabeling (Ret+/+: 73.78 ± 2.17% vs. Ret-/-: 44.00 ± 5.84%; a 
40.4% reduction; p = 0.0015). There was also a substantially reduced intensity of 
Phox2b in neurons that retained a positive signal (Figure 4.4D). To determine whether 
this loss of Phox2b expression was coupled with a change in the proportion of neurons 
expressing the somatosensory transcriptional fate determinant Brn3a (Huang et al., 
2001), or the broadly expressed TrkB receptor involved in GG survival (Patel and 
Krimm, 2010), we examined TuJ1, Brn3a, and TrkB expression, followed by 
quantification of the proportion of each subgroup. There was no change in the 
proportion of neurons expressing Brn3a (Ret+/+: 32.67 ± 2.37% vs. Ret-/-: 30.60 ± 6.57%; 
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p = 0.7587; Figure 4.4F, 4.4G). Likewise, there was no change in the proportion of 
neurons expressing TrkB (Figure 4.4E, 4.4G), which was expressed widely in both 
chemosensory and somatosensory GG neurons alike (Ret+/+: 97.06 ± 0.49% vs. Ret-/-: 
98.08 ± 0.31%; p = 0.1161). To validate our immunostaining for TrkB, we also 
immunostained for TuJ1, Islet1 (a pan-sensory neuron marker), and GFP on P0 TGs 
isolated from TrkBGFP/+ or TrkBGFP/GFP mice. TrkB labeling overlapped nearly completely 
with GFP in TrkBGFP/+ mice, which retain one functional copy of TrkB protein, but no 
TrkB immunolabeling was observed in TrkBGFP/GFP knockout mice (Li et al., 2011), 
despite the presence of GFP+ neurons (Figure 4.5).  
 
Ret is required for the amplification of Phox2b 
Two possibilities can explain the loss of Phox2b expression in Ret knockout mice at 
E18.5: (1) Ret is required for the initiation of Phox2b expression within the 
chemosensory GG population; or (2) Ret is required for the amplification of Phox2b 
expression within chemosensory GG neurons. To distinguish between these two, we 
crossed Ret conditional knockout mice (Retfx/fx)(Luo et al., 2007) with Phox2b-Cretg/+ 
mice (Ret-cKO). Retfx/fx; Phox2b-Cre+/+ (Ret-WT) mice were analyzed as a control. 
These mice will only undergo recombination following the initiation of Phox2b 
expression, thereby testing whether Ret is needed for the initiation of Phox2b. Tissues 
were immunostained for Phox2b and TuJ1 and total neuron numbers and the proportion 
of Phox2b+ GG neurons were quantified. Interestingly, there was no difference in total 
neuron numbers (Figure 4.6A-B; Ret-WT: 723.60 ± 13.47 vs. Ret-cKO: 789.15 ± 25.43; 
p = 0.0712) or in the proportion of Phox2b+ neurons (Figures 4.6A-C; Ret-WT: 65.07 ± 
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1.02% vs. Ret-cKO: 61.39 ± 2.98%; p = 0.3503), indicating that Ret is dispensable for 
Phox2b maintenance. To further explore this hypothesis, we crossed Ret conditional 
knockout mice with conventional germline knockout mice to generate Retfx/- mice (and 
Retfx/+ mice as a control). The Ret conditional knockout mice were created to harbor a 
single nucleotide missense mutation (V805A) in the tyrosine kinase domain, which is 
functionally silent but makes Ret in these mice susceptible to a highly selective 
chemical inhibition of kinase activity with the pharmacologic inhibitor 1NM-PP1 (Chen et 
al., 2005a). Ret signaling in vivo generally functions via a positive feedback loop, where 
Ret activation promotes further Ret expression, and blocking Ret activation therefore 
impairs Ret expression (Luo et al., 2007; Tsui-Pierchala et al., 2002c). We used this 
system as a reversible means of reducing Ret levels and activity during a defined 
developmental time window.  
 
To verify that daily systemic administration of 1NM-PP1 was effective in reducing total 
Ret levels, pregnant dams were injected daily with 1NM-PP1 from E14.5-E17.5, and 
spinal cords were isolated from E18.5 Retfx/+ and Retfx- embryos, followed by 
quantitative immunoblotting for Ret and actin (as a loading control, Figure 4.7A). This is 
an especially strict confirmation of Ret knockdown, as 1NM-PP1 must pass through the 
blood brain barrier to achieve adequate inhibition of spinal cord neurons, in contrast to 
the GG in the periphery. Importantly, we observed that administration of 1NM-PP1 to 
Retfx/- mice led to a substantial reduction in total Ret levels, as predicted (Retfx/+: 1.00 ± 
0.19 arbitrary units (a.u) vs. 0.23 ± 0.05 a.u.; 77% reduction; p = 0.0048; Figure 4.7B). 
Having demonstrated that this technique is effective in knocking down Ret in a 
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temporally controlled manner, we administered 1NM-PP1 to Retfx/- and Retfx/+ mice from 
E9.5-E12.5, with analysis at E18.5, and from E13.5-E17.5, with analysis at E18.5. 
Interestingly, when compared to GGs collected from Retfx/+ mice, Retfx/- animals 
administered 1NM-PP1 from E9.5-E12.5 again had no change in total neuron numbers 
(Retfx/+: 710.25 ± 20.67 vs. Retfx/-: 659.60 ± 26.30; p = 0.2056; Figure 4.7C, 4.7D), but 
displayed a 29.9% reduction in the proportion of Phox2b+ neurons (Retfx/+: 65.92 ± 
4.54% vs. Retfx/-: 46.24 ± 2.74%; p = 0.0041; Figure 4.7C, 4.7D). This was in contrast to 
the cohort of mice administered TMX from E14.5-E17.5, in which no changes were 
observed in total neuron numbers (Retfx/+: 698.44 ± 35.74 vs. Retfx/-: 676.18 ± 23.46; p = 
0.6167; Figure 4.7E) or in the proportion of Phox2b+ neurons (Retfx/+: 63.78 ± 3.70% vs. 
Retfx/-: 61.56 ± 2.01%; p = 0.6118; Figure 4.7F). These data indicate that Ret is required 
for the early amplification of Phox2b expression in chemosensory neurons, but is 
dispensable for its maintenance, concordant with the observed spatiotemporal 
expression pattern of Ret. Additionally, the data demonstrate that an early disruption of 
Ret signaling, between E9.5-E12.5, is sufficient to irreversibly impair Phox2b 
expression. Lastly, Ret is not required for the survival of GG neurons, and appears to 
specifically regulate chemosensory cell fate determination. 
 
Loss of Ret results in fungiform papilla chemosensory innervation deficits 
Germline Phox2bLacZ/LacZ knockout mice have normal total GG neuron numbers 
(D'Autreaux et al., 2011). In these mice, however, chemosensory neurons transitioned 
to a molecular profile consistent with a somatosensory neuronal fate (Brn3a+, Runx1+, 
Drg11+), accompanied by a conversion to somatosensory axonal projection patterns. 
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Although loss of Ret only leads to a partial disruption in Phox2b expression in 
chemosensory neurons, we hypothesized that chemosensory innervation of fungiform 
papillae would also be disrupted. Anterior tongues were collected from E18.5 Ret+/+ and 
Ret-/- mice, and stained for TuJ1, P2X3 (a selective marker of chemosensory nerve 
fibers)(Ishida et al., 2009), and K8 (to label early taste buds). When analyzing the entire 
papilla, no difference was observed in the amount of K8+ immunolabeling (Figure 4.8A, 
4.8B; p = 0.5367) or in the density of TuJ1+ immunolabeling (Figure 4.8A, p = 0.3629) 
between Ret+/+ and Ret-/- mice. Interestingly, we observed a highly significant reduction 
in P2X3-labeled nerve fibers within the total fungiform papillae area (Figure 4.8A, 4.8C; 
29.0% reduction; p < 0.0001). Correspondingly, we observed a substantial reduction in 
P2X3-labeled fibers when restricting analysis to the K8+ taste bud region (Figure 4.8D; 
38.9% reduction; p < 0.0001), despite a small but significant increase in total TuJ1+ 
immunolabeling within the taste bud area (p = 0.0199). Collectively, these data indicate 
that loss of Ret leads to subsequent loss of chemosensory differentiation, ultimately 
leading to deficits in the axon terminal expression of the neurotransmitter receptor 
P2X3.  
 
Ret reemerges in a unique subpopulation of chemosensory neurons postnatally 
Building on the demonstrated embryonic role for GDNF-Ret signaling in prenatal 
chemosensory cell fate determination, we determined whether Ret expression remains 
extinguished postnatally. Using Rosa26LSL-tdTomato; Ret-Cre/ERT2 mice we examined Ret 
expression within the first week of postnatal life, a time during which the peripheral taste 
system is still maturing, and in adulthood, when complete maturation is reached. TMX 
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was administered daily to P3-P7 or P60-P64 mice with analysis commencing one day 
following the last TMX administration (postnatal day 8 and 65, respectively). 
Surprisingly, given that Ret expression was nearly completely lost by late embryonic 
development (E18.5 timepoint from Figure 4.2B re-graphed in Figure 4.9C), we 
observed an upregulation of Ret within a subpopulation of chemosensory GG neurons 
at P8 (14.53 ± 0.64%; Figure 4.9A-C), which was further increased by P65 (20.11 ± 
2.72%; Figure 4.9B-C).  
The low abundance of Ret+ chemosensory GG neurons is reminiscent of 
subpopulations within the DRG and TG, where distinct subpopulations of neurons can 
be defined by their expression of neurotrophic factor receptors, somal diameter, and 
molecular properties, all of which influence their sensory properties (Liu and Ma, 2011). 
Within the GG chemosensory population, there is evidence that these neurons are 
heterogeneous in terms of size, electrical properties, and neurochemical signature (Al-
Hadlaq et al., 2003; Boudreau et al., 1971; Fei and Krimm, 2013; Grigaliunas et al., 
2002; Kitamura et al., 1982; Lundy and Contreras, 1999; Yokota and Bradley, 2016). To 
further characterize the Ret+ population within the GG and determine whether these 
neurons represent a distinct subpopulation, we analyzed the somal diameter of Ret+ 
chemosensory neurons (RFP+/Phox2b+) compared to Ret+ somatosensory neurons 
(RFP+/Phox2b-), which represent 82.28% and 17.72% of the total Ret+ neurons in the 
GG, respectively (Figure 4.10A). The Ret+ chemosensory neurons, on average, were 
significantly larger than Ret+/Phox2b- neurons (Figure 4.10B, C; 22.34 ± 0.23 µm vs. 
20.51 ± 0.43 µm; p = 0.0005), and 23.22% of Ret+ chemosensory GG neurons have 
somal diameters greater than 27 µm, compared to 10.53% of Ret+ somatosensory 
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neurons. Interestingly, 66.59% of neurons expressed Ret, but not TrkB (Ret+/TrkB-), 
whereas 33.41% of neurons expressed both receptors (Ret+/TrkB+; Figure 4.10D, 
4.10E; yellow arrows). The Ret+/TrkB- neurons were typically larger than Ret+/TrkB+ 
neurons (p < 0.0058; 23.81 ± 0.26 µm for Ret+/TrkB- compared to 22.65 ± 0.33 µm for 
Ret+/TrkB+) and also Ret-/TrkB+ neurons (p = 0.0001; 19.28 ± 0.15 µm for Ret-/TrkB+). 
Ret+/TrkB+ neurons were also significantly larger than the Ret-/TrkB+ neurons (p < 
0.0001). These data argue for the existence of at least three distinct subpopulations of 
neurons within the GG based on morphological properties of the cells as well as 
neurotrophic factor receptor expression. 
Ret signaling defines a subpopulation of large-diameter neurofilament heavy 
chain-enriched (NF200+) low threshold mechanoreceptors within the DRG (Bourane et 
al., 2009; Luo et al., 2009). Given that GG Ret+ neurons were of larger diameter, we 
examined whether Ret+ GG neurons expressed NF200. Additionally, we analyzed 
which GFRα co-receptors were expressed within GG neurons. Interestingly, we 
observed GFRα1 immunoreactivity within Ret+/NF200+ GG neurons (Figure 4.9D), but 
were unable to detect either GFRα2+ or GFRα3+ GG neurons (Figure 4.11A), despite 
the presence of strong immunoreactivity for both co-receptors within the TG (Figure 
4.11B), as has been previously reported (Heuckeroth et al., 1999; Naveilhan et al., 
1998). Additionally, to further characterize the NF200+ population of neurons, we 
analyzed adult Rosa26LSL-tdTomato/+; Phox2b-Cretg/+ GGs. As expected, Brn3a and 
Phox2b immunolabeling were almost mutually exclusive with only rare examples of 
double-labeled neurons (green arrows, Figure 4.11C). Although examples of 
Brn3a/NF200+ neurons (yellow arrows) were observed, Phox2b/NF200+ neurons (blue 
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arrows) were much more abundant, indicating that a large population of transcriptionally 
chemosensory neurons express the mechanoreceptor marker NF200 (Figure 4.11C). 
To validate the postnatal increase in expression, lysates were prepared from P0 or adult 
GG and quantitative immunoblotting was performed (Figure 4.11D). As expected, we 
observed a statistically significant increase in normalized Ret expression in adult mice 
compared to P0 (Figure 4.11E), further substantiating the postnatal increase in Ret 
expression. Collectively, these data indicate that Ret expression re-emerges postnatally 
within large diameter chemosensory neurons expressing Ret, GFRα1 and NF200, and 
thus, molecularly define a unique subpopulation of lingual GG sensory neurons that are 
likely to be mechanoreceptors.  
 
Examination of Ret+ nerve fibers within fungiform papillae 
To investigate whether Ret-expressing chemosensory GG neurons project into TBs, we 
immunostained anterior tongues dissected from TMX-labeled adult Rosa26LSL-tdTomato; 
Ret-Cre/ERT2 mice for TuJ1 (green), RFP (Ret; red), and K8 (blue). Fungiform papillae 
were imaged in their entirety, and we documented anterior, middle, and posterior 
locations on the tongue. To determine the projection pattern of Ret+ nerve fibers, 
maximum projection images were utilized, along with the original composite z-stack to 
assess whether nerve fibers were terminating within the K8+ taste bud area. RFP+ 
nerve fibers (red) terminating within the K8+ area were classified as intragemmal, while 
those terminating outside the K8+ area were classified as extragemmal. There was 
variability in the extent of innervation of fungiform papillae, although 94.89% of all FP 
had either a combination of extragemmal and intragemmal (Figure 4.12A) Ret+ nerve 
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fibers or exclusively extragemmal nerve fibers (Figure 4.12B). To quantify the extent of 
Ret+ innervation within each category (extragemmal and intragemmal), we further 
divided each group into three categories: (1) no innervation; (2) less than 3 nerve 
branches; and (3) greater than 3 nerve branches. When analyzing extragemmal Ret+ 
fibers, we observed that 85.2% of FP were extensively innervated by Ret+ fibers (> 3 
branches), 13.1% of FP were moderately innervated by Ret+ fibers (1-3 branches), and 
1.7% of FP had no extragemmal Ret+ fibers (Figure 4.12C), although in all three of 
these cases no nerve fibers were observed. When analyzing intragemmal Ret+ fibers 
(those within the K8+ region), we observed 13.1% of FP had >3 branches, 31.8% had 
1-3 branches, and 56.25% had no intragemmal Ret+ nerve fibers (Figure 4.12D). To 
determine whether the location of FP on the dorsal tongue influenced innervation 
density or pattern, when normalizing for the total number of FP counted within each 
region (tip vs. middle vs. posterior tongue), we observed no changes in the distribution 
of either extragemmal or intragemmal nerve fibers (Figure 4.13A, 4.13B). Additionally, in 
7.96% of FP, we observed elongated Ret+ TRCs which extended the full length of the 
taste bud (Figure 4.13C), and in all instances these were present on the anterior-most 
tip of the tongue. 
 
GDNF is expressed within fungiform papillae, but not geniculate ganglion 
neurons 
Based on the expression of GFRα1 within GG neurons, and the complete lack of 
GFRα2 and GFRα3, the expression pattern of GDNF was examined. We used 
Rosa26LSL-tdTomato; GDNF-IRES-Cre/ERT2 mice, and these adult mice were administered 
188 
 
TMX on 5 successive days, euthanized, and GG and anterior tongues were collected. 
Tongues were immunostained for TuJ1, RFP (GDNF), and K8 or E-Cadherin (E-Cad), a 
marker of cells within the lingual epithelium. Importantly, GDNF was expressed 
predominantly within the basal epithelium layer, both in the fungiform papilla walls as 
well as the cells within and around the taste bud (Figure 4.12E). No GDNF+ nerve fibers 
were observed, indicating a lack of GDNF expression by GG neurons themselves. 
Correspondingly, analysis of the GG confirmed this result, as no examples of GDNF+ 
neurons were observed within the GG, although GDNF+ satellite cells within the facial 
nerve were occasionally seen (Figure 4.14E).  
  
Differences in the innervation patterns have been reported between extragemmal 
nerve fibers originating from the Phox2b-/Brn3a+ TG, somatosensory in nature, and 
intragemmal nerve fibers originating from the Phox2b+/Brn3a- GG, chemosensory in 
nature (Dauger et al., 2003b; Zaidi and Whitehead, 2006). We further examined this 
model using adult Rosa26LSL-tdTomato/+; Phox2b-Cretg/+ mice to selectively label and trace 
GG/CT chemosensory afferent fibers within FP. To our surprise, when analyzing FP, we 
observed that 31.8% of FP analyzed had > 3 nerve fibers outside the K8+ region 
(Figure 4.14A), 18.5% of FP had 1-3 nerve fibers outside the K8+ region (Figure 4.14B), 
and 49.7% of FP had no extragemmal nerve fibers (Figure 4.14C; quantifications 
provided in Figure 4.12D). Confirming previous studies, all papillae analyzed (151/151) 
had intragemmal labeling. These data suggest that some Phox2b+ GG neurons may 
project extragemmally, to an area adjacent to the K8+ taste bud region. Thus, while 
analysis of intragemmal nerve fibers is a strong predictor of chemosensory innervation 
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origin, analysis of extragemmal innervation may represent a mixture of somatosensory 
TG afferents and Phox2b+/chemosensory GG/CT afferents. However, we cannot rule 
out the potential contribution of Phox2b+ sympathetic nerve fibers to the FP. Although 
only 43.75% of Ret+ nerve fibers project intragemmally, a proportion of the observed 
extragemmal nerve fiber labeling (98.30% of all FP) may also be of chemosensory 
origin.  
 
Ablation of Ret+ geniculate neurons results in a loss of tactile, but not chemical 
or cold responses 
We next sought to determine whether Ret+ GG neurons underlie a particular lingual 
sensory modality. Ret-Cre/ERT2 mice were crossed with a transgenic Rosa26LSL-DTA/LSL-
DTA line (abbreviated DTA+/+), whereupon TMX administration leads to ablation of all 
Ret+ cells, thereby eliminating all GG neurons expressing Ret (Figure 4.15A). These 
DTA mice have been previously characterized, and show very rapid loss of cells 
following Cre induction (Wu et al., 2006). TMX was administered to adult RetCre/+; 
DTA+/+ (Ret-ablated) mice or Ret+/+; DTA+/+ (wildtype) mice, as a control, for three days, 
followed by whole nerve recording from the CT nerve. In all mice, efficacy of Ret+ 
neuron ablation was confirmed histologically following electrophysiological recordings 
by analyzing total Phox2b+ neurons. Ret-ablated mice had fewer Phox2b+ neurons 
compared to WT mice (WT: 384.5 ± 15.6 neurons vs. Ret-ablated: 336.6 ± 27.8 
neurons; a 12.5% reduction; n=9 and n=14, respectively; representative image shown in 
Figure 4.15B), although some variability was observed. Given our data indicating that 
approximately 20% of adult neurons express Ret, and most of these (82.28%) neurons 
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are chemosensory, we reasoned that our ablation efficacy was similar to the expected 
value (16.5%). Additionally, other phenotypic effects in Ret-ablated mice were observed 
that indicated a reliable ablation of Ret+ cells, such as an enlarged gastrointestinal tract, 
indicative of a Hirschsprung’s-like phenotype. Interestingly, when focusing our analysis 
on the mice verified to have strong deletion meeting the inclusion criteria (see methods), 
we observed no differences in chemical responses (Figure 4.16A, Figure 4.15C) or cold 
responses (Figure 4.16B, Figure 4.15D) in any of the Ret-ablated mice compared to WT 
controls. In stark contrast, we observed a complete loss of tactile responses in 4/7 Ret-
ablated mice, despite the presence of spontaneous nerve activity. Additionally, we 
observed a substantially weakened tactile response in 1/7 Ret-ablated mouse, and no 
change in tactile responses in 2 Ret-ablated mice (Figure 4.16C, Figure 4.15E). 
Because responses to tactile stimuli are rapidly adapting, and not sustained, we present 
raw responses rather than summated recordings for tactile stimulation. These data 
indicate that the Ret-expressing GG neurons projecting via the chorda tympani nerve to 
FPs are a population of functionally-unique mechanoreceptors, although we cannot rule 
out that they may be multimodal in function.  
 
Discussion 
Ret specifies chemosensory cell fate acquisition 
The coexistence of distinct chemosensory and somatosensory neurons within the same 
ganglion, each with unique transcriptional codes and subsequent peripheral and central 
projection patterns, makes the GG is an interesting model in which to study sensory 
neuron specification. Our analysis of mice with germline Ret deletion (Figure 4.4A-C), 
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conditional deletion of Ret following Phox2b expression (Figure 4.6A-C), and temporal 
pharmacologic inhibition of Ret (Figure 4.7C-G) support the notion that Ret is required 
for Phox2b amplification, but not its initiation or maintenance. Interestingly, Ret deletion 
did not impact neuronal survival and we observed no significant change in the 
expression pattern of the neurotrophic factor receptor TrkB (Figure 4.4D, 4.4F), the 
neurotrophic signaling pathway supporting GG neurons during axon guidance and 
target-dependent survival (Ma et al., 2009). Additionally, the loss of Ret impaired 
chemosensory innervation of developing taste buds within the fungiform papillae (Figure 
4.8A-F), arguing that loss of chemosensory cell fate leads to a subsequent impairment 
in peripheral projections of GG neurons. However, whether this reflects a complete loss 
of these nerve fibers, or simply a loss of the chemosensory-specific neurotransmitter 
receptor P2X3 used to label these fibers, is unknown. 
 
A previous study analyzing Phox2bLacZ/LacZ knockout mice demonstrated that loss of 
Phox2b in chemosensory GG neurons results in acquisition of Brn3a expression 
(D'Autreaux et al., 2011). Despite loss of Phox2b expression, we did not see an 
increase in the proportion of geniculate neurons expressing the determinant Brn3a 
(Figure 4.4F, G). Although our data support the notion that Ret promotes Phox2b 
expression within chemosensory neurons, and its removal results in a substantial loss 
of Phox2b, Ret deletion is not synonymous with the complete knockout of Phox2b. 
These results may reflect the partial nature of the Ret knockout phenotype, as only a 
30-40% reduction in the proportion of chemosensory neurons expressing Phox2b was 
observed (depending on the experimental model analyzed). In addition, many more 
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neurons had a qualitative reduction Phox2b expression, with some residual expression 
remaining. Two previous studies investigating the interrelationship of Brn3a with Ret in 
the DRG (Zou et al., 2012) and the TG (Huang et al., 1999) demonstrated that Brn3a 
and Ret are spatially segregated in their expression patterns, and that Ret+ neurons are 
spared in Brn3a knockout mice. For these reasons, it is perhaps not surprising that Ret 
deletion does not impact Brn3a. Likely, the residual low level of Phox2b expression is 
sufficient to inhibit Brn3a expression within these neurons, suggesting that the role of 
Ret in this process is to amplify the expression of Phox2b, but Ret signaling itself does 
not directly influence Brn3a expression. Building on the aforementioned studies, and 
based on our results, we propose a model in which (1) Phox2b induces Ret expression 
in chemosensory neurons; (2) Ret, acting as part of a positive feedback loop, amplifies 
the expression of Phox2b during the early embryonic window prior to target innervation; 
(3) Phox2b represses Brn3a expression. Thus, there is a critical window in which the 
interaction between Ret and Phox2b is required for the acquisition of the appropriate 
transcriptional fate.  
 
Ret specifies a distinct subpopulation of chemosensory neurons postnatally 
Based on experiments analyzing Ret reporter mice, approximately 20% of GG neurons 
express Ret in adult mice. These findings bear some similarity to other sensory neuron 
populations wherein there are subpopulations of neurons with differential neurotrophic 
factor receptor expression that can be delineated based on molecular, physical, and 
functional characteristics (Lallemend and Ernfors, 2012). Most Ret+ GG neurons were 
chemosensory as defined by Phox2b expression (82.28%; Figure 4.10A), with 
193 
 
approximately a 2:1 ratio of neurons lacking TrkB (Ret+/TrkB-) compared to neurons 
expressing both receptors (Ret+/TrkB+; Figure 4.10D-E). These neurons were large in 
diameter, when compared to neurons positive for only TrkB (Figure 4.10), and 
expressed the mechanoreceptor marker NF200 (Figure 4.10D). Additionally, when 
analyzing GFRα co-receptors present within the GG, which are required for downstream 
Ret signaling, only GFRα1 was detectable (Figure 4.10D, 4.11). Correspondingly, we 
observed many Ret+ nerve fibers, both intragemmal and extragemmal in nature (Figure 
4.12), as well as many GDNF+ cells within the fungiform papillae, including those within 
and immediately surrounding the taste bud region (Figure 4.12E).  Finally, 
electrophysiological recordings of mice in which Ret+ neurons were ablated indicate 
that these Ret+ neurons function as a unique subpopulation of GG/CT afferent 
mechanoreceptive neurons (Figure 4.16).   
 
While several studies have begun to expand our knowledge of the heterogeneity within 
the GG (Boudreau et al., 1971; Fei and Krimm, 2013; Finger et al., 2005; Lundy and 
Contreras, 1999; Yokota and Bradley, 2016), our understanding of the cellular basis 
defining the multi-modality of orofacial chemosensory neurons remains quite 
rudimentary in comparison to TG and DRG somatosensory neurons, where as many as 
11 molecularly distinct subpopulations have been described (Usoskin et al., 2015). This 
is the first study demonstrating the existence of a molecularly, morphologically, and 
functionally distinct lingual GG neuron subtype. Given that Ret+ neurons are 
chemosensory (Phox2b+) in molecular profile, but have physiological and morphological 
properties of mechanoreceptors, they represent a unique population dissimilar from 
194 
 
pinna-projecting somatosensory neurons within the GG, lingually-projecting 
chemosensory neurons within the GG, as well as Ret+ mechanoreceptors in the TG and 
DRG. As such, the specific nomenclature for these transcriptionally chemosensory, but 
functionally somatosensory, neurons is a subject for debate. Interestingly, mice 
administered pharmacologic purinergic receptor inhibitors (Vandenbeuch et al., 2015) 
as well as P2X2/P2X3 double knockout mice (Finger et al., 2005) lose chemical, but not 
tactile responses. Furthermore, loss of the fungiform TBs following pharmacologic 
inhibition of the sonic hedgehog pathway disrupts chemical, but not tactile, chorda 
tympani responses (Kumari et al., 2015), suggesting that the taste bud itself is not 
required for the mechanical responses. Thus, it remains unknown what the gating 
mechanisms are for these mechanical responses, as well as what pre-synaptic lingual 
sensory end-organs are responsible for communicating with these fibers. Further 
defining the receptive fields and adaptation properties of these neurons remains an 
important future direction, as does the identification of the physiological significance of 
these neurons.    
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Experimental Procedures 
 
Production of Embryos, Tamoxifen Delivery, and 1NM-PP1 Administration 
Retfx/fx (Luo et al. 2007), Ret-/- (Schuchardt et al., 1994), Ret-Cre/ERT2 (Luo et al. 2009), 
Rosa26LSL-TdTomato (Madisen et al., 2010), Phox2b-Cretg/+ (Rossi et al., 2011), GDNF-
IRES-Cre/ERT2 (Cebrian et al., 2014), and Rosa26LSL-DTA (Wu et al., 2006) mice have all 
been previously described. All mice were maintained in mixed genetic backgrounds and 
all comparisons were made using littermates. For timed mating experiments, noon of 
the day on which a vaginal plug was detected was considered E0.5. For the 
experiments tracing Ret or GDNF expression, tamoxifen (TMX; T5648, Sigma Aldrich, 
St. Louis, MO) was dissolved in corn oil and administered via intraperitoneal injection at 
a dose of 0.25 mg/g body weight, at timepoints described in the figure legends, with 
Cre-negative littermate controls analyzed in all experiments. For the experiments 
utilizing the pharmacologic inhibitor 1NM-PP1 (catalog #529581, EMD Millipore, 
Temecula, CA), pregnant dams were given i.p. injections daily (16.6 ng/g body weight, 
as previously described)(Chen et al., 2005a) at the indicated timepoints, and 1NM-PP1 
was also maintained in the drinking water at a concentration of (1 mM) to maintain 
chemical inhibition. All experiments were carried out in compliance with the guidelines 
of the Association for Assessment and Accreditation of Laboratory Animal Care 
International (AAALAC) and were approved by the Institutional Animal Care and Use 
Committee (IACUC) of the University of Michigan.  
 
Neuron Counts, Somal Diameter Measurements, and Innervation Classification 
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The average somal diameter of GG neurons was observed to be 22.02 ± 0.20 µm, and 
for this reason we performed cell counts on 20 µm serial sections of the entire GG. For 
experiments analyzing TGs from Rosa26LSL-tdTomato/+; Phox2b-Cretg/+ mice, counts were 
performed on 3 sections per ganglion, approximately 200 µm apart. Somal diameters 
were measured at the widest aspect of each neuron using the TuJ1 channel. For 
innervation classifications, maximum projections as well as the original composite z-
stack images were utilized to assess whether nerve fibers were terminating within the 
K8+ taste bud area. Nerve fibers terminating within the K8+ area were classified as 
intragemmal, while those terminating outside the K8+ area were classified as 
extragemmal. Greater than 3 nerve fibers was chosen as an arbitrary cutoff point to 
subcategorize FP into those having extensive (>3 fibers) or slight-moderate (1-3 fibers) 
innervation density. Detailed description of the protocol used for Fiji quantification of 
fungiform papilla innervation and Phox2b expression are expanded in the Supplemental 
Information.  
 
Statistics and Data Analysis 
All results are expressed as the mean ± s.e.m. All statistical tests were performed using 
two-tailed parameters with a significance level of p ≤ 0.05 to test for statistical 
significance. A two-tailed student’s t-test was utilized for all comparisons between two 
treatment groups.  Comparisons between more than two treatment groups were 
performed with one-way ANOVA. The data were originally entered into Excel and 
imported into GraphPad Prism, which was used for all statistical tests and graph 
production. The presence of asterisks indicates statistical significance. * = p < 0.05, ** = 
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p < 0.01, *** = p < 0.001, **** = p < 0.0001. The sample sizes are indicated in the results 
and figure legends. No sample sizes of less than 3 independent experiments were 
utilized. For all GG counts, when possible, each animal represents the average count of 
two GGs to increase statistical accuracy. For all pooled analyses of FP, statistical tests 
were performed on both the pooled data and the individualized animal data to ensure 
that no differences in outcome were obtained.  
 
Chorda Tympani Nerve Recordings 
Mice were anesthetized with a ketamine-xylazine mixture (80-100 mg/kg ketamine, 5-10 
mg/kg xylazine delivered i.p.) and maintained with ketamine (80-100 mg/kg) as needed. 
The CT was exposed by a lateral approach, dissected, cut centrally, and placed on a 
recording electrode. An indifferent electrode was placed in nearby tissue. Amplified 
neural activity was observed in an oscilloscope and passed through an analog-to-digital 
converter and recorded using the Spike2 program (Cambridge Electronic Design). The 
amplified signal was also passed through an integrator circuit with 0.5 sec time 
constant. Tactile stimuli consisted of stroking the anterior tongue quadrant five times 
over a period of 5s, while thermal stimuli consisted of application of 4°C water. The 
indicated chemical stimuli were dissolved in distilled water at room temperature, and 3-5 
mL was applied to the tongue using a syringe. Chemicals remained on the tongue for 
20s, followed by a distilled water rinse for 30s. NaCl and NH4Cl were applied throughout 
the nerve recording to monitor stability and changes from baseline. The initial increase 
in integrated recordings at onset and rinse of chemicals from the tongue includes the 
stimulus artifact, seen when a chemical or rinse contacts the tongue (Yokota and 
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Bradley, 2016), and the initial high frequency transient response can be useful for 
measuring response latency or assessing temporal aspects of the summated response. 
Neither integrated onset or offset is related to the somatosensory response. The tactile 
responses observed were to a moving, light stroking stimulus only.  
 
 
Fixation, Sectioning, and Immunostaining 
GG and TG were collected and fixed overnight in 4% paraformaldehyde at 4°C, while 
tongues were dissected within the mandible and fixed for 2-3 hours, dissected free from 
the mandible, and fixed for another 2-3 hours at room temperature.  Tissues were 
cryopreserved, embedded in OCT (Tissue Tek, VWR, Radnor, PA) and stored at -80°C 
until sectioning. GGs and TGs were sectioned at a thickness of 20 µm on a cryostat 
(CM1950, Leica Biosystems, Germany), except for one cohort of animals where 
sections were produced at 40 µm. In all cases, sections were collected serially. 
Tongues were sectioned at a thickness of 20 µm for Ret and GDNF expression tracing 
experiments, while 50 µm sections were produced and collected serially for the analysis 
of Ret knockout mice to avoid double counting FPs. For immunostaining, sections were 
first rehydrated in PBS for 30 minutes at room temperature, following by blocking in 
10% normal donkey serum (Jackson ImmunoResearch, West Grove, PA), 0.25-0.5% 
bovine serum albumin (Sigma, Billerica, MA), and mouse-on-mouse blocking reagent (1 
drop per 1.5 ml blocking solution; Vector Laboratories, Burlingame, CA) in 0.3% triton X-
100/PBS (PBS-X). Following blocking, the following primary antibodies were diluted in 
0.3% PBS-X and incubated on the sections overnight at 4°C (48 hours at 4°C for 50 µm 
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tongue sections) in a humidified chamber: α-RFP (1:200-1:500; 600-401-379; Rockland, 
Limerick, PA), α-Phox2b (1:200-1:500; AF4940; R&D, Minneapolis, MN), α-TuJ1 (βIII-
Tubulin; 1:200; T8578; Sigma), α-TrkB (1:250-1:400, AF1494, R&D), α-Brn3a/Pou4f1 
(1:25; MAB1585; Millipore), α-P2X3 (1:200-1:400; AB5895, Millipore), α-GFRα1 (1:50; 
AF560; R&D), α-GFRα2 (1:100; AF429; R&D), α-GFRα3 (1:100; AF2645; R&D), α-
NF200 (1:200-1:500; NFH, Aves Labs Inc., Tigard, OR combined with 1:500; ab8135; 
Abcam, Cambridge, MA), α-Islet1 (1:200; 39-4D5-s; Developmental Studies Hybridoma 
Bank, Iowa City, IA), α-cytokeratin-8 (TROMA-I; 1:50 [supernatant], DSHB), and α-E-
Cadherin (1:1000-1:2000; AF748; R&D). Slides were washed 3-4 times with 0.3% PBS-
X, and secondary antibodies against the intended species were added at a 
concentration of 1:200 (GG and TGs) or 1:400 (tongues) (all raised in donkey; CF488, 
CF543, or CF633 from Biotium Biosciences, Fremont, CA). After secondary antibody 
incubation, slides were washed with 0.3% PBS-X 3 times, followed by washes in PBS. 
Slides were coverslipped with DAPI Fluoromount-G (Southern Biotech, Birmingham, 
AL) and stored in darkness until imaging. All imaging was performed on a Leica SP5 
confocal microscope using the LAS-AF software (Leica Microsystems, Wetzlar, 
Germany). Images were taken at 20X or 63X magnification with high resolution 
(2048x2048) and a z-step size of 1 µm (tongues) or 2.0 µm (GG and TGs). For tongues, 
every FP (identified using DAPI) was imaged in its entirety (15-25 optical sections). For 
GGs and TGs, every section containing neurons (identified using TuJ1 channel) was 
imaged. Maximum projection and Median noise reduction (pixel width of 5 Kernels; LAS 
Software, Leica Biosystems, Buffalo Grove, IL) was applied to all files to generate a 
single composite image for all subsequent analyses.  
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Fiji Quantification of Fungiform Papilla Innervation and Phox2b Expression 
All FP from 50 µm sections produced from E18.5 Ret+/+ and Ret-/- anterior tongues were 
imaged in their entirety. During both image capture and analysis, the experimenters 
were naïve to the experimental conditions. All imaging of individual papillae took place 
at 63x magnification. Following image collection and processing, images were imported 
into ImageJ using the Fiji image processing package (Schindelin et al., 2012). 
Quantifications were performed in two ways: quantification of the P2X3+ and TuJ1+ 
pixels within the K8+ region, or quantification of the K8+, P2X3+, and TuJ1+ pixels 
within the entire fungiform papilla. The K8+ region was defined by setting the threshold 
to 1, and outlining all positive pixels, while the basal epithelium defining the fungiform 
papilla trench was used to delineate the entire fungiform papillae. Once the borders 
surrounding the full fungiform papilla or K8+ region were determined, the channels are 
split, converted to greyscale, and thresholds are set for each channel to minimize 
inclusion of background quantification. To control for variability in threshold setting, all 
quantifications were performed by two independent investigators (naïve to experimental 
conditions) and averaged together. Quantifications with greater than 10% variability 
between were omitted from inclusion. For the experiments analyzing residual Phox2b 
expression in Ret germline knockout mice, GGs were collected, sectioned, and imaged 
as described above. Channels were separated, converted to greyscale, and individual 
neurons were sampled by an observer naïve to experimental conditions. The data are 
reported as the mean pixel count per GG neuron ± s.e.m.  
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Tissue Lysis and Quantitative Immunoblotting 
Spinal cords were harvested from 1NM-PP1-treated Retfx/+ and Retfx/- mice at E18.5 
(Figure 3) and GG from P0 and adult C57BL/6J mice (Jackson Laboratory, Strain 
#000664) were placed in a 2.0 mL tube with 250 µL lysis buffer (pH 7.4 Tris-buffered 
saline, 10% glycerol, 500 µm sodium vanadate, and complete protease inhibitors) 
lacking detergent, along with a steel grinding ball (5mm, Qiagen, Valencia, CA). For the 
experiments utilizing GGs, ganglia were collected bilaterally along with the facial nerve, 
and 3 animals were pooled for each tube to increase protein yields. Tissues were then 
mechanically homogenized using the TissueLyzer II (Qiagen) at a frequency of 20 Hz 
for 5 minutes. The homogenates were mixed with equal volume of lysis buffer 
containing 2% Nonidet P-40 (NP-40), and incubated for 1 hour at 4°C under gentle 
agitation. Homogenates were then centrifuged for 10 minutes at 16,100xg twice to 
remove insoluble material. Samples were then prepared for sodium dodecyl sulfate-
polyacrylate gel electrophoresis (SDS-PAGE) by adding 2X sample buffer (pH 6.8 tris-
buffered saline, 20% glycerol, 10% β-mercaptoethanol, 0.05% bromophenol blue, and 
4% SDS) and boiling the samples. Samples for western blotting were subjected to SDS-
PAGE followed by electroblotting onto polyvinylidene difluoride membranes (Immobilon 
P, Millipore). Western blot analysis was performed using the following antibodies at the 
indicated concentrations: α-Ret (AF482, R&D, 1:1000) and α-actin (JLA-20, Iowa 
Hybridoma, 1:2000). For quantifications, scanned images of x-ray films were imported 
into ImageJ (National Institutes of Health, Bethesda, MD) and processed using the gel 
analysis toolkit. Integrated density values were reported as the mean ± s.e.m in arbitrary 
units (a.u.) on the vertical axis. Total Ret levels were normalized to actin as a loading 
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control. 1NM-PP1 experiments were performed on n=7 Retfx/+ and n=10 Retfx/- mice 
from 3 separate litters. Experiments comparing P0 vs. adult expression of Ret in the GG 
were performed on 5 (P0) or 6 (adult) separate lysates.  
 
Verification of Diphtheria Toxin Ablation 
Ret+ neuron ablation was verified in TMX-treated Ret-Cre/ERT2; Rosa26LSL-DTA/LSL-DTA 
mice by serially sectioning GG of Ret+/+; DTA+/+ and RetCre/+; DTA+/+ mice and 
performing Phox2b counts. Ret-ablated mice having full electrophysiological traces and 
demonstrating a loss of Phox2b+ neurons greater than one statistical deviation from the 
mean of the control group (a number chosen based on the adult expression data) were 
subsequently included in the analysis, while those not meeting these criteria were 
excluded.  
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Figures: 
Figure 4.1. Characterization of Phox2b-Cretg/+ mice and Phox2b immunostaining. 
(A) GGs were collected from P0 Phox2b-Cre+/+; Rosa26LSL-TdTomato/+ (upper panels) or 
Phox2b-Cretg/+; Rosa26LSL-TdTomato/+ (lower panels) and stained for TuJ1 (green), Phox2b 
(blue), RFP (indicates Ret; red), with the merged image displayed in the right most 
panels. Nearly complete overlap (98.84 ± 0.11%) was observed of Phox2b-
immunoreactivity and RFP staining, indicating high reliability of Phox2b immunostaining. 
(B) TGs from the mice Phox2b-Cretg/+; Rosa26LSL-TdTomato/+ had a nearly complete 
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absence of Phox2b immunoreactivity (blue) and a corresponding absence of RFP 
labeling, further validating Phox2b immunostaining and the Phox2b-Cretg/+ reporter. 
Similar results were observed in GG from n = 4 separate mice. Scale bar represents 
100 µM.  
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Figure 4.2. Ret is highly expressed in chemosensory geniculate neurons early in 
development. 
(A) Experimental strategy for tracing Ret expression in embryonic geniculate ganglia. 
Tamoxifen (TMX) was administered to Ret-Cre/ERT2; Rosa26LSL-TdTomato/+ reporter mice 
at E9.5-E12.5 with E13.5 analysis (upper) and E14.5-E17.5 with E18.5 analysis (lower). 
(B) Quantification of the proportion of chemosensory (Phox2b+) neurons expressing Ret 
demonstrates widespread expression within chemosensory neurons (E13.5; n=3), but 
Ret expression is extinguished perinatally (E18.5; n=4). (C) Quantification of the 
proportion of somatosensory (Phox2b-) neurons expressing Ret. (D-F) 
Immunofluorescence with TuJ1 (green), Phox2b (blue), and RFP (indicating Ret; red) 
with merged images on the right. (D) Staining in a Ret+/+ littermate demonstrates 
specificity of RFP antibody. (E) Ret was widely expressed in chemosensory neurons at 
the E13.5 analysis timepoint, but (F) largely absent upon analysis at E18.5. Note that 
the TG in the upper right hand corner of the image has many Ret+ neurons at this age. 
Scale bar represents 50 µm. 
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Figure 4.3. Validation of TrkB immunostaining. 
Ganglia from P0 heterozygous TrkBGFP/+ (one functional copy of TrkB protein; left 
column) or homozygous TrkBGFP/GFP (no TrkB protein produced; right column) mice 
were sectioned and immunostained for Islet1 (pan sensory marker; red), GFP 
(indicating cells normally expressing TrkB; green), and TrkB (labeling actual TrkB 
protein; blue). Trigeminal ganglia were imaged. Nearly complete overlap of GFP and 
TrkB staining was observed in TrkBGFP/+ neurons, while no TrkB staining was observed 
in TrkBGFP/GFP ganglia, despite the remaining presence of TrkB+ large-diameter 
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neurons. These data provide evidence for reliable TrkB immunostaining using this 
antibody and immunostaining method. Similar results were observed from n = 3 
separate TGs. Scale bar represents 50 µM.   
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Figure 4.4. Ret is required for the expression of the chemosensory fate 
determinant Phox2b, but is dispensable for chemosensory neuron survival. 
(A) GGs were taken from E18.5 Ret+/+ and Ret-/- mice and immunostained for TuJ1 and 
Phox2b. The left panel displays the entire ganglion, and the area bordered by the white 
box is magnified on the right. Ret-/- mice had substantially fewer Phox2b+ neurons, and 
those with residual expression appeared reduced in Phox2b staining intensity. (B) The 
total number of GG neurons was assessed by counting TuJ1+ neurons. No difference 
was observed in total numbers of Ret+/+ GGs (n=6) compared to Ret-/- GGs (n=9; p = 
0.9014). (C) Quantification of the proportion of neurons expressing Phox2b. Ret-/- GGs 
had a reduction in Phox2b+ neurons compared to Ret+/+ GGs (40.1% reduction; p = 
0.0015). (D) The intensity of Phox2b expression was quantified in Ret+/+ and Ret-/- GG. 
Ret-/- GGs had significantly lower Phox2b immunolabeling (p < 0.0001) compared to 
Ret+/+ GGs. (E) Immunostaining was performed on Ret+/+ and Ret-/- GGs for the 
somatosensory transcription factor Brn3a and the BDNF receptor TrkB. (E) No 
differences were observed in TrkB expression (p = 0.1161, n=7 Ret+/+ and n=6 Ret-/- 
mice). (F) No differences were observed in Brn3a expression (p = 0.7587; n=7 Ret+/+ 
and n=6 Ret-/- mice). (G) Representative immunolabeling for TuJ1 (green), Brn3a (red), 
and TrkB (blue). The merged image demonstrates TrkB is widely expressed throughout 
the ganglion, while Brn3a expression is expressed in a polarized manner. (Scale bars 
represent 100 µm. Statistical significance for each comparison was determined with a 
two-tailed t-test. 
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Figure 4.5. Characterization of Ret+ adult geniculate ganglion neurons. 
(A) Classification of Phox2b expression in Ret-Cre/ERT2; Rosa26LSL-TdTomato/+ reporter 
mice given TMX as described in figure 5. 82.28% of all Ret+ neurons counted from n = 
5 mice were chemosensory (Phox2b+). (B) Histogram displaying the distribution of 
somal diameters, measured at the widest aspect of each RFP+ (Ret-expressing) 
neuron, in RFP+ chemosensory (Phox2b+) and somatosensory (Phox2b-) GG neurons. 
A trend was observed for RFP+/Phox2b+ neurons to be larger in diameter compared to 
RFP+/Phox2b- neurons (p = 0.0005). (C) Graphical representation of the somal 
diameter of RFP+/Phox2b- (blue dots) and RFP+/Phox2b+ neurons (orange dots) with 
the mean somal diameter indicated by the black line. Many more chemosensory Ret+ 
neurons were >30 µM in somal diameter. Two-tailed t-test indicated that the 
RFP+/Phox2b+ neurons were significantly larger than RFP+/Phox2b- neurons (p = 
0.0005). (D) Characterization of overlap in Ret expression with TrkB protein expression 
in Ret-Cre/ERT2; Rosa26LSL-TdTomato/+ reporter GGs administered TMX as described in 
Figure 5. Ret expression was observed to be more restricted compared to TrkB. 
Examples of RFP+/TrkB+ and RFP+/TrkB- (yellow arrow) neurons could be observed. 
Scale bar represents 50 µM. (E) Classification of overlap in RFP and TrkB expression (n 
= 4). Approximately 2/3 of neurons expressed Ret but not TrkB, while 1/3 of neurons 
expressed both receptors. (F) Histogram displaying the distribution of somal diameters 
in Ret-/TrkB+ (dark blue bars), Ret+/TrkB+ (light blue bars) and Ret+/TrkB- (red bars) 
GG neurons. As in B, somal diameter of Ret+/TrkB- neurons was shifted to the right 
(larger) compared to Ret+/TrkB+ and Ret-/TrkB+ neurons. (G) Graphical representation 
of the somal diameter of Ret-/TrkB+ (dark blue dots), Ret+/TrkB+ (light blue dots) and 
Ret+/TrkB- (red dots) with mean indicated by the black bars. A statistically significant 
increase in somal diameter was observed (one-way ANOVA) between all groups, with 
Ret+/TrkB- being significantly larger than Ret+/TrkB+ (p = 0.0058) and Ret-/TrkB+ (p < 
0.0001) neurons. Ret+/TrkB+ neurons were also found to be significantly larger than 
Ret-/TrkB+ neurons (p < 0.0001). 
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Figure 4.6. Expression profile of GFRα2, GFRα3, and NF200 in the geniculate 
ganglion. 
(A) GGs taken from adult Ret-Cre/ERT2; Rosa26LSL-TdTomato/+ reporter mice administered 
TMX were immunostained for TuJ1 (green), RFP (Ret; red), and GFRα2 (blue; upper) or 
GFRα3 (blue; lower), with the merged image displayed on the right. Although some 
GFRα2+ nerve fibers could be visualized within the nearby facial nerve, no neuronal 
staining was observed for either co-receptor within the GG. (B) To confirm that the 
GFRα2 and GFRα3 immunostaining procedure was working, we analyzed TGs taken 
from the mice described above. Clear examples of GFRα2+ (upper) and GFRα3+ 
(lower) TG neurons were observed, most of which co-expressed Ret. Similar results 
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were obtained in n=3 individual mice with similar results. Collectively, these data 
indicate that GFRα2 and GFRα3 are not present within GGs, providing further evidence 
for a GDNF-GFRα1-Ret signaling axis in adult GGs. (D) GGs were collected from adult 
Rosa26LSL-tdTomato/+; Phox2b-Cretg/+ mice and stained for NF200 (green), Brn3a (blue), 
and Phox2b (RFP; red) to ascertain the transcriptional profile of NF200+ GG neurons. 
We observed almost complete segregation of Brn3a and Phox2b expression (lower left 
panel merged), as expected based on previous literature. Rare examples of 
Brn3a+/Phox2b+ neurons were observed (green arrows). While some examples of 
Brn3a+/NF200+ neurons were observed (lower middle panel; yellow arrows), many 
more examples of Phox2b+/NF200+ neurons were observed (lower right panel; blue 
arrows). Scale bar represents 50 µM. 
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Figure 4.7. Ret is required for the amplification of Phox2b early in development. 
(A) The selective Ret inhibitor, 1NM-PP1 was administered to mice of the indicated 
genotypes at E14.5 until E18.5. Spinal cords were collected, homogenized, and 
detergent extracted, followed by immunoblotting for Ret, or actin (as a loading control). 
(B) Quantification of total Ret levels (normalized to actin). We observed a reduction of 
approximately 77% of total Ret levels following 1NM-PP1 administration in Retfx/- mice 
(n=7) compared to Retfx/+ mice (n=10; p = 0.0048). (C) Retfx/+ and Retfx/- mice were 
administered 1NM-PP1 via daily from E9.5-E12.5. Mice were euthanized on E13.5 and 
GGs were immunostained for TuJ1 and Phox2b. Similar to the results observed in Ret 
germline knockout mice, Retfx/- mice had substantially fewer Phox2b+ neurons with no 
apparent change in total neuron number. Total neurons (D) and the proportion of 
Phox2b+ neurons (E) were quantified. No difference was observed in total neuron 
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numbers (p = 0.2056; n = 4-6). Retfx/- had a reduction in the proportion of Phox2b+ 
neurons compared to Retfx/+ (p = 0.0041; n = 4-6). (F) Retfx/+ and Retfx/- mice were 
administered 1NM-PP1 as described in C from E14.5 to E17.5. GGs were again 
immunostained for TuJ1 and Phox2b. No significant differences were observed between 
genotypes in the total number of neurons (p = 0.6167; n = 5 for each) or (G) the 
proportion of Phox2b+ neurons (0.6118; n = 5 for each). Scale bar represents 100 µm.   
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Figure 4.8. Loss of Ret results in deficits in fungiform papilla chemosensory 
innervation.  
(A) Tongues were collected from E18.5 Ret+/+ and Ret-/- mice, serially sectioned at 50 
µm, and immunostained for TuJ1 (green), P2X3 (red), K8 (blue) and merged. Many 
more examples of FP lacking apically projecting P2X3+ fibers were observed in Ret-/- 
compared to Ret+/+ tongues (yellow arrow). (B) All fungiform papillae from n = 4 mice 
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were imaged (n = 300 Ret+/+ FP and n = 230 Ret-/- FP) and quantified as described in 
the Methods. When analyzing the entire papilla, no differences were observed in the 
number of K8+ pixels per FP (p = 0.5367). (C) A highly significant reduction in P2X3+ 
pixels was observed in Ret-/- mice (p < 0.0001). When analyzing only the nerve fibers 
present within the K8+ region, (F) P2X3+ pixels were substantially reduced (p < 
0.0001). The graphs in B-D display the individual data points (colored circle and 
squares), while the mean ± s.e.m. is indicated by the black line. Scale bar represents 25 
µm.  
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Figure 4.9. Ret is expressed postnatally in a subpopulation of GFRα1/NF200+ 
chemosensory neurons. 
(A) Ret-Cre/ERT2; Rosa26LSL-TdTomato/+ mice were administered TMX at P3-P7 and 
analyzed at P8 or (B) P60-P64 and analyzed at P65. GGs were stained for TuJ1 
(green), RFP (indicating Ret, red), and Phox2b (blue). (C) Quantification of Ret 
expression at E18.5 (re-graphed from figure 1B), P8, and P65 indicated that a 
substantial number of chemosensory neurons upregulate Ret postnatally. (D) Adult GGs 
from TMX-labeled Ret-Cre/ERT2; Rosa26LSL-TdTomato/+ were immunostained for RFP 
(red), GFRα1 (blue) and the mechanoreceptor marker neurofilament heavy chain 
(NF200). Many neurons demonstrated overlapping expression of all Ret, GFRα1, and 
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NF200 (representative image from n=4 individual experiments). Scale bars represent 50 
µm.  
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Figure 4.10. Characterization of Ret expression in fungiform papillae. 
(A) To determine whether any regional differences in Ret expression exist, we analyzed 
FP from adult Ret-Cre/ERT2; Rosa26LSL-TdTomato/+ reporter tongues labeled with TMX as 
described in figure 5. To control for the increased density of FP on the tip of the anterior 
tongue compared to the middle and posterior aspect of the anterior tongue, the number 
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within each group was divided by the total number of FP within that region to yield a 
percentage of all FP counted (n=5 individual mice). Regardless of regional localization, 
a similar distribution pattern was observed for extragemmal fibers (>3 fibers/tip: 81.65%; 
>3 fibers/middle: 83.78%; >3 fibers/posterior 90.00%; 1-3 fibers/tip: 15.59%; 1-3 
fibers/middle: 10.81%; 1-3 fibers/posterior: 10.00%; no fibers/tip: 2.75%; no 
fibers/middle: 5.41%; no fibers/posterior: 0.00%). (B) Similarly, intragemmal fibers were 
classified to identify potential regional differences as described in A. No differences in 
distribution pattern were observed (>3 fibers/tip: 11.01%; >3 fibers/middle: 10.81%; >3 
fibers/posterior 16.67%; 1-3 fibers/tip: 30.28%; 1-3 fibers/middle: 32.43%; 1-3 
fibers/posterior: 36.67%; no fibers/tip: 58.72%; no fibers/middle: 56.76%; no 
fibers/posterior: 46.67%). A small increase overall was seen in intragemmal Ret+ fibers 
in the posterior region when discounting innervation density categories (53.54% Ret+ 
intragemmal fibers in posterior vs. 43.24% and 41.29% Ret+ intragemmal fibers in 
middle and tip of the anterior tongue, respectively). (C) A small number of Ret+ taste 
receptor cells (TRC) were observed (8% of FP overall; always present in tip of the 
tongue). These Ret+ TRCs were generally of an elongated morphology, spanning 
apically to basally within the taste bud. Scale bar represents 25 µM. 
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Figure 4.11. Expression profile of GFRα2, GFRα3, and NF200 in the geniculate 
ganglion.  
(A) GGs taken from adult Ret-Cre/ERT2; Rosa26LSL-TdTomato/+ reporter mice administered 
TMX were immunostained for TuJ1 (green), RFP (Ret; red), and GFRα2 (blue; upper) or 
GFRα3 (blue; lower), with the merged image displayed on the right. Although some 
GFRα2+ nerve fibers could be visualized within the nearby facial nerve, no neuronal 
staining was observed for either co-receptor within the GG. (B) To confirm that the 
GFRα2 and GFRα3 immunostaining procedure was working, we analyzed TGs taken 
from the mice described above. Clear examples of GFRα2+ (upper) and GFRα3+ 
(lower) TG neurons were observed, most of which co-expressed Ret. Similar results 
were obtained in n=3 individual mice with similar results. Collectively, these data 
indicate that GFRα2 and GFRα3 are not present within GGs, providing further evidence 
for a GDNF-GFRα1-Ret signaling axis in adult GGs. (D) GGs were collected from adult 
Rosa26LSL-tdTomato/+; Phox2b-Cretg/+ mice and stained for NF200 (green), Brn3a (blue), 
and Phox2b (RFP; red) to ascertain the transcriptional profile of NF200+ GG neurons. 
We observed almost complete segregation of Brn3a and Phox2b expression (lower left 
panel merged), as expected based on previous literature. Rare examples of 
Brn3a+/Phox2b+ neurons were observed (green arrows). While some examples of 
Brn3a+/NF200+ neurons were observed (lower middle panel; yellow arrows), many 
more examples of Phox2b+/NF200+ neurons were observed (lower right panel; blue 
arrows). Scale bar represents 50 µM.  
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Figure 4.12. Distribution pattern of Ret+ nerve fibers and GDNF+ cells within 
fungiform papillae. 
(A) Whole tongues from adult Ret-Cre/ERT2; Rosa26LSL-TdTomato/+ mice were 
immunostained for RFP (indicates Ret, red), K8 (blue) and TuJ1 (green; present in 
merged image). 176 FP from n=5 individual mice were imaged and the pattern of Ret 
expression was categorized as intragemmal (within the K8+ region) or extragemmal 
(outside of the K8+ region). Panel A shows an example of a FP with extensive (> 3 
fibers) intragemmal and extragemmal innervation by Ret+ fibers. (B) Example of a FP 
with extensive (>3 fibers) extragemmal labeling but no intragemmal Ret+ fibers. (C) 
Quantification of the innervation density of Ret+ extragemmal fibers indicates that the 
vast majority of FP have extragemmal fibers present (98.3%), most of which (85.2%) 
have greater than 3 fibers. (D) Quantification of the innervation density of intragemmal 
Ret+ fibers demonstrates that many FP (43.7%) have an intragemmal projection 
pattern. (E) 5 daily doses of TMX was administered to adult GDNF-IRES-Cre/ERT2; 
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Rosa26LSL-TdTomato/+ via i.p. injection. Tongues were then fixed, preserved, serially 
sectioned, and immunostained for RFP (indicating GDNF; blue) and E-Cadherin (red; 
left panel, FP 1) or K8 (red; right panel, FP 2). All FP were imaged from n=4 individual 
mice. We observed a variable pattern of expression of GDNF within the TB region 
(ranging from 0-2 cells generally present within the basal aspect of the TB, but strong 
labeling of GDNF in the perigemmal space immediately surrounding the TB. In addition, 
GDNF+ cells were observed in the E-Cad+ trenches at the base of the FP. On 
occasion, GDNF+ cells were observed in the mesenchymal core of the FP. Scale bar 
represents 50 µm. In all cases Cre-negative littermate controls were always utilized to 
control for RFP immunostaining specificity.  
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Figure 4.13. Characterization of Ret expression in fungiform papillae.  
(A) To determine whether any regional differences in Ret expression exist, we analyzed 
FP from adult Ret-Cre/ERT2; Rosa26LSL-TdTomato/+ reporter tongues labeled with TMX as 
described in figure 5. To control for the increased density of FP on the tip of the anterior 
tongue compared to the middle and posterior aspect of the anterior tongue, the number 
within each group was divided by the total number of FP within that region to yield a 
percentage of all FP counted (n=5 individual mice). Regardless of regional localization, 
a similar distribution pattern was observed for extragemmal fibers (>3 fibers/tip: 81.65%; 
>3 fibers/middle: 83.78%; >3 fibers/posterior 90.00%; 1-3 fibers/tip: 15.59%; 1-3 
fibers/middle: 10.81%; 1-3 fibers/posterior: 10.00%; no fibers/tip: 2.75%; no 
fibers/middle: 5.41%; no fibers/posterior: 0.00%). (B) Similarly, intragemmal fibers were 
classified to identify potential regional differences as described in A. No differences in 
distribution pattern were observed (>3 fibers/tip: 11.01%; >3 fibers/middle: 10.81%; >3 
fibers/posterior 16.67%; 1-3 fibers/tip: 30.28%; 1-3 fibers/middle: 32.43%; 1-3 
fibers/posterior: 36.67%; no fibers/tip: 58.72%; no fibers/middle: 56.76%; no 
fibers/posterior: 46.67%). A small increase overall was seen in intragemmal Ret+ fibers 
in the posterior region when discounting innervation density categories (53.54% Ret+ 
intragemmal fibers in posterior vs. 43.24% and 41.29% Ret+ intragemmal fibers in 
228 
 
middle and tip of the anterior tongue, respectively). (C) A small number of Ret+ taste 
receptor cells (TRC) were observed (8% of FP overall; always present in tip of the 
tongue). These Ret+ TRCs were generally of an elongated morphology, spanning 
apically to basally within the taste bud. Scale bar represents 25 µM. 
  
229 
 
 
230 
 
Figure 4.14. Many chemosensory nerves terminate outside the taste bud region. 
To ascertain whether all chemosensory GG neurons projected to the taste bud region 
proper, tongues were collected from adult Phox2b-Cretg/+; Rosa26LSL-TdTomato/+ and 
stained for K8 (blue) and RFP (chemosensory axons; red), with the merged image 
displayed. 151 fungiform papillae from n = 5 individual mice were serially imaged and 
categorized as having (A) >3 extragemmal branches, (B) 1-3 extragemmal branches (≤ 
3), or (C) no extragemmal branches (intragemmal only). All FP analyzed had 
intragemmal labeling (A-C). All FP had intragemmal labeling of FP. (D) A Pie chart is 
used to graphically describe the proportion of FP within each category. Surprisingly, we 
observed 50.3% of FP had extragemmal labeling in total (31.8% with >3 fibers; 18.5% 
with 1-3 fibers), while the remaining 49.7% had no extragemmal labeling. These data 
may suggest that a substantial portion of FP have chemosensory axons projecting 
outside the K8+ region. Scale bar represents 25 µM. (E) GGs were taken from n=4 adult 
GDNF-IRES-Cre/ERT2; Rosa26LSL-TdTomato/+ mice and stained for TuJ1 (green), RFP 
(indicating GDNF, red), and Phox2b (blue) to ascertain whether GDNF is expressed by 
GG neurons. No instances of GDNF+ neurons were observed. On occasion, GDNF+ 
satellite cells within the facial nerve were labeled (blue arrow). Scale bar represent 50 
µm.   
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Figure 4.15. DTA deletion and additional electrophysiological traces from 
wildtype and Ret-ablated mice. 
(A) Schematic demonstrating the ablation of Ret+ neurons in vivo prior to 
electrophysiological recordings. TMX was administered daily for 3 days, and mice were 
subsequently utilized for whole nerve recordings from the chorda tympani. (B) GGs from 
Ret+/+; DTA+/+ (WT) and RetCre/+; DTA+/+ (Ret-ablated) mice were serially sectioned, 
immunostained for Phox2b (blue) and TuJ1 (green, overlaid in merge). Ret-ablated 
mice had fewer total numbers of Phox2b+ GG neurons, indicating reliable deletion. 
Scale bar represents 100 µm. (C-E) Representative chorda tympani integrated nerve 
responses to various taste stimuli (C), 4°C water (D), or raw responses to tactile stimuli 
(E) are displayed. For each panel, the WT animal is displayed in the top trace, while the 
middle trace represents the electrophysiological responses of a Ret-ablated mouse 
meeting the inclusion criteria, yet retaining tactile responses (n = 2). The bottom trace is 
an additional representative trace from a Ret-ablated mouse with a complete loss of 
tactile responses (n = 4 complete loss, n = 1 partial loss). 
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Figure 4.16. Ablation of Ret+ neurons results in deficits in tactile, but not 
chemical or thermal responses. 
Chorda tympani integrated nerve responses to (A) taste stimuli and (B) cold stimuli are 
unaffected in RetCre/+; DTA+/+ mice (Ret-ablated; lower trace) compared to control 
animals. (C) A representative trace demonstrating the loss of chorda tympani responses 
to tactile stimulation (upper: WT; lower: Ret-ablated). Of the 7 RetCre/+; DTA+/+ mice 
tested, 4 had loss of tactile responses, 1 had substantially weakened responses, and 
two had a residual response (additional traces displayed in Supplementary Figure 9). 
Despite the loss of tactile responses, spontaneous neural activity remains intact in Ret-
ablated nerves. Because responses to tactile stimuli are not sustained, tactile 
responses are not integrated but presented as whole nerve recordings. 
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CHAPTER 5: CONCLUSION AND FUTURE DIRECTIONS 
 
A Key Role for p75 in Augmenting GFL-Ret Signal Transduction 
 Our demonstration of the important role of p75 in augmenting Ret 
signaling in nonpeptidergic nociceptors in Chapter 2 of this thesis generates several 
intriguing questions. Given that p75- and Ret-deficient mice overtly share few 
phenotypic similarities with one another, wherein p75-null mice are viable, while Ret-null 
mice die at birth (Lee et al., 1992; Trupp et al., 1996), it is clear that p75 is not required 
for Ret signal transduction in all cell types. Even among Ret+ sensory neurons, no loss 
of Ret-dependent low threshold mechanoreceptors was observed in our study.  Given 
these observations, what makes Ret+ nociceptors uniquely depend on p75? The 
investigation of this receptor complex in both sensory and sympathetic neurons led to 
the discovery of important differences in neurotrophic factor signaling between these 
two populations. In the same experiments performed in parallel in both neuron 
populations, p75 was required for GFL activation in sensory, but not sympathetic 
neurons. Even Rethigh MrgD+ nociceptors are lost in the absence of p75, indicating that 
it’s not simply a function of Ret levels that dictate the requirement for p75.  
 One possibility is that redundancies exist in the mechanisms underlying Ret 
trafficking. SorLA, a member of the sortilin-related receptor family, was recently shown 
to target Ret for endocytosis, preventing its degradation and thereby potentiating 
signaling in midbrain neurons (Glerup et al., 2013). Thus, it is possible, and perhaps 
likely, to suggest that differential expression of cell type-specific regulators of Ret 
trafficking may underlie the differential requirement for p75 in augmenting Ret signaling 
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in various tissues. To determine which cell types in particular require p75 for GFL/Ret-
mediated signal transduction, the generation of a transgenic model such as Retfx/fx; p75-
Cre mice would facilitate this investigation. Additionally, enhanced understanding of the 
structural basis underlying the interaction between p75 and Ret, and the subsequent 
creation of mutant animals that prevent the interaction between them would be key in 
understanding the cell type-specific requirement for p75. Finally, given that p75 
potentiates GFL-Ret signal transduction, and that overactive Ret signaling has been 
implicated in numerous cancers including human pheochromocytoma and papillary 
thyroid carcinoma, whether mutations in p75 can also lead to overactivated Ret 
signaling leading to human disease is an intriguing question. In concordance with this 
idea, p75 was shown to be overexpressed in human papillary thyroid carcinoma 
samples, while p75 was not observed in normal thyroid tissue (Rocha et al., 2006). 
Further studies investigating the functional consequences for p75 potentiation of Ret 
signaling is therefore an important future direction. 
 
Non Cell-Autonomous Functions for p75 in Sensory Neuron Development During 
Embryogenesis 
Perhaps a more surprising finding than the role for p75 in augmenting GFL signaling is 
the observation that sensory neuron-specific deletion of p75 did not phenocopy p75 
germline null mice (Chapter 2). As one of the first knockout strains to be produced, and 
at the time when p75 was already understood to be a major regulator for neurotrophin 
signaling, the most overt phenotype observed in p75-null mice were hindpaw clubbing 
resulting from sensory abnormalities. Subsequent studies discovered that in sensory 
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neurons in vitro, p75 enhanced NGF binding to TrkA, shifting the dose response to 
enhance the TrkA signaling and NGF-mediated survival (Barker and Shooter, 1994; 
Davies et al., 1993; Hantzopoulos et al., 1994). For this reason, the function of p75 in 
DRG sensory neurons was assumed to be restricted to potentiating the function of 
NGF/TrkA signaling. Surprisingly, our data suggest that p75 is dispensable for NGF-
mediated survival, as the survival of peptidergic nociceptors is unaffected despite less 
than 10% of p75 remaining following Islet1-Cre-mediated deletion of p75.  
In lieu of these findings, why do germline p75-null mice lose approximately 50% 
of sensory neurons by birth, when the function of p75 in sensory neurons appears to be 
dispensable during embryonic development? We posit that the most likely explanation 
for these findings is an early embryonic function for p75 in Schwann cells. It has been 
shown previously that deficits in Schwann cell development caused by loss of ErbB2 
results in a severe loss of sensory and motor neurons by E11.5, along with a severe 
reduction in neurite extension and target innervation (Morris et al., 1999; Woldeyesus et 
al., 1999). In support of this model, p75 is known to be highly expressed in Schwann 
cells, and Bentley and Lee (2000) demonstrated that p75-deficient mice mimic the 
phenotype observed in ErbB2-/- mice, albeit less severely (Bentley and Lee, 2000). 
Specifically, although neuron counts were not performed, the authors observed that 
peripheral axon outgrowth was stunted beginning at E11.5 in p75-/- mice, along with a 
loss of the Schwann cell marker S100β. Additionally, using in vitro functional assays, 
the authors found that the migration of Schwann cells cultured from p75-deficient DRGs 
was severely diminished, suggesting p75 is an important regulator of Schwann cell 
migration. In future studies, the comparison of p75 conditional knockouts using various 
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Schwann cell-specific Cre lines to allow for the elimination of p75 function during 
several distinct developmental windows using mouse lines such as Wnt1-Cre, P0-Cre, 
and ErbB2-Cre. Experiments such as these will be vital for our understanding of the 
embryonic function of p75 in sensory neuron development.   
 
Ret as a Novel Regulator of Cell Death 
To date, a small number of studies have suggested that Ret acts as a 
dependence receptor to promote apoptosis. To arrive at this conclusion, Ret was 
overexpressed in heterologous cell lines, and the extent of apoptosis subsequently 
quantified in the presence or absence of GDNF (Bordeaux et al., 2000). Importantly, we 
find no evidence of a dependence receptor model of Ret signal transduction. As noted 
in the introduction, there are several tissues in which Ret is not co-expressed with the 
GFRα co-receptors (Golden et al., 1998; Nosrat et al., 1997), and many tumor 
populations in which Ret is upregulated in the absence of its co-receptors, yet these 
populations are not eliminated (Santoro et al., 1990). Whether Ret can serve as a 
dependence receptor in a physiological system remains to be demonstrated, but in the 
studies reported here, we find no evidence of this phenomenon.  
No studies to date have demonstrated a role for receptor tyrosine kinases in cell 
death during normal organismal development. However, TrkA activation has been 
shown to induce apoptosis in pediatric neuroblastoma tumor cells. Interestingly, TrkA 
does not mediate these effects through a direct mechanism, but instead interacts with 
CCM2 (Malcavernin) through its PTB domain to mediate these effects. CCM2, in turn, 
has a Karet domain which is essential for the pro-apoptotic effects, although the 
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mechanism underlying these interactions is unclear (Harel et al., 2009). These findings 
bear some similarity to our discovery that Ret promotes developmental cell death in 
sympathetic neurons indirectly through its ability to augment the function of p75, which 
itself promotes apoptosis through the interaction with cell death pathways. Similar to the 
studies performed to identify the structural basis of the interaction of TrkA with CCM2, 
determining the precise means by which Ret and p75 physically associate remains an 
important future direction, which could lead to the development of new tools to 
investigate this developmental function of Ret. 
 
Dual Functions of a Novel p75-Ret Receptor Complex 
In a recent study by Lin et al. (2015), a genetic approach was undertaken using 
alanine-scanning mutagenesis to dissect how p75 is able to interact with many different 
co-receptors to promote different signaling pathways capable of promoting survival, 
apoptosis, or growth cone collapse. In this study, the authors found that pro-apoptotic 
and pro-survival pathways mapped to different regions of the p75 death domain, with 
pro-apoptotic regions inducing JNK activation while pro-survival regions promoted 
activation of NF-κB (Charalampopoulos et al., 2012). Interestingly, in this thesis we 
discover the existence of a p75-Ret receptor complex that can promote both survival 
and apoptotic signaling pathways, depending on which ligand promotes the assembly of 
the complex. Given the structure-function analysis performed above, it would be 
interesting to identify how p75 and Ret physically associate, and whether the ligand 
promoting the assembly of the receptor complex would change how these two receptors 
interact.  
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 Although these studies took advantage of the developmental dependence of 
sensory neurons on Ret signaling for survival, as well as the well-characterized role for 
p75 in developmental cell death in sympathetic neurons, we have identified a receptor 
complex with dual functions, the output of which depends on which ligand activates the 
assembly of the complex, and thus, which receptor becomes activated (Figure 5.1). it 
would be interesting to investigate how this receptor complex may function if both 
signaling pathways were activated simultaneously. For example, while sympathetic 
neurons were utilized to investigate the role for Ret in p75-mediated apoptosis due to its 
well characterized pro-apoptotic roles in developmental cell death in this system, p75 
also mediates apoptosis of other neuronal populations including sensory and cerebellar 
neurons. In these systems, it is tempting to suggest that p75 may serve as a 
“coincidence detector” – acting as an integrator for both neurotrophic factor and 
competition factor signals to ultimately trigger survival and apoptosis. One might posit 
that under these conditions, maximal concentrations of GFLs would silence BDNF-
mediated apoptosis, thereby promoting survival, and that maximal concentrations of 
BDNF with sub-threshold levels of GFLs would promote apoptosis.  
 
Ret as a Novel Regulator for Phox2b Expression 
 In chapter 4, we investigate the roles of GDNF-Ret signaling in chemosensory 
neuron development and function. During embryogenesis, like other placodally-derived 
cranial sensory ganglia, the geniculate ganglion begins as a homogenous placode of 
Neurogenin2-positive cells (Krimm, 2007). Through a series of differentiation steps, two 
anatomically and functionally-distinct groups of neurons develop: a proximal 
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somatosensory population, innervating the external ear, and a distal chemosensory 
population, innervating taste buds on the soft palate and the anterior two-thirds of the 
dorsal tongue. In our study, we demonstrated that Ret expression leads to the initial 
amplification of Phox2b expression in chemosensory neurons of the geniculate 
ganglion. While Ret knockout mice have a substantial reduction in Phox2b expression, 
no phenotype was observed when Ret was deleted after Phox2b expression had been 
initiated, using both a pharmacologic and conditional genetic approach. While these 
data provide the novel insight that Ret is upstream of Phox2b, the question that remains 
is what governs the expression of Ret? And spatiotemporally, why is Ret expression 
restricted to distal neurons that are destined to be lingually-projecting chemosensory 
neurons?  
 While little is known regarding Ret initiation in chemosensory neurons, a 
considerable breadth of literature is available regarding transcriptional regulation of Ret 
in autonomic and enteric neuron populations. There are several reports suggesting that 
Phox2b expression promotes the expression of Ret, as Phox2b-/- mice lose Ret 
expression in all autonomic ganglia (D'Autreaux et al., 2011; Dauger et al., 2003; Pattyn 
et al., 1999). Interestingly, while the authors conclude from these findings that Phox2b is 
upstream of Ret, they do not directly demonstrate that Ret expression depends on 
Phox2b expression. Given that many phenotypic changes occur in the autonomic 
ganglia of Phox2b-/- mice, including a loss of the biosynthetic machinery for adrenergic 
neurotransmitters and a change of in several additional autonomic transcription factors, 
it is possible that the loss of Ret is secondary to the loss of another regulator. 
Additionally, the experiments conducted so far do not rule out the possibility that Ret 
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initiates Phox2b expression, which in turn acts to further promote the expression of Ret, 
thereby serving as a positive feedback loop. It is interesting to consider that Phox2b and 
Ret-deficient mice share several characteristics, including loss of autonomic and enteric 
ganglia, reduction in several cranial sensory ganglia, and an association with 
Hirschsprung’s Disease in human patients with loss of function mutations in either gene 
(Pattyn et al., 1999; Sasselli et al., 2012). To understand whether Phox2b globally 
specifies Ret expression, or vice versa, a broad phenotypic analysis of Retfx/fx; Phox2b-
Cre and Ret-Cre; Phox2bfx/fx mice should be undertaken, with special attention given to 
autonomic, enteric, and cranial sensory ganglia. Interestingly, our creation of Retfx/fx; 
Phox2b-Cre mice allowed us the observation that these mice are viable, fertile, and 
have normal life expectancy (data not shown), indicating that in other populations Ret is 
also likely to be dispensable for maintenance of Phox2b.  
 
Heterogeneity Within the Geniculate Ganglion 
 In this thesis, we demonstrate the existence of a unique subpopulation of 
chemosensory GG neurons, which are molecularly, morphologically, and functionally 
distinct. Given the complex sensory modalities that exist within the geniculate ganglion, 
the absence of literature to date that describes the cellular basis for the observed 
heterogeneity in GG neuron function is surprising. While the DRG sensory system has 
been described to possess at least six molecularly and functionally distinct 
subpopulations (Chiu et al., 2014), and perhaps as many as eleven subpopulations 
(Usoskin et al., 2015), much less is known regarding GG subpopulations. In a recent 
study by Dvoryanchikov et al. (2017), single cell RNA sequencing of 96 GG neurons 
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was undertaken with subsequent hierarchical clustering and principal component 
analysis to determine whether distinct subpopulations could be categorized based on 
transcriptome analysis (Dvoryanchikov et al., 2017). In this study, the authors were able 
to identify three subclusters of neurons, each possessing unique transcription factors 
and neurotransmitter receptor profiles indicative of individual subpopulations of neurons. 
Although this study significantly advanced our understanding of cellular heterogeneity 
within the GG, it seems likely that additional subpopulations exist that remain to be 
identified. Studies undertaken in the DRG sensory neurons that identifed six and eleven 
subpopulations involved single cell sequencing on 334 (Chiu et al., 2014) and 622 
(Usoskin et al., 2015) neurons, respectively, allowing enhanced depth of sequencing 
and greater representation of rare groups of neurons. This approach is hindered by the 
cost and time associated with single cell RNA sequencing. Interestingly, Macosko et al. 
(2015) describe a new approach, Drop-Seq, which partially subverts this limitation. In 
this strategy, cells are separated into nanoliter-sized droplets, and the RNA from each 
cell is subsequently tagged with a unique barcode, allowing the RNAs from thousands 
of individual cells to be collected and sequenced together while retaining the ability to 
identify the cellular origins of each transcript. This approach allowed the authors to 
perform an unparalleled single cell sequencing of 44,408 mouse retinal cells, leading to 
the identification of at least 39 transcriptionally-distinct cell populations (Macosko et al., 
2015). It seems likely that further studies utilizing powerful single cell transcriptomics of 
GG neurons such as Drop-Seq based approaches will allow for the identification of 
many additional populations, which will pave the way for investigators to identify 
functionally distinct gustatory neurons and address questions related to taste coding. 
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Within the three subclusters of neurons observed by Dvoryanchikov et al. (2017), 
a small cluster of neurons expressing both gustatory and mechanosensory-related 
genes was described, in part corroborating our identification and the description of a 
chemosensory mechanoreceptor. Interestingly, the neurons within this small cluster 
were demonstrated to express Ret as well as Gfrα2. Although our study identifies these 
neurons as expressing GFRα1 rather than GFRα2, it is likely that this subcluster is the 
population identified in our study. As a future direction, it would be interesting to identify 
how the central projections of these neurons differ from other gustatory GG neurons. It 
is also interesting to consider, in the future, the evolutionary origins and functional 
significance of these neurons. Given that mechanoreceptors within the trigeminal 
ganglion abundantly innervate the tongue, providing the majority of lingual 
mechanosensation, the physiological significance of this small population of gustatory 
mechanoreceptors is unclear. As these neurons possess both gustatory and 
mechanosensory qualities, it is tempting to speculate that they may be involved in the 
detection of food texture, integrating the physical and chemical properties of food. 
Interestingly, even in the fruit fly Drosophila melanogaster, there is a clear preference 
for food with a specific hardness or viscosity, and this preference has been 
demonstrated to be mediated by a unique population of multidendritic neurons that 
innervates the base of taste hairs (Zhang et al., 2016). Corroborating these findings in 
mammalian systems will depend on the development of behavioral assays that are able 
to adequately control for variations in the chemical properties of taste while allowing for 
the manipulation of the physical properties of food. One approach that could be 
undertaken would be to develop behavioral food texture assays utilizing P2X2/P2X3 
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double knockout animals, which lack the ability to respond to chemical tastants but 
retain somatosensory responses (Finger et al., 2005), which may allow for the 
determination of whether these neurons play a role in food texture decisions.  
 
Concluding Remarks: 
 The work completed in this thesis project details several examples of novel 
neurotrophic factor signaling mechanisms and physiological functions regulating neuron 
development during organogenesis. These studies also provided, with clarity, specific 
examples of crosstalk between neurotrophic factor signaling pathways in neuron 
differentiation, survival, and apoptosis. Collectively, broadening our understanding of 
neurotrophic factor signaling mechanisms during development and in postnatal neuron 
maintenance will enhance our understanding of peripheral neuron development, and 
improve our ability to design novel therapeutics utilizing these factors to treat nervous 
system injuries and neurodegenerative diseases. 
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Figure 5.1. Dual functions of a p75-Ret receptor complex. 
Both GFLs and BDNF can promote the interaction between p75 and Ret. GFL-mediated 
activation of p75-Ret receptor formation leads to downstream survival and growth 
response through Ret-mediated pathways, while proBDNF and BDNF (or NGF 
deprivation) induce p75-mediated apoptosis. We posit axon pruning may also depend 
on this receptor complex.  
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